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Terminology 
(i) The term anabolic-androgenic hormones refers to all endogenous and exogenous 
(synthetic) anabolic-androgenic horm_ones. 
(ii) The term anabolic..,androgenic steroids, used in its abbreviated form AAS, refers to 
exogenous (synthetic) anabolic-androgenic hormones only, and includes all AAS 
admini_stered orally as well as those administered parenterally (parenteral AAS are 
administered by intra-muscular injection). 
(iii) The term endogenous anabolic-androgenic hormones refers· to all the endogenous 
anabolic-androgenic hormones, including androstenedione, dihydrotestosterone and 
testosterone. 
(iv) Unless stated directly, all references to lipoproteins are to plasma lipoproteins. This also 
applies to ail the other haematology, i.e. a concentration refers to a plasma concentration, 
unless otherwise indicated. · 
. (v) . The term premature atherosclerosis implies that atherosclerotic disease becomes evident 
. . . 
at an earlier age than expected. As atherosclerosis may be caused by multiple factors 
acting simultaneously, an additional atherogenic factor will serv~ to reduce the age at 
which the disease becomes manifest. 
(vi) The term premature CHD implies an earlier incidence of CHD-(a clinical manifestation 
of atherosclerosis) due to premature atherosclerosis.· 
(vii) The terms men or·women imply adult males or females. 
(viii) The term 'atherogenic dyslipidaemia' is not in common usage, and is thus enclosed in 
inverted commas. 
'------------·----~---------- ------· ··----.. ---
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Preface 
There is controversy in the scientific "literature as to whether endogenous testosterone 
constitutes an atherogenic factor in males,. and whether, and in what setting, supplementation 
with anabolic-androgenic steroids (AAS) may constitute an additional atherosclerotic risk. A 
better understanding of this question is important because: (i) the use of AAS by males and 
females, to improve athletic performance or physical appearance is becoming increasingly 
widespread (Yesalis et al., 1993), and (ii) there is renewed interest in using synthetic testosterone 
as a male contraceptive (Bagatell and Bremner, 1996), and for hormone replacement therapy in 
elderly hypogonadal men (Swerdloff and Wang, 1993). Therefore, the aims of this thesis were 
to: (i) review the current literature, to gain perspective on the basis for the divergent opinions in 
this field, and (ii) investigate the poorly understood relationship between the anabolic-androgenic 
hormones and 'atherogenic dyslipidaemia'. This phenotype is characterised by an abnormal 
triglyceride metabolism, small dense low density lipoproteins and a low high density lipoprotein 
(HDL) concentration, which confers a high risk of premature atherosclerosis (Grundy, 1996). 
This thesis comprises; (i) an introductory chapter, in which the relevant literature is reviewed, 
and the theoretical basis for the present studies is presented; (ii) a methodological chapter, in 
which the clinical and laboratory procedures are described in detail; (iii) two experimental 
chapters, one on healthy men undergoing a reversible suppression of testosterone production, and 
one on bodybuilders using AAS. The experimental chapters include an introduction to the 
specific study, a brief description of methods and results, and a discussion of the results in the 
context of current knowledge. The thesis concludes with a general discussion and 
recommendations for future studies. 
VIII 
Abstract 
It has been hypothesised that endogenous testosterone and AAS may predispose humans to 
premature CHD. However, there is no direct evidence to link these hormones with a greater 
prevalence of premature CHD. The aim of this thesis was to better describe atherosclerotic risk 
associated with these hormones by clarifying their effect on additional risk factors for premature 
atherosclerosis. Little is kno\\-n about the effect of testosterone and AAS on 'atherogenic 
dyslipidaemia', a phenotype characterised by elevated postprandial triglyceridaemia, small dense 
LDL and a low HDLC concentration, which confers a high risk of CHD. Accordingly, the 
magnitude of postprandial triglyceridaemia, LDL and HDL particle size, and LDLC, HDLC and 
Lp(a) concentration were compared in male (n=9) and female (n=3) bodybuilders after self 
administration of AAS for 5-6 weeks (ON cycle) and again after a 4-6 week 'washout' period 
(OFF cycle), and in normal males (T) (n=lO) before and during a reversible suppression of 
endogenous testosterone, induced using a GnRH agonist (triptorelin), and in a control group (C) 
(n=8). Lipoprotein size was assessed by gradient gel electrophoresis (GGE), lipoprotein 
concentrations by immuno and enzymatic assay, and postprandial triglyceridaemia by a 
standardised oral fat tolerance test (65g/m2). HDLC decreased in male bodybuilders (0.94±0.30 
vs 0.70±0.27 mmol/L, p=0.004; x ± SD) and female bodybuilders (1.3±0.5 vs 0.8±0.2 mmol/L) 
ON cycle. GGE studies suggested that mostly HDL2 was reduced. There were no significant 
reductions in LDL particle size ON cycle. Two males had larger LDL species ON cycle. Lp(a) 
decreased in male bodybuilders (124.7±128.0 to 69.3±73.3 U/L, p=0.008). ON cycle postprandial 
triglyceride excursion was unchanged in female bodybuilders and reduced (11.6±10.0 vs 
7.5±5.4 mmol/L.hr; p=0.027) in male bodybuilders. In the triptorelin study, HDLC was increased 
in T (1.07±0.18 vs 1.41±0.28 mmol/L, p=0.002) and not in C. GGE studies indicated an increase 
ofHDL2 in five T subjects and no increase in C. Total cholesterol increased in T (4.77±0.80 vs 
5.24±1.04 mmol/L, p=0.039) but not in C. LDL size increased in four T subjects, and not in C. 
Lp(a) increased in T (277.9±149.l vs 376.5±222.2 U/L, p=0.004), but not in C. Postprandial 
triglyceridaemia was unchanged in both T and C. The results of these studies did not show any 
additional atherogenic effects of endogenous testosterone or AAS in humans. Rather, a 
suppression ofLp(a) may be an antiatherogenic effect of these hormones. A reduced postprandial 
triglyceridaemia and increased LDL size in individuals who are predisposed to 'atherogenic 
dyslipidaemia', may be further antiatherogenic effects of AAS use. 
Introduction 
'Atherosclerosis is a degenerat_ive disease of arteries (Thompson, 1994). The atherosclerotic 
process is the principal contributor to the pathogenesis of myocardial and cerebral infarction, · 
gangrene and loss of function in the extremities (Ross, 1993 ). Atherosclerosis is currently the 
commonest cause of death and disability in most Westernised countries (Thompson, 1994 ). The 
pathogenesis of atherosclerosis is exceedingly complex, there being multiple factors which can 
either predispose to, or protect from, the initiation and/or progression of atherosclerosis. The 
complex interrelationship between these factors makes it difficult to predict with certainty those 
who will suffer from this disease. 
Endogenous testosterone and AAS are regarded as factors which may predispose to 
premature atherosclerosis (Bagatell and Bremner, 1995; Glazer, 1991; Kalin and Zumoff, 1990). 
However, it has proven difficult to establish causality between these hormones and premature 
atherosclerosis in humans (Melchert and Welder, 1995). To confirm causality, it would be 
necessary to compare the progression of atherosclerosis between groups of normal individuals 
having either reduced, unchanged or elevated concentrations of testosterone or AAS. However, 
ethical and practical considerations constrain the duration of such studies, making it difficult to 
assess whether the atherosclerotic process has been modified in the vessel wall or in clinical 
outcome. Indeed, a review of the current literature reveals that evidence to provide a direct link 
between both endogenous testosterone and AAS, and premature atherosclerosis in humans is 
limited. Unfortunately, relatively few animal studies have been completed to date, and the results 
from those that have been published are equivocal (Alexandersen et al., 1996). While animal 
studies could clarify the role of anabolic-androgenic hormones in atherosclerosis, it remains 
uncertain whether data obtained in animal atherosclerosis models can be extrapolated to humans. 
Another means of establishing a link between the anabolic-androgenic hormones and 
premature atherosclerosis is by inference. If the anabolic-androgenic hormones adversely affect 
other risk factors for premature atherosclerosis, it may be inferred that the anabolic-androgenic 
hormones also constitute an atherogenic risk factor. In this context, a risk factor is defined as any 
measurable trait or characteristic that predicts an individual's probability of developing clinically 
manifest disease, but does not necessarily imply a causal relationship (McGill, 1996). Some of 
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the major risk factors for premature atherosclerosis are hypertension, diabetes, smoking, obesity, 
a family history of the disease, and an abnormal lipoprotein profile (Thompson, 1994). Currently, 
the proposal that endogenous testosterone and AAS may be atherogenic stems primarily from the 
finding that these hormones modify lipoprotein profiles in an apparently atherogenic manner. 
However, it is unknown whether the lipoprotein changes per se induced by endogenous 
testosterone make a significant contribution to the sex difference in the prevalence of premature 
coronary heart disease (CHD), or whether the lipoprotein changes evident in AAS users later 
manifest as premature CHD. In the absence of studies to prove the hypothesis that testosterone 
and AAS cause premature atherosclerosis in humans, the possibility cannot be excluded that 
these hormones may induce other anabolic responses which alter the putative deleterious actions 
of these hormones on circulatory structure and function (Rockhold, 1993). Two observations 
suggest that the atherogenicity of testosterone and AAS may have been overstated: (i) prospective 
and cross sectional studies suggest either a neutral or beneficial effect of endogenous testosterone 
in males (Alexandersen et al., 1996), and (ii) the frequency of reported atherosclerotic 
complications relative to the total estimated population of AAS users appears to be lower than 
would be expected, given the apparent atherogenicity of AAS (Wilson, 1988; Windsor and 
Dumitru, 1988; Street et al., 1996). 
Until such time as it becomes possible to perform studies which can provide direct evidence 
of the association between the anabolic-androgenic hormones and atherosclerosis, it seems 
prudent to extend the scope of inferential atherosclerotic risk assessment, to permit a better 
estimation to be made of risk for premature CHD associated with these hormones. 
3 
Aims of the Thesis 
The aim of this thesis was to provide new insight into the atherosclerotic risk associated with 
endogenous testosterone and AAS. In order to clarify the present understanding of this 
association, the relationship between endogenous testosterone, AAS and risk for premature 
atherosclerosis, is examined in a number of different settings in chapter 1: (i) Does endogenous 
testosterone increase risk for premature atherosclerosis in males? (ii) Does synthetic testosterone 
replacement therapy in hypogonadal males increase their risk for premature atherosclerosis? 
(iii) Does the use of 17P-esterified (parenteral) AAS increase risk for premature atherosclerosis? 
(iv) Does the therapeutic use of 170:-alkylated (oral) AAS increase risk for premature 
atherosclerosis? (v) Does the non-therapeutic use of a combination of 17P-esterified (parenteral) 
and 170:-alkylated (oral) AAS increase risk for premature atherosclerosis? While the distinction 
drawn between these settings may be somewhat arbitrary, they do serve to illustrate the basis of 
some of the controversy in this field. The literature review also forms the basis of the assertion 
that additional research is still required before a. consensus can be reached, on whether, and in 
what setting, endogenous testosterone and AAS constitute a significant atherogenic factor in 
humans (Rockhold, 1993). Based on this opinion, the studies described in this thesis were 
performed to better describe the effect of endogenous testosterone and AAS on lipid and 
lipoprotein risk factors for premature atherosclerosis in humans. 
At present there is a paucity of information about the association between anabolic-
androgenic hormones and 'atherogenic dyslipidaemia'. This lipoprotein phenotype is 
characterised by a low high density lipoprotein cholesterol (HDLC) concentration, increased 
small dense low density lipoprotein (LDL) particles and an abnormal triglyceride metabolism 
which can manifest as an exaggerated postprandial triglyceridaemia or a mild fasting 
hypertriglyceridaemia, leading to an increase in very low density lipoprotein (VLDL) remnants. 
'Atherogenic dyslipidaemia' has more recently been identified as one of the two major patterns 
of atherogenic lipoprotein disorders along with hypercholesterolaemia ( elevated low density 
lipoprotein cholesterol (LDLC) concentration) (Grundy, 1996). In fact, some investigators 
believe that this phenotype rivals hypercholesterolaemia as a risk factor for CHD (Grundy, 1996). 
This area was consequently identified as the research focus of the two experimental chapters 
described in this thesis. 
Chapter 1: Literature Review. Endogenous testosterone, AAS 
and risk for premature atherosclerosis 
4 
The following review chapter introduces the reader to endogenous testosterone and AAS, and 
critically examines whether there is sufficient evidence to conclude the hypothesis that these 
hormones predispose humans to premature atherosclerosis. This chapter begins with a brief 
review of lipid and lipoprotein risk factors for premature atherosclerosis, since much of the 
evidence to show a link between testosterone, AAS and premature atherosclerosis is based on 
changes in lipoprotein risk factors induced by these hormones. 
Lipids, lipoproteins and risk for premature atherosclerosis 
Plasma lipoproteins are the prominent constituents of a complex transport system that 
provides for the movement of exogenous (intestinal) and endogenous (liver) lipid between the 
organs and tissues. Lipids have important biological functions that include; (i) the use of 
triglyceride for energy production or as stored fat in adipose tissue and, (ii) the use of cholesterol 
as a component, in conjunction with phospholipid, of cellular membranes or in the synthesis of 
steroid hormones or bile (Thompson, 1994). Since lipids are not water soluble, and thus cannot 
bind receptors, they must combine with apolipoproteins to form micellar lipid-protein complexes 
or lipoproteins. These water soluble particles are spherical, have finite dimensions, and contain 
cholesterol (free and esterified), triglyceride, phospholipid, and various apolipoproteins 
(Thompson, 1994). 
The apolipoproteins of the lipoprotein particle have several functions: (i) effecting the 
aqueous solubility of lipids, (ii) helping to solubilise cholesterol esters and triglyceride by 
interacting with phospholipid, (iii) regulating the reaction of lipids with enzymes and other 
proteins, and (iv) binding to cell surface receptors and thus determining the sites of uptake and 
rates of degradation of other lipoprotein constituents, notably cholesterol (Thompson, 1994). For 
reference, the apolipoprotein composition of lipoproteins in fasting plasma is included in 
Appendix I. In brief, apolipoprotein A (apoA) is the chief protein constituent of HDL and is 
subdivided into apoA-I and apoA-II. Apolipoprotein B (apoB) is heterogeneous; apoB100 is found 
mainly in VLDL and LDL, whereas apoB48 is found only in chylomicrons, and represents the 
amino-terminal half of apoB 100• ApoB100 is a ligand for the LDL receptor, but apoB48 is not. 
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Apolipoprotein C (apoC) comprises at least three distinct apolipoproteins, which occur as major 
constituents of VLDL and minor constituents of HDL. Apo C-II activates lipoprotein lipase 
(LPL) and apoC-III inhibits it, whereas the role of apoC-I is not clear. Apolipoprotein E (apoE) 
is found in VLDL, IDL and HDL, entering plasma mainly in the form of nascent HDL. 
Plasma lipoproteins differ according to ultracentrifugal flotation rate (S}, density ( d), size and 
electrophoretic mobility. Currently, the most popular classification is that based on differences 
in gravitational density, recognising four basic classes of lipoprotein: (i) chylomicron, derived 
from intestinal absorption of triglyceride; (ii) VLDL, derived from the liver for the export of 
triglyceride; (iii) LDL, representing a final stage in the catabolism of VLDL; and (iv) HDL, 
involved in the reverse transport of cholesterol (Thompson, 1994). Other lipoprotein subfractions 
do exist, and include intermediate-density lipoprotein (IDL), an intermediary step in VLDL -
catabolism; HDL that is typically studied as two separate subfractions: HDL2 and the more dense 
HDL 3; and lipoprotein(a) (Lp(a)). Lp(a) is a lipoprotei.1 particle that is similar to LDL in terms 
of lipid and protein composition, but it additionally contains a highly glycosylated protein, 
designated apolipoprotein(a) (apo(a)), that is linked through a disulphide bridge to apoB 100 
(Gaubatz et al., 1983). Apo(a) is formed by three different structural domains. One of the 
domains, called kringle 4, is present in multiple copies, the number of which varies and is 
genetically determined, giving rise to different sizes of apo(a) and consequently Lp(a) 
(Uterman, 1989; MBewu and Durrington, 1990). 
There are a number of lipid and lipoprotein risk factors for premature atherosclerosis. These 
include: (i) An elevated LDLC concentration; high concentrations of LDLC are known to directly 
promote atherosclerosis, by allowing excessive cholesterol deposition in the arterial wall, and 
therapeutic lowering of high LDLC concentrations is known to reduce the risk of CHD, and 
retard the progression of atherosclerosis (Blankenhom et al., 1987; Brown et al., 1990; 
Gordon et al., 1981; Lipid Research Clinics Program, 1984, 1984a; Stamler et al., 1986). 
(ii) A low HDLC concentration (Assmann and Schulte, 1992; Gordon et al., 1989; Miller and 
Miller, 1975), although the mechanism whereby HDL influences atherosclerosis remains to be 
established (Gordon et al., 1989; Vega and Grundy, 1996). Two mechanisms have been proposed 
to explain this relationship: a direct mechanism, where HDL acts as a 'protective' lipoprotein, 
providing direct protection against the development of atherosclerosis; and an indirect 
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mechanism, where a low HDLC concentration is caused by some other metabolic abnormality, 
which is itself atherogenic. (iii) An elevated plasma triglyceride concentration (Austin and 
Hokanson, 1996; Criqui, 1996; Drexel et al., 1996; Tenkanen et al., 1996); hypertriglyceridaemia 
is characterised by the accumulation of chylomicron and VLDL remnants, small dense LDL and 
a low HDLC concentration, all of which are thought to be atherogenic. (iv) An elevated Lp(a) 
concentration, although the pathogenicity of Lp(a) appears to be modulated by the concentration 
ofLDLC (Armstrong et al., 1986). The evidence supporting a role for Lp(a) in the atherosclerotic 
process stems from observations that it accumulates in atherosclerotic plaques, stimulates smooth 
muscle proliferation, binds apoB-containing lipoproteins, avidly binds to arterial proteogly<;:ans 
and fibronectin, and promotes cholesterol accumulation in cells (Maher and Brown, 1995). It may 
also promote thrombosis because it has structural similarities to plasminogen, binds fibrin, 
competes with plasminogen for binding sites on cells, and exhibits antifibrinolytic actions in vitro 
(Maher and Brown, 1995). 
Endogenous anabolic-androgenic hormones 
The anabolic-androgenic hormones play an important physiological role in the normal healthy 
adult male. Endogenous anabolic-androgenic hormones are required for the maintenance of the 
reproductive tissues, and have a key role in stimulating and maintaining sexual function (Bagatell 
and Bremner, 1996). Endogenous anabolic-androgenic hormones also play a role in regulating 
both bone and muscle mass (Swerdloff and Wang, 1993), and in regulating the proportion of 
depot fat mass in central and peripheral adipose tissue (Marin et al., 1995). The endogenous 
anabolic-androgenic hormones are 19-carbon steroid rings derived from cholesterol. The first 
stage in the synthesis of steroid hormones is the conversion of cholesterol to pregnenolone, from 
which progesterone is synthesised. The synthesis of endogenous anabolic-androgenic hormones 
starts with the hydroxylation of progesterone at C-17. The side chain consisting of C-20 and C-21 
is then cleaved to yield androstenedione, an endogenous anabolic-androgen. Testosterone, 
another endogenous anabolic-androgen, is formed by the reduction of the 17-keto group of 
androstenedione. Oestrogens are synthesised from androstenedione and testosterone by the loss 
of the C-19 methyl group and the formation of an aromatic A ring. Oestrone, an oestrogen, is 
derived from androstenedione, whereas oestradiol, another oestrogen, is derived from 
testosterone (Stryer, 1995). 
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The hypothalamus secretes gonadotropin~releasing hormone, which stimulates the pituitary 
to secrete luteinizing hormone and follicle-stimulating hormone. In men, luteinizing hormone 
stimulates Leydig cells in the testes to produce testosterone. Follicle-stimulating hormone acts 
on Sertoli cells in the testes, thereby stimulating spermatogenesis. Approximately 7 mg of 
testosterone is produced daily in men (Bagatell and Bremner, 1996). Testosterone may also be 
aromatised to oestradiol (Ei) by the aromatase enzyme complex, which is most abundant in 
adipose tissue, liver, and certain central nervous system nucleii (Bagatell and Bremner, 1996). 
Men have about one-fifth of the amount of oestrogen fourtd in the nonpregnant woman, much 
of which is derived from the conversion of testosterone and androstenedione to oestrogens 
(Longcope et al., 1978). Endogenous oestrogen may play an important role in men by modulating 
some of the effects of the anabolic-androgenic hormones (Applebaum-Bowden, 1984; Tikkanen 
and Nikkila, 1987). Moreover, some of the differences in the effects between the various AAS 
may be due to their relative resistance to aromatisation (Friedl et al., 1990). 
The anabolic-androgenic hormones have both a masculinizing (androgenic) effect, coupled 
with an tissue building (anabolic) effect. The anabolic and androgenic components are not due ' 
to different actions of the hormone but result from interaction of the hormone with the same 
receptor molecule in different tissues (Wilson, 1988). Testosterone is the most abundant 
circulating endogenous anabolic-androgen in men; smaller amounts of dihydrotestosterone and 
adrenal androgens are also found in the plasma. Testosterone circulates primarily in a bound 
form, mostly to sex hormone binding globulin (SHBG); only 1 to 2 percent is unbound. Adrenal 
androgens are relatively weak in terms of both receptor binding and biological effects; therefore 
they play only a small role in the normal male physiology (Bagatell and Bremner 1996). At the 
cellular level, testosterone may be converted to dihydrotestosterone by the 5a-reductase enzymes. 
Both testosterone and dihydrotestosterone bind to the androgen receptor, but dihydrotestosterone 
has a higher affinity for the receptor and is therefore a more potent androgen (Bagatell and 
Bremner, 1995). 
The mechanism of action of the anabolic-androgenic hormones is fairly well understood. 
Once in the bloodstream, the anabolic-androgen passes through the cell wall of its target tissue 
and attaches to steroid receptors located in the cytoplasm. The binding to these receptors is highly 
specific, but of relatively low affinity. This hormone-receptor complex is translocated to the 
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nucleus of the cell and attaches to sites on the nuclear chromatin. Transcription ensues, resulting 
in the production of specific messenger RNA. Ribosomal translation of the code results in highly 
specific new proteins that mediate the function of the hormone (Lukas, 1993). 
Is endogenous testosterone atherogenic? 
The proposal that endogenous testosterone may be atherogenic stems from a number of 
observations: (I) hypertestosteronaemic women with polycystic ovary syndrome have an 
increased risk for myocardial infarction (Dahlgren et aL, 1992; Kalin and Zumoff, 1990); 
(ii) hypotestosteronaemic men with cirrhosis of the liver have a decreased prevalence of coronary 
disease (Kalin and Zumoff, 1990); (iii) experimentally induced male plasma testosterone 
concentration in female monkeys with diet-induced atherosclerosis, results in coronary 
atherosclerosis which is approximately twice as extensive as in controls (Adams et al., 1995); 
(iv) endogenous testosterone is the major determinant of the lower HDLC and HDL2C 
concentration in men compared to women (Asscheman et al., 1994). The latter conclusion is 
derived from the observation that suppression of endogenous testosterone concentration in men 
results in HDLC concentrations more typically seen in women, and vice versa 
(Asscheman et al., 1994; Goh et al., 1995). Similarly, male HDLC concentrations fall at puberty, 
correlating with the rise in plasma testosterone concentration (Kirkland et al., 1987), whereas · 
female HDLC concentrations do not change at puberty, despite the rise in oestrogen 
concentration (Godsland et al., 1987). 
It is, however, difficult to exclude possible confounding factors in (i) and (ii) above: women 
with polycystic ovary syndrome are characterised by other atherogenic factors 
(Dahlgren et al., 1992), and cirrhosis in men may reduce the incidence of CHD by decreasing the 
concentration of coagulation factors. Moreover, in (i) and (iii) above, one wonders if the 
atherogenic effects of the endogenous sex hormones may differ in women and men. Indeed, in 
a study on castrated, cholesterol fed male rabbits, Larsen et al. (1993) found no consistent 
significant differences in aortic cholesterol content between the group in which plasma 
testosterone concentration was restored, compared to the group that was castrated only. In fact, 
the aortic cholesterol content tended to be lower in the testosterone group than the placebo group, 
although not significantly. The suppressive effect of endogenous testosterone on HDLC 
concentration in men compared to women may possibly contribute to the increased risk of CHD 
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in men (Bagatell and Bremner 1995). It is, however, difficult to determine whether equivalent 
HDLC con_centration confers equivalent risk in men and women. Indeed; a low HDLC 
concentration appears to be a stronger predictor of atherosclerotic disease in women than in men 
(Gordon et al., 1989). 
If endogenous testosterone had a significant atherogenic effect in men, one would expect to 
find a lower incidence of premature CHD in men who tended to be hypotestosteronaemic 
compared to men with normal testosterone concentration. In fact, the opposite trend.appears to 
be the case. In a recent review of studies dealing with the relationship between circulating 
testosterone concentration and CHD in men, Alexandersen et al. (1996) examined five 
prospective studies, none of which showed any relation, and twenty-nine cross-sectional case-
control studies, all but one of which showed either an inverse or a neutral association. They 
concluded that these studies suggest either a neutral or a favourable effect of endogenous 
testosterone on CHD in men. The association of endogenous testosterone with more favourable 
cardiac health in men is consistent with the finding that low concentrations of SHBG and 
testosterone are associated with the atherogenic smaller, denser LDL in normoglycaemic men 
(Haffner et al., 1996). This association is also consistent with a review by Bagatell and Bremner 
(1995) of 18 cross-sectional reports which examined the relationship between plasma 
testosterone and plasnia HDLC concentration. Most of these studies reported a positive 
relationship. In only two studies were testosterone concentrations associated with lower 
concentrations ofHDLC (although a recent study by Handa et al. (1997) must also be added to 
this total), and in three additional studies, no relationship was observed. 
It is likely that the association between HDLC and endogenous testosterone concentration 
may be influenced by multiple factors, including disease states and lifestyle ( e.g., smoking, 
exercise), and factors such as body mass index, fat distribution and waist to hip ratio (Bagatell 
and Bremner, 1995). In general, factors that decrease HDLC concentration also decrease 
testosterone concentration (Plyrnate and Swerdloff, 1992). In particular, insulin has been shown 
to suppress SHBG, which in turn results in a reduction in the total plasma testostero~e_ 
concentration (Bagatell and Bremner, 1995; Plyrnate and Swerdloff, 1992). Therefore, it is not 
surprising that on a population basis, men with high plasma insulin concentration might also 
show lower concentrations of testosterone and HDLC (and higher triglyceride concentration), and 
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conversely, men with higher testosterone concentration would also have a higher HDLC 
concentration and a lower triglyceride concentration (Bagatell and Bremner, 1995). It is also 
possible that the apparent association between low testosterone concentration and poor cardiac 
health might be accounted for by a secondary reduction in testosterone caused by the disease 
process. Indeed, rabbits with diet induced atherosclerosis show increased oestradiol and insulin 
concentrations, and decreased testosterone and thyroid hormone concentrations, which suggests 
that the hormonal changes may in some cases be a consequence of the disease 
(Wojcicki et al., 1989). 
An increase in Lp(a) concentration in males following ·orchidectomy indicates that 
endogenous testosterone has a suppressive effect on Lp(a) concentration (Berglund et al., 1996). 
Endogenous oestrogen is not likely to influence Lp(a) concentration significantly in males, as 
synthetic oestrogen (polyoestradiol phosphate 480mg/mth i.m.), causing a twenty fold increase 
in plasma oestrogen concentration, has no effect on Lp(a} concentration in orchidectomised 
males (Berglund et al., 1996). In contrast, synthetic testosterone (250mg/wk), causing a doubling 
of plasma testosterone concentration, significantly reduces Lp(a) concentration in normal males 
(Berglund et al., 1996). Contradictory results have been reported on the correlation between 
endogenous testosterone concentration and plasma Lp(a) concentration. One study reported that 
low plasma testosterone concentrations may be correlated with high plasma Lp(a) concentrations 
(Dionyssiou and Katimerzi, 1993 ), whereas two other studies concluded that endogenous 
testosterone is unlikely to be associated with Lp(a) concentrations in men (Haffner et al., 1994; 
Marcovina et al., 1996). 
In summary, there appears to be only one study on the atherogenicity of endogenous 
testosterone in male animals. This study compares the progression of atherosclerosis in 
hypotestosteronaemic compared to eutestosteronaemic rabbits. The results of this study do not 
favour the hypothesis that endogenous testosterone is ·atherogenic in males. There also appears 
to be only one study on the atherogenicity of testosterone in female animals. This study compares 
the progression of atherosclerosis in female monkeys with male pattern testosteronaemia, 
compared to controls. The results of this study suggest that an elevated plasma testosterone 
concentration may be atherogenic in females. Evidence to show an association between 
endogenous testosterone and premature atherosclerosis in human males is limited. While a lower 
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HDLC concentration in men· compared to women may confer increased risk for atherosclerosis, 
it is difficult to quantify the magnitude of this _risk. A suppressive effect on Lp(a) concentration 
may be an antiatherogenic effect of endogenous testosterone in males. The neutral relationship 
between endogenous testosterone and CHD seen in epidemiological studies suggests that 
testosterone may have beneficial cardiovascular effects in men which may counteract apparently 
atherogenic effects. On the whole, there appears to be insufficient evidence to conclude that 
testosterone contributes to the sex difference in the prevalence of premature CHD observed in 
humans. 
Anabolic-androgenic steroids (AAS) 
Several synthetic analogues and derivatives of testosterone were developed when it became 
apparent that testosterone in its natural form cannot be given effectively either orally or by 
parenteral injection. Oral ingestion is followed by rapid ... bsorption into portal blood and first pass 
extraction and degradation by the liver so that only small amounts reach the systemic circulation. 
When testosterone is administered parenterally it is promptly absorbed from the injection vehicle 
and rapidly degraded so that effective concentrations are not sustained in the plasma. Three 
general types of modification have been made to the molecule so as to make it useful for 
therapeutic uses; (i) esterification of the l 7P-hydroxyl group, (ii) alkylation at the l 7cx-position, 
. and (iii) modification of the ring structure of the steroid, particularly substitution at the carbons 
at position 1, 2, 9, or 11 (Wilson) 1988). Most synthetic steroids contain a combination of 
structural changes of the ring and either 17P-hydroxy esterification or 17cx-alkylation 
(Wilson, 1988). 
Alkylation at the l 7cx-position with either a methyl or ethyl group is a common feature of 
most orally active AAS. Such derivatives are effective when given orally because they are more 
resistant to hepatic metabolism, and hence some of the ·agent can pass through the liver to reach 
the systemic circulation in effective amounts. There is no known mechanism for the enzymatic 
removal of the alkyl groups in the body, and they cannot be aromatised to oestradiol, nor can they 
be reduced to dihydrotestosterone. Their metabolites are unlike _those of endogenous anabolic-
androgenic hormones, and some of their physiological effects differ from those ofendogenous 
anabolic-androgenic hormones as well (Wilson, 1988). 
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Parenteral administration of AAS is made possible by the 1 7P-esterification of the steroid 
with various carboxylic acids. This process decreases the polarity of the steroid, making it 
hydrophobic, and more soluble in the oily vehicles used for injection, thereby slowing the release 
of the hormone into the circulation (Wilson, 1988). In general, the longer the carbon chain in the 
ester, the more non-polar and fat-soluble the steroid becomes, and the slower the release of the 
steroid into the circulation (Wilson, 1988). For example, testosterone propionate (3 carbon chain) 
must be administered daily whereas testosterone enanthate (7 carbon chain) and testosterone 
cypionate (8 carbon chain) can be administered every 1 to 3 weeks. After injection, testosterone 
is hydrolysed from the ester and is metabolically identical to endogenous testosterone (Bagatell 
and Bremner, 1996). 
Alteration of the ring structure of the steroids has been utilised both for oral agents and for 
parenteral formulations (Wilson, 1988). In some instances the effect is to slow the rate of 
inactivation; in others it enhances the potency of a given molecule or alters its metabolism. These 
various agents are not converted in the body to testosterone, and like the 17 alkyl derivatives, 
circulate in plasma and are excreted as unique metabolites. Alterations of the ring structure also 
make these steroids resistant to aromatisation (Friedl et al., 1990). 
Another important goal of synthetic anabolic-androgenic hormone development was to 
dissociate the androgenic and anabolic effects so that only the anabolic effects were maintained 
and the androgenic side effects were minimised. As yet it has not been possible to completely 
dissociate the two, and since all androgenic hormones also exert anabolic effects to some degree, 
the term anabolic-androgenic steroid (AAS) is preferred for the synthetic androgenic hormones 
(Lukas, 1993). Substitutions and alterations of testosterone esters other than at the Cl 7 position 
have been employed in the development of high anabolic and low androgenic compounds. For 
instance, 19-nortestosterone esters such as nandrolone decanoate, which have no methyl group 
at C 19, have been found to be long-acting highly anabolic steroids (Hickson, 1989). 
Therapeutic and Nontherapeutic use of AAS 
AAS may be indicated for a number of therapeutic uses. Men with documented testosterone 
deficiency due to either primary (hypergonadotropic) or· secondary (hypogonadotropic) 
hypogonadism, as well as boys with constitutional delay of puberty are candidates for 
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testosterone-replacement therapy (Bagatell and Bremner, 1996). Synthetic testosterone 
replacement in men with hypogonadism induces greater interest in sexual activity and 
improvement in other aspects of sexual behaviour (Bagatell and Bremner, 1996). AAS therapy 
may also be beneficial in patients with haematologic disorders, hereditary angiodema and 
endometriosis (Bagatell and Bremner, 1996). 
Synthetic testosterone replacement therapy may also be beneficial in some elderly men. 
Testosterone concentrations tend to decrease with agi_ng in men. Testosterone deficiency in 
elderly men may lead to asthaenia, decrease in muscle mass, osteoporosis, decrease in sexual 
activity, and in some cases, changes in mood and cognitive function (Swerdloff and 
Wang, 1993). Synthetic testosterone replacement therapy in elderly hypogonadal men improves 
muscle mass by stimulating the rate of protein synthesis (Brodsky et al., 1996; 
Urban et al., 1995), increases muscle strength, decreases bone resorption, increases bone 
formation markers (Wang et al., 1996) and improves mood (Wang et al., 1996a). Moreover, 
visceral obesity in males, which is characterised by relative hypogonadism (Marin et al., 1995), 
is associated with a greater risk of premature CHD than parietal obesity (Casassus et al., 1992). 
Synthetic testosterone supplementation inhibits triglyceride uptake and lipoprotein lipase 
activity (LPLa) and causes a more rapid turnover of triglyceride in the abdominal adipose tissue 
region only (Marin et al., 1995). 
The possibility has been raised that synthetic testosterone may be used as an effective male 
contraceptive. Exogenously administered testosterone inhibits gonadotropin secretion, 
secondarily inhibiting spennatogenesis (Bagatell and Bremner, 1996). A number of clinical trials 
have been conducted recently to evaluate the safety and efficacy of high dose synthetic 
testosterone as a male contraceptive (Matsumoto, 1990). Synthetic testosterone therapy may also 
have a beneficial effect on relieving myocardial ischemia and angina pectoris, by inducing 
dilation of coronary arteries in vivo (Chou et al., 1996; Wu and Weng, 1993; Yue et al., 1995). 
The observation that AAS promote nitrogen retention and muscle mass led to their 
nontherapeutic use to improve physical performance as early as the 1940's, and by the 1950's they 
were being used by weight lifters (Strauss and Yesalis, 1991 ). AAS are now widely used by both 
male and female, professional and recreational athletes alike, to improve athletic performance. 
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Steroid use is becoming increasingly widespread in individuals, such as body builders, who seek 
improvement of physical appearance. In a survey in 1993 it was estimated that there were more 
than one million current or former steroid users in the United States, and that more than three 
hundred thousand individuals used steroids in the year of the study (Yesalis et al., 1993). Doubt 
about the true performance enhancing effects of AAS were finally dispelled in a review of the 
subject by Haupt and Rovere (1984). Their findings were confirmed in a recent study, in which 
it was concluded that supraphysiological doses of synthetic testosterone, especially when 
combined with strength training, increase fat-free mass, and muscle size and strength in normal 
men (Bhasin et al., 1996). 
The therapeutic and nontherapeutic use of AAS has been associated with the risk of 
developing a wide range of temporary and permanent side effects (World Health 
Organisation, 1993). These can be generalised as follows; effects on secondary sex 
characteristics, liver toxicity and liver tumours, infertility and virilisation, psychological effects, 
and cardio- and cerebrovascular effects (World Health Organisation, 1993 ). The undesired effects 
of AAS depend on both the type and dose administered. In general, doses used for replacement 
therapy, and the use of testosterone esters are associated with fewer complications than is the use 
of 17a-alkylated (oral) AAS, particularly at the high doses of alkylated AAS used by many 
athletes and bodybuilders (Bagatell and Bremner, 1996). For example, the apparent 
hepatotoxicity of AAS is unique to the 17a-alkylated (oral) AAS and does not occur with the use 
of I 7P-esterified (parenteral) AAS (Haupt and Rovere, 1984). Similarly, induction of insulin 
resistance and hyperinsulinaemia by AAS appears to occur with oral but not parenteral agents 
(Glazer and Suchman, 1994). More recently it has been proposed that the incidence of serious 
health problems associated with the use of androgens by athletes may have been overstated 
(Street et al., 1996). Based on the available evidence, it has been suggested that the 
administration of moderate doses of an injectable androgen, such a testosterone enanthate or 
nandrolone decanoate, in healthy adult males could induce positive changes in body composition 
and athletic performance with little or no side effects (Street et al., 1996). 
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Are AAS atherogenic? 
Case reports of adverse cardiovascular events associated with the use of AAS 
To date there have been nineteen case reports documenting adverse cardiovascular events in 
twenty-one subjects self-administering AAS (Akter et al., 1994; Appleby et al., 1994; 
Bowman et al., 1989; Bowman, 1990; Dickerman et al., 1995;· Ferenchick et al., 1991; 
Ferenchick et al., 1992; Fisher et al., 1996; Frank!e et al., 1988; Huie, 1994; Jaillard et al., 1994; 
Kennedy, 1993; Kennedy et al., 1993a; Laroche, 1990; Luke et al., 1990; Lyngberg, 1991; 
McNutt et al., 1988; Mewis et al., 1996; Mochizuki and· Richter 1988; Siekierzynska-
Czarnecka et al., 1990). All of these subjects were male, sixteen were bodybuilders, four 'weight 
lifters' and one a 'college athlete'. Ten subjects were in their third decade, six in their fourth, two 
in· their fifth and the rest unknown. Myocardial infarction was diagnosed in twelve cases, 
cerebrovascular accident in five and cardiopulmonary arrest, sudden cardiac death, pulmonary · 
embolism and congestive heart failure in the remainder. There have been eight case reports, 
documenting adverse cerebrovascular events in fourteen patients receiving therapeutic 
administration of AAS (De Stefano et al., 1988; Krauss et al., 1991; Nagelberg et al., 1986; 
Reeves et al., 1976; Shah et al., 1987; Shiozawa et al., 1982; Shiozawa et al., 1986; 
Tully et al., 1990). Many of these appear to have been acute thrombotic events. 
Information obtained from these case studies is, however, difficult to interpret. It is seldom 
possible to assess whether AAS induced premature atherosclerosis may have contributed to the 
aetiology of the event. An attempt was made to assess the extent of atherosclerosis in only seven 
of these cases; no evidence of atherosclerosis was found in four cases (Ferenchick and 
Adelman, 1992; Fisher et al., 1996; Kennedy et al., 1993a; Luke et al., 1990), 'mild' 
atherosclerosis was reported in one (Dickerman et al., 1995) and marked atherosclerosis was 
reported in two (Bowman et al., 1989; Mewis et al., 1996). Moreover, in cases where indiv~duals 
may have premature atherosclerosis, it is seldom possible to account in full for other potential 
confounding factors, such as a genetic predisposition to cardiovascular disease, unhealthy 
lifestyle habits, or an underlying disease state which may predisposes to premahl!:~ 
atherosclerosis. 
Chapter I : Literature Review 16 
The data obtained from case reports may be used to indicate that AAS might predispose 
particular individuals to premature atherosclerosis. The observation that adverse cardiovascular 
events appear to be precipitated by an acute thrombosis in many of the cases, indicates that 
particular attention should be paid to the proposal that AAS may be thrombogenic in some 
individuals (Ferenchick, 1990; Ferenchick, 1991; Ferenchick et al., 1992). It is possible that the 
use of AAS together with other drugs and supplements may create a particularly thrombogenic 
setting in some weightlifters and bodybuilders (Welder and Melchert, 1993). It should be noted, 
however, that the data obtained from these case reports provides no indication of whether AAS 
users are more likely to suffer from premature atherosclerotic disease than non-users. 
Does synthetic testosterone replacement in hypogonadal males increase risk of premature 
atherosclerosis? 
It is unknown whether synthetic testosterone replacement will increase the incidence of CHD 
in hypogonadal males. An indication of potential risk for premature atherosclerosis is currently 
sought in the traditional lipoprotein risk factors. In a recent study by Zgliczynski et al. (1996), 
testosterone enanthate (200mg/2wk i.m.) was administered to eleven men (18-77yr.} with 
hypopituitarism and eleven otherwise healthy elderly men with low testosterone concentrations 
for one year. It was found that synthetic testosterone replacement therapy may have a beneficial 
effect on lipid metabolism in hypogonadal and elderly men, by decreasing LDLC concentration 
without significant alterations in HDLC concentration. These data are consistent with earlier 
studies on elderly hypogonadal men, in which a similar dose of synthetic testosterone was 
administered for a period of three months, resulting in a decrease in total cholesterol without a 
change in HDLC concentration (Morley et al., 1993; Tenover, 1992). 
Results from studies on young hypogonadal men have been equivocal. Two studies have 
examined young hypogonadal men, having either idiopathic hypogonadism or Klinefelters 
syndrome. In one study, LDLC concentration increased by 14% and HDLC concentration was 
unchanged, four weeks after a testosterone ester implant (Jones et al., 1989). In the other study, 
LDLC concentration was increased by 6% and HDLC concentration by 13%, three weeks after 
a course of synthetic testosterone (Sustanon 250mg/wk) (Ozata et al., 1996). One other study has 
examined young hypopituitary males. A four week treatment with testosterone enanthate 
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(100mg/2wk) resulted in non-significant decreases in both HDLC and LDLC concentration 
(Sorva et al., 1988). 
In summary, it remains unclear whether synthetic testosterone replacement therapy will 
increase dsk for premature atherosclerosis in young hypogonadal men. Preliminary assessment 
of lipoprotein risk factors does not indicate an increased risk for premature atherosclerosis in 
, elderly hypogonadal men receiving synthetic testosterone replacement therapy. Since 
cardiovascular disease is a major cause of morbidity and mortality in older men, further research 
will be required before an evaluation can be made on the practicality of synthetic testosterone 
replacement therapy on a widespread basis (Bagatell and Bremner, 1995). 
Does the administration of 17P-esterified (parenteral) AAS increase risk for premature 
atherosclerosis? 
There appears to be no direct evidence linking t:1e use of parenteral AAS with premature 
atherosclerosis in humans. Accordingly, an indication of atherosclerotic risk associated with 
parenteral AAS use in humans, is currently sought in the traditional lipoprotein risk factors. The 
effects of testosterone enanthate (200mg/wk) on HDLC and LDLC concentration have been 
monitored in five studies for up to twelve months, (Anderson et al., 1995; Bagatell et al., 1994; · 
Meriggiola et al., 1995; Thompson et al., 1989; Zmuda et al., 1993). These studies reported 
HDLC concentration reductions of between 9-21 %, with no change in LDLC concentration in 
fow studies, and a significant decrease in LDLC concentration in the other (Thompson et al., 
1989). One other study has examined the effects of testosterone enanthate (280mg/wk) on HDLC 
and LDLC concentration, finding no significant changes in either after a twelve week course of 
treatment (Friedl et al., 1990). 
Two studies have examined the effects of testosterone cypionate on HDLC and/or LDLC 
concentration (Crist et al., 1986; Kouri et al., 1996). In one study testosterone cypionate 
(1 OOmg/wk) was found to reduce HDLC concentration by 13% (Crist et al., 1986), and in the 
other, testosterone cypionate (300mg/wk) was found to reduce HDLC concentration by 21 %, 
with no further reductions after doubling the dose to 600mg/wk for an additional three weeks 
(Kouri et al., 1996). Testosterone cypionate had no effect on LDLC concentration 
(Kouri et al., 1996). An additional two studies have examined the effect of nandrolone decanoate 
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(1 OOmg/wk) on HDLC and LDLC concentration (Glazer and Suchman,_ 1994; Crist et al., 1986). 
In one study no effect was detected (Glazer and Suchman, 1994) and in the other a 16% reduction 
in HDLC concentration was reported (Crist et al., 1986). 
The effects of testosterone enanthate (200mg/wk) on Lp(a) concentration has been examined 
in three studies, all of which reported a significant reduction in the mean Lp(a) concentration, of 
between 22-37% (Anderson et al., 1995; Marcovina et al., 1996; Zmuda et al., 1996). The Lp(a) 
response to synthetic testosterone treatment was found to vary widely among subjects and 
appears to be dependent on the pretreatment concentration, with no significant change being seen 
in those with a concentration less than 25 nmol/L, and a significant reduction being seen in those 
with a concentration greater than 25 nmol/L (Marcovina et al., 1996). 
A literature search revealed only one study which has examined the atherosclerotic effect of 
testosterone supplementation in male animals. In this study, excess synthetic testosterone was 
administered to one week-old male chicks (Toda et al., 1984). A seven week treatment of 30mg 
synthetic testosterone per day had little effect on plasma lipid metabolism. However, this 
treatment resulted in the activation of fibroblasts in the comb, activation of fibroblast-like and 
smooth muscle cells in the aorta, and degeneration of smooth muscle cells in the aorta. In the 
same study, treatment of one week-old male chicks with 150mg of synthetic testosterone per day 
for seven weeks induced hyperlipidaemia and lipid-rich aortic lesions (Toda et al., 1984). The 
high doses of testosterone administered, and the early developmental stage of these animals 
makes the relevance of this data to adult humans uncertain. 
A literature search revealed only one study which has examined the atherosclerotic effect of 
parenteral AAS in female animals. In this study, nandrolone decanoate (25 mg/3 wk) was 
administered to female cynomolgus monkeys fed a moderately atherogenic diet for two years 
(Obasanjo et al., 1996). It was found that the extent of coronary artery atherosclerosis was 
significantly greater in the group administered nandrolone decanoate compared to controls. 
Interestingly, the nandrolone decanoate group had significantly larger arteries and lumen area 
than the control monkeys. Longer treatment with nandrolone decanoate did however result in 
increased atherosclerotic plaque size and the possible benefit of increased lumen size was 
compromised (Obasanjo et al., 1996). 
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In summary, the reduction of HDLC concentration by the parenteral AAS may indicate an 
increase in risk for premature atherosclerosis in humans. In contrast, the reduction in Lp(a) 
concentration may indicate a decrease in risk for premature atherosclerosis. It is unknown if these 
factors will counteract each other. Evidence to provide a direct link between the 1 7P-esterified 
(parenteral) AAS and premature atherosclerosis in humans is limited. One study in male animals 
indicates an atherogenic effect of supraphysiological doses of synthetic testosterone in one week-
old chicks, and one study in female animals indicates an atherogenic effect of nandrolone 
decanoate in monkeys. Although it is uncertain whether this data can be extrapolated to humans, 
close attention needs to be paid to the possibility that the effects of the 17P-esterified (parenteral) 
AAS may differ in adolescents and women compared to men. 
Does the therapeutic use of 17a-alkylated (oral) AAS increase risk for premature 
atherosclerosis? 
Ten studies have examined the effect of AAS therapy on lipid and lipoprotein risk factors in 
humans, using l 7a-alkylated (oral) AAS (Albers et al., 1984; Applebaum-Bowden et al., 1987; 
Cheung et al., 1980; Crook et al., 1992; Farish et al., 1995; Friedl et al., 1990; 
Haffner et al., 1983; Olsson et al., 1974; Taggart et al., 1982; Thompson et al., 1989). All of 
these studies reported significant reductions in HDLC concentration of between 35-50%, and 
significant elevations in LDLC concentration of between 10-30% (excluding Albers et al. who 
reported a non-significant increase in apoB concentration). The Lp(a) concentration was 
measured in three studies, all of which reported significant reductions· of between 38-79% 
(Albers et al., 1984; Crook et al., 1992; Farish et al., 1995). 
There appears to be no direct evidence linking the use of 17a-alkylated (oral) AAS with 
premature atherosclerosis in humans. One animal study has examined the effect of stanozolol on 
HDLC concentration, LDLC concentration and atherosclerotic development in cholesterol fed 
rabbits (Fogelberg et al., 1990). No significant influence of stanozolol on either atherosclerotic 
extent or on HDLC or LDLC concentration was found. The authors did, however, comment that 
the influence of stanozolol on the development of atherosclerosis could not be excluded, because 
of the finding that two out often stanozolol treated rabbits on normal diet developed macroscopic 
atherosclerosis compared to none out of the seventy-two rabbits of the same age from previous 
studies given the same normal diet. 
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In summary, the combination of a significant increase in LDLC concentration and significant 
decrease in HDLC concentration is strongly suggestive of an increase· in risk for premature 
atherosclerosis in humans. It is uncertain how the reduction in Lp(a) concentration will modify 
this relationship. Evidence to provide a direct link between the therapeutic use of 17a-alkylated 
(oral) AAS and premature atherosclerosis in humans and animals is limited. 
Does the non-therapeutic use of combined 17P-esterified (parenteral) and 17a-alkylated 
(oral) AAS increase risk for premature atherosclerosis? 
Athletes and bodybuilders who use AAS, typically self-administer high doses of a 
combination of several different oral and parenteral agents (Lukas, 1993). The possible 
atherosclerotic effect of this practise has been the subject of intense interest. To date, twenty-two 
studies have examined the relationship between the (self-administered) non-therapeutic use of 
AAS and lipid and lipoprotein profiles (Alen and Rahkila, 1984; Alen et al., 1985; 
. Baldo-Enzi et al., 1990; Baumstark et. al., 1988; Cohen et al., 1986; Cohen et al., 1988; 
Cohen et al., 1996; Costill et al., 1984; Faber et al., 1986; Hurley et al., 1984; 
Kantor et al., 1985; Kiraly, 1988; Kleiner et al., 1989; Kuipers et al., 1991; Lajarin et al., 1996; · 
Lenders et al., 1988; McKillop and Ballantyne, 1987; Moffat et al., 1990; Peterson arid 
Fahey, 1984; Webb et al., 1984; Yeater et al., 1996; Zuliani et al., 1988). All of these studies 
. report that this pattern of AAS use is associated with a marked reduction in HDLC concentration 
(except for Cohen et al. (1988) who did not report HDLC concentration). Studies which have 
compared HDLC concentration before and after mixed non-therapeutic steroid use, report HDLC 
concentration reductions of between 50-70% (Alen and Rahkila, 1984; Alen et al., 1985; 
Baldo-Enzi et al., 1990; Faber et al., 1986; Hurley et al., 1984; Kleiner et al., 1989; 
Kuipers et al., 1991; Lajarin et al., 1996; Lenders et al., 1988; Peterson and Fahey, 1984; 
Webb et al., 1984; Zuliani et al., 1988). Studies which have compared LDLC concentration 
before and after mixed non-therapeutic steroid use, report LDLC concentration increases of 
. between 25-35% (Baldo-Enzi et al., 1990; Faber et al., 1986; Hurley et al., 1984; 
Kleiner et al., 1989; Lajarin et al., 1996; Lenders et al., 1988; Webb et al., 1984). 
Two studies have examined the effects of mixed non-therapeutic AAS use on Lp(a), both of 
which reported a suppression of Lp(a). concentration (Cohen et al., 1996; Lajarin et al., 1996). 
One study found that Lp(a) was undetectable in their subjects four weeks after commencing 
r 
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steroid use (Lajarin et al., 1996). There appear to be no controlled studies to provide a direct link 
between the non-therapeutic use of AAS with an increased incidence of premature atherosclerosis 
in athletes or bodybuilders. Moreover, there appear to be no animal studies in which the pattern 
of steroid use typically seen in athletes and bodybuilders is simulated. 
In summary, (self-administered) non-therapeutic use of AAS results in marked reductions in 
HDLC and Lp(a) concemration, -and elevations in LDLC concentration. Reduction of HDLC 
concentration tends to be slightly greater (approximately 10%) than.the reductions seen in 
controlled studies. The combination of a significant increase in LDLC concentration and 
significant decrease in HDLC concentration is a strong indicator of an increase in risk for 
premature atherosclerosis. However, the lack of prospective or retrospective data to establish a 
link between AAS and premature atherosclerosis makes the significance of an AAS induced 
lipoprotein profile change in otherwise healthy individuals uncertain. 
It has been estimated that if the contributions to CHD risk ofHDLC concentration depression· 
and LDLC concentration elevation are considered together, CHO risk is increased about 3-6 
times in athletes and bodybuilders who use AAS (Glaze~, 1991). Giv~n the apparent increase in 
. atherosclerotic risk, one would expect to have seen a significant increase in atherosclerotic 
complications in AAS users (Wilson, 1988). It is perhaps surprising, that in spite of there having 
been more than one million AAS users in the United States alone (Y esalis et al., 1993 ), and that 
AAS were first used by athletes as early as the 1950's (Strauss and Yesalis, 1991), little direct 
evidence has been forthcoming to support the hypothesis that AAS use will cause premature 
atherosclerosis. In mitigation, the relative paucity of reports linking AAS with atherosclerotic 
complications may be accounted for by a number of factors: (i) individuals may be reluctant to 
admit AAS use, since non-therapeutic use of these agents is illegal in many countries (including 
South Africa), (ii) the identification of AAS as a causative factor in cardiovascular events is 
difficult; (iii) it is possible that a lag phase may be required for .the true prevalence of vascular 
complications to become evident (Wilson, 1988), and (iv) ethical and funding constraints have 
impeded efforts to coµduct definitive studies on the role played by AAS in atherosclerosis 
(Cowart, 1989). Nevertheless, it has also been argued that the intensity of medical interest in 
reporting assumed cases is likely to compensate for ~he reluctance of AAS users to admit use 
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(Rockhold, 1993). Moreover, the possibility cannot at present be excluded that the adverse 
cardiovascular effects of AAS may have been overstated (Street et al., 1996). 
Mechanism of anabolic-androgenic hormone induced lipoprotein concentration changes 
The higher endogenous testosterone concentration in men compared to women induces a 
relatively increased hepatic triglyceride lipase activity (HTGLa) (Applebaum-Bowden, 1984). 
HTGL is responsible for the catabolism of HDL and for conversion oflipoprotein particles from 
the HDL2 density fraction to the HDL 3fraction (Eisenberg, 1984). Increased lipolytic degradation 
due to an increased HTGLa is believed to be the principal cause of the reduced HDLC and 
particularly HDL2C concentration in men compared to women (Applebaum et al., 1987; 
Baldo-Enzi et al., 1990; Crook et al., 1992; Haffner et al., 1983; Kantor et al., 1985). 
Endogenous testosterone appears to have relatively little effect on plasma LDLC, VLDLC or on 
fasting triglyceride concentrations (Asscheman et al., 1994; BagateU and Bremner, 1995). The 
sex. difference in LDLC concentration is more likely to be due to the higher oestrogen 
concentration in women, than to a high testosterone concentration in men. Oestrogen appears to 
lower LDLC concentration by accelerating the rate of LDL catabolism, possibly by increasing 
LDL receptor messenger RNA transcription and thereby increasing the number of hepatic LDL 
receptors (Sacks et al., 1995). 
The cause of the disparity in the magnitude of HDLC concentration depression between the 
parenteral and the oral AAS remains unclear. It is likely that differences in their routes of 
administration and their metabolic pathways contribute to the observed difference. Orally 
administered agents are absorbed into the portal circulation but are somewhat resistant to hepatic 
metabolism, resulting in high hepatic AAS concentrations shortly after ingestion (Bagatell and 
Bremner, 1995). HTGL, is found in highest concentration in the liver, and it is likely that high 
local concentrations of AAS stimulate its activity (Bagatell and Bremner, 1995). Indeed, 
significant elevations in HTGLa are consistently reported in studies in which oral AAS are 
administered, whereas elevations in HTGLa are relatively small with parenteral AAS use 
(Bagatell and Bremner, 1995; Glazer and Suchman, 1994). The significant increase in HTGLa 
caused by the 17a-alkylated AAS is believed to increase LDLC concentration as the final product 
of an accelerated VLDL catabolism (Baldo-Enzi et al., 1990). Modification of apoB synthesis, 
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and a decreased lecithin cholesterol acyl transferase (LCAT) activity, could also be partially 
responsible for the increase in LDLC concentration in users of AAS (Albers et al., ·1984; 
Crook et al., 1992). 
The aromatisation of AAS to oestrogens also accounts in part for the lesser suppression of 
HDLC concentration by the 17P-esterified AAS compared to the 17a-alkylated AAS (Bagatell 
and Bremner, 1995). Testosterone esters readily aromatise to 17P-oestradiol while the 17a-
alkylated AAS do not form potent oestrogens (Friedl et al., 1990). Since oestrogens decrease 
HTGLa and AAS increase HTGLa, each producing inverse changes in HDLC concentration, 
aromatisation of synthetic testosterone to oestradiol may mitigate an anabolic-androgenic effect. 
Blocking synthetic testosterone aromatisation augments the elevation in HTGLa and. the 
reductions in HDL2C and apoA-I concentrations (Thompson et al., 1989). The net effect of AAS 
administration on HDLC concentration may thus be related to the metabolic fate of that particular 
AAS, particularly in the degree of aromatisation to oe~trogens (Friedl et al., 1990). 
Anabolic-androgenic hormones may also reduce HDLC concentration by reducing HDL 
synthesis, and by increasing removal by receptors (Baldo-Enzi et al., 1990). AAS use reduces 
HDLC concentration by affecting apolipoprotein metabolism, causing a significant decrease in 
apoA-I concentration in the HDL2 subfraction and a significant decrease in both apoA-I and 
apoA-II concentration in the HDL3 subfraction (Baldo-Enzi et al., 1990). Treatment with the oral 
AAS, stanozolol, is associated with a decrease in residence times for apoA-I and apoA-II, as well 
as a marked decrease in the rate of apoA-I synthesis but essentially no change in the rate of apoA-
II synthesis (Haffner et al., 1983). The low apoA-I concentration could explain the reduced 
percentage of cholesterol esterification observed in steroid users, because this apolipoprotein acts 
as a cofactor of LCAT (Baldo-Enzi et al., 1990). LCAT concentration also decreases markedly 
during treatment with stanozolol (Albers et al., 1984). A significant decrease in both LCAT 
substrate particles and LCA T could potentially retard reverse cholesterol transport. 
HDLC concentrations fall to their nadir within one week after initiating AAS use and tend 
to return to pretreatment concentrations 3-5 weeks after cessation of AAS use with no significant 
residual HDLC concentration depression (Glazer, 1991). In particularly heavy users, the HDLC 
concentration may not reach the baseline value until 12 to 14 weeks after cessation 
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(Alen et al., 1985; Lajarin et al., 1996). There is a lack of dose relationship in AAS induced 
HDLC concentration depression, which may be explained by a similar increase in HTGLa, 
regardless of whether AAS dose is therapeutic or supra-therapeutic. Similar hepatic triglyceride 
lipase (HTGL) induction by the various AAS doses may reflect a saturation of receptors 
mediating AAS induced HTGL increase that occurs at or below therapeutic AAS dosages 
(Glazer, 1991). 
Exogenous anabolic-androgenic hormones have a profound suppressive effect on Lp(a) 
concentration (Crook et al., 1992; Farish et al., 1995). The mechanisms for Lp(a) synthesis and 
clearance have, however, not been clarified (Berglund et al., 1996). AAS may affect Lp(a) 
concentration by reducing apo(a) synthesis or secretion by impairing Lp(a) assembly, or by 
affecting Lp(a) catabolism (Crook et al., 1992). Anabolic steroids modify the action of various 
enzyme systems, including hepatic hydrolytic enzymes, which could lead to an effect on 
synthesis or processing ofLp(a) (Crook et al., 1992). Because apoB usually does not decrease 
with anabolic-androgenic hormone treatment, it is likely that Lp(a) is under separate metabolic 
control from VLDL and LDL, and furthermore Lp(a) is probably not a catabolic product of 
VLDL (Albers et al., 1984). 
Conclusion of literature review 
It has been hypothesised that testosterone may contribute to the sex difference in the 
prevalence of premature CHD in humans. Evidence reviewed in this chapter suggests that male 
pattern testosteronaemia may be atherogenic in females. However, there appears to be 
insufficient evidence to conclude that endogenous testosterone is atherogenic in males. 
Additional animal studies, particularly in hypogonadal compared to eugonadal male animals, will 
help to clarify whether endogenous testosterone is atherogenic. Although equivalent human 
studies are limited by ethical and practical constraints, the recent development of drugs which 
allow a reversible suppression of endogenous testosterone may provide new opportunities to 
investigate the effect of endogenous testosterone on atherosclerotic risk factors in human males. 
Anecdotal accounts indicate a widespread belief that AAS users will suffer from premature 
atherosclerotic disease. The recent publication of a number of case reports showing adverse 
Chapter 1 : Literature Review 25 
cardiovascular events associated with_ AAS use, may be viewed as supportive of this belief. 
However, it is seldom possible to conclude from these reports whether AAS induced premature 
atherosclerotic disease caused the adverse cardiovascular events. Studies seeking inferential 
evidence for an atherosclerotic effect of AAS, indicate that l 7P-esterified (parenteral) AAS may 
have fewer potentially atherogenic effects than l 7a-alkylated (oral) AAS. There appear to be few 
animal studies which have investigated the atherosclerotic effects of AAS. Data obtained in 
female animals suggests. that close attention needs to be paid to the possibility that the adverse 
effects of AAS may differ in males compared to females. On the whole, adverse cardiovascular 
events associated with AAS use in humans appear to be rare. Moreover, there appears to be 
insufficient evidence to prove the hypothesis that AAS users have a greater prevalence of 
premature atherosclerotic disease compared to matched non-users. Until such time as data 
becomes available to allow a comparison of atherosclerotic progression in AAS users compared 
to non-users, additional studies into the effect of AAS on· risk factors for premature 
atherosclerosis will allow a better prediction to be made about the potential adverse 
cardiovascular events associated with the use of these agents. 
There is presently very little information to show whether endogenous testosterone and AAS 
may influence the lipid and lipoprotein components of the 'atherogenic dyslipidaemia' 
phenotype. The effect of AAS on plasma triglyceride clearance has been investigated in only two 
studies (Olsson et al., 1974; Thompson et al., 1989), neither of which discussed their data in 
relation to 'atherogenic dyslipidaemia'. It is also unknown how AAS influence LDL particle size. 
There is a paucity of information about the effect of endogenous testosterone suppression in 
healthy men, on postprandial triglyceridaemia and LDL size. Moreover, it is unknown whether 
the increased HDLC concentration associated with a reduced testosterone concentration is 
related, at least in part, to the magnitude of postprandial triglyceridaemia. There appears to be· 
only one study which has investigated the effect of endogenous testosterone suppression on Lp(a) 
concentration (von Eckardstein et al., 1997). Accordingly, the studies described in the subsequent 
experimental chapters were undertaken to clarify these issues. 
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Chapter 2: The theoretical basis for the experimental chapters 
The underlying cause of 'atherogenic dyslipidaemia' appears to be an overproduction and/or 
an impaired clearance of triglyceride rich lipoproteins (TGRL ). The following chapter describes 
the metabolism of TGRL, the potential atherogenic effects of these lipoproteins, and their 
potential to influence the atherogenicity of LDL and HDL. Because the exact relationship 
between HDL and atherosclerosis remains unclear, this chapter also provides a briefreview of 
the present understanding of the role played by HDL in atherosclerosis. 
Digestion and absorption of dietary triglyceride 
Enzymatic hydrolysis of triglycerides begins in the stomach, where as much as 30% of the 
dietary triglyceride may be digested (Carey et al., 1983). The stomach chyme is propelled into 
the intestine, where bile and pancreatic secretions (lipase and co lipase) mix. Triglyceride is 
hydrolysed into a 2-monoglyceride and two free fatty acids, which cross the .microvillus 
membrane into the enterocyte by passive diffusion (Guyton, 1986). Normally, over 90% of 
triglyceride is absorbed, which means that, in an average adult, roughly 80-170 mmol (70-1 SOg) 
of exogenous triglyceride enters the circulation per day. Short chain fatty acids can at this point 
pass through the cell and be accepted onto albumin which will carry them to th~ liver by the 
portal circulation (Guyton, 1986). The long chain fatty acids and to some extent also short chain 
fatty acids that have been elongated, are re-esterified to triglyceride in the smooth endoplasmic 
reticulum of the enterocyte (Guyton, 1986). The re-esterified triglyceride forms oil droplets 
within the smooth endoplasmic reticulum which are associated with phospholipid, cholesterol 
and cholesterol ester. Some apolipoproteins, notably apoB48, apoA-I, and apoA-IV, are added, 
and the vesicles are secreted through the basolateral aspect of the enterocytes into lacteals 
(Thompson, 1994). These particles, which are now assembled lipoproteins, are termed 
chylomicrons, and act as the transporters of most of the dietary triglycerides. The lacteals 
converge and ultimately drain into the cystema chyli just below the diaphragm. From here the 
thoracic duct takes the chyle upwards until it joins the left brachiocephalic vein, where it mixes 
with the systemic venous blood (Guyton, 1986). 
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Chylomicron and chylomicron remnant metabolism 
Once in the general circulation, these very large (> 100 run in diameter), triglyceride enriched 
lipoproteins undergo several modifications associated with triglyceride hydrolysis and are 
ultimately converted to chylomicron remnants, which are then cleared from the blood primarily 
by the liver (Mahley and Hussain, 1991 ). There ate three primary intra-vascular modifications: 
(i) The chylomicrons acquire C apolipoproteins from other circulating lipoproteins. ApoC-11 
facilitates binding of chylomicrons to LPL, which is found mainly in adipose tissue and skeletal 
and cardiac muscle, where it is attached to the luminal surface of the capillary endothelium. LPL 
catalyses the hydrolysis of triglyceride, while the particles are bound to the capillary endothelium, 
resulting in the liberation of free fatty acids, which are taken up, modified and stored as 
triglycerides in adipose tissue, or are used as an energy source in muscle and other tissues 
(Olivecrona and Bengtsson-Olivecrona 1990; Olivecrona and Bengtsson-Olivecrona 1990a). The 
rate of removal of chylomicrons from plasma is rapid, with a half-life of less than one hour 
(Thompson 1994). (ii) The particles lose lipids and proteins from their surface as a result of a 
reduced volume caused by the loss of the triglyceride core. It is believed that sheets of 
phospholipid and apolipoproteins (especially apoA-1) are shed from the partially hydrolysed 
chylomicrons. These sheets give rise to HDL particles and represent one source of intra vascular 
HDL formation (Tall, 1996). Residual triglyceride in the chylomicron remnants is hydrolysed by 
HTGL located on the luminal surface of hepatic endothelial cells (Mahley and Hussain, 1991). 
Although less active than LPL, HTGL is unaffected by the inhibitors and activators of the of the 
extrahepatic enzyme. (iii) The hydrolysed chylomicrons (chylomicron remnants) acquire apoE 
from other plasma lipoproteins. This modification targets the remnants primarily to the liver, 
where they are catabolized (Mahley and Hussain, 1991 ). The apoB48 associated with chylomicron 
lacks the receptor-binding domain present in apoB 100 thus, the apoE on chylomicron remnants 
appears to be the critical protein determining their plasma clearance and hepatic uptake, binding 
to LDL receptor and the related receptor, LDL receptor related protein. 
VLDL metabolism 
Although similar to chylomicrons in structure and composition, VLDL are small~r 
.(40-100 run), contain less triglyceride and more cholesterol, phospholipid and protein, primarily 
apoC, apoE and apoB100 (Thompson, 1994). VLDL particles show a considerable variation in 
size, smaller particles having a lower ratio of apoC:apoB than larger ones (Thompson, 1994). 
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VLDL are mainly synthesized in the liver and their chief function 1s the transport of 
endogenously synthesised triglyceride (Thompson, 1994). VLDL synthesis is promoted by (i) an 
increase in the flux of free fatty acid to the liver, originating from the hydrolysis of exogenous 
lipid, (ii) an increase in the rate of hepatic synthesis of endogenous fatty acids, as occurs during 
a period of high carbohydrate intake (Thompson, 1994), and (iii) when supplied by incoming fat 
in the form of chylomicron remnants (Bradley and Gianturco, 1994). 
Triglyceride hydrolysis of VLDL is mediated by apoC-U interaction with LPL, which reduces 
the size of these particles, and they are then referred to as VLDL remnants or intermediate.density 
lipoprotein (IDL) (Thompson, 1994). The ability of LPL to effect removal of triglyceride is 
potentially saturable arid excessive accumulation of VLDL in plasma can impair chylomicron 
metabolism (Karpe et al., 1993). The function of HTGL in VLDL clearance is less well 
established, but it is probably involved in the hydrolysis of most of the residual triglyceride in 
the VLDL ·remnant particles, resulting in the formation of LDL. There is evidence that a gr~ater 
proportion of small VLDL particles (S1 20-60) are converted into LDL via IDL as compared with 
large VLDL (Sr60-400), which are converted to a form ofIDL which is removed from plasma 
before undergoing conversion to LDL (Packard et al., 1984). The rate of VLDL clearance in 
humans is less rapid than that of chylomicrons, with a half life of 2 - 4 hours. LDL particles have 
a much longer half life. The catabolism of VLDL into IDL and then into LDL thus leads to the 
transport of cholesterol by the LDL receptor pathway (Thompson, 1994). Any cell with a 
cholesterol requirement can upregulate the LDL receptor to increase cholesterol uptake. 
Postprandial triglyceridaemia 
Postprandial triglyceridaemia comprises the (non-steady) state of plasma lipoproteins 
between fat ingestion and the postabsorptive state, until triglyceride metabolism has again 
reached a state of equilibrium. The time taken between swallowing and digestion is a minimum 
of about 25 minutes. The rise of plasma triglyceride concentration occurs about 1 hour after 
ingestion of a fatty meal, peaks between 3 and 6 hours later, and usually reaches baseline by 8-12 
hours. This means that the systemic circulation is exposed to absorbed fat, in a pulsed fashion 
after each meal. Both chylomicron and VLDL contribute to postprandial triglyceridaemia 
(Cohn et al., 1989), and are collectively known as the triglyceride rich lipoproteins (TGRL). 
Increase in plasma triglyceride concentration in healthy human subjects usually peaks once or 
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twice in the twelve-hour period following the ingestion of a fat-rich meal, and intestinal 
lipoproteins make a significant contribution to both earlier and later peaks (Cohn et al., 1989; 
Karpe et al., 1993). 
The magnitude of postprandial triglyceridaemia is defined as the extent and duration of the 
rise of plasma triglycerides in response to a standardised fatty meal. While a number of factors 
may influence the magnitude of postprandial triglyceridaemia (in the absence of gastrointestinal 
disease, variations in fat digestion and absorption can be ignored), the efficiency of triglyceride 
clearance by LPL and HTGL is clearly the most important (Ebenbichler et al., 1995). A 
deficiency in triglyceride clearance leads to the accumulation ofTGRL in plasma and an elevated 
postprandial triglyceridaemia. It important to emphasise that an exaggerated postprandial 
triglyceridaemia is not necessarily associated with an elevated fasting triglyceride concentration 
or hypertriglyceridaemia (Patsch et al., 1983). An exaggerated postprandial triglyceridaemia 
could however be viewed as a transient hypertriglyceridaemia (Karpe et al., 1994). 
The role of TGRL in the development of atherosclerosis 
Until recently, the close metabolic relationship between triglyceride, HDL and LDL 
subfractions has been poorly understood, because lipid and lipoprotein analysis has traditionally 
been confined to the post-absorptive ( overnight fasting) state. Studies into postprandial lipid 
metabolism were largely neglected, which is surprising, since we spend most of our lives in the 
postprandial state. The fact that epidemiological studies did not include determinations of 
postprandial lipoproteins, may have contributed to the persisting confusion concerning the role 
of triglyceride as a risk factor for CHD, and has led historically to a downgrading of plasma 
triglyceride as a coronary risk factor in multivariate analyses (Karpe et al., 1994). In the past 
decade, however, studies on lipoproteins in the postprandial state have provided compelling 
evidence that TGRL play a central role in the pathogenesis of atherosclerosis (Groot et al., 1991; 
Uiterwaal et al., 1994), exerting their effect both directly on the arterial wall, and indirectly by 
modifying other lipoprotein classes in an atherogenic fashion (Ryu et al., 1992; 
Zilversmit, 1979). 
Under normal metabolic conditions the liver favours the production of smaller 
VLDL (S1 <60), which appear to be the precursors of LDL (approximately 70% of VLDL are 
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S1 20-60 in normal subjects) (Karpe et al., 1993a). The impaired peripheral clearance of . 
triglyceride leads to the return of remnants to the liver, which promotes the formation of larger 
VLDL's (S1 60-400), enriched in cholesterol and cholesterol ester. These are resistant to lipase 
activity and can further impede the undisturbed passage of other TGRL through the lipolytic 
cascade. Potentially atherogenic cholesterol-enriched chylomicron remnants and IDL, may 
accumulate. Larger VLDL may also be removed directly from plasma, and not lipolysed to form 
LDL (Packard et al., 1984). It has been hypothesised that large VLDL and some dietary TGRL 
rriay have an abnormal ability to interact with arterial ceils through rapid receptor mediated 
processes. Thus only a portion of the VLDL apoB enters the LDL pool, unlike in normal subjects, 
where most VLDL apoB is converted into LDL apoB. Although it was traditionally believed that 
TGRL could not participate in endothelial cholesterol deposition, because their large size 
precluded entry into the arterial wall, it has recently been confirmed that TGRL are indeed 
present in atherosclerotic lesions, and can thus contribute to the initiation and progression of 
atherosclerosis (Rapp et al., 1994). A large VLDL carries five times or more total cholesterol per 
lipoprotein particle than LDL, and by this criterion, has a greater potential for the deleterious 
delivery of cholesterol (Bradley and Gianturco, 1994 ). 
Virtually all major lipoprotein classes, including VLDL, IDL, LDL and HDL, are influenced 
by postprandial triglyceridaemia, and its magnitude and duration determine·s how much these 
lipoproteins are affected. These effects are mediated by cholesterol ester transfer protein (CETP), 
which catalyses the transfer of cholesterol esters from HDL and LDL to chylomicrons, VLDL 
and IDL and the reciprocal transfer of triglycerides. During postprandial triglyceridaemia, the 
action of CETP increases remnant-cholesterol, VLDLC and IDLC concentrations and decreases 
the HDLC concentration. Triglycerides transferred to LDL and HDL are susceptible to lipase-
mediated hydrolysis, so that the size of these lipoproteins is reduced in impaired triglyceride 
tolerance. Frequently occurring elevations ofTGRL species could provide favourable conditions 
for the sequential actions of lipid transfer proteins and HTGL which lead to accumulation of 
dense, lipid-depleted LDL particles. A predominance of small, dense low LDL in plasma is 
thought to be particularly atherogenic, and has been associated with up to a three-fold incre~e 
in risk of acute myocardial infarction (Austin et al., 1988), and the presence of coronary artery 
disease (Campos et al., 1992). Another reason for the increased atherogenicity of postprandial 
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LDL appears to be a greater susceptibility to chemical modification such as oxidation 
(Chait et al., 1993; Lechleitner et al., 1994). 
HDL metabolism 
The plasma HDL are small lipoproteins consisting of about 50% protein and 50% lipid. The 
major lipids are phospholipids, cholesterol, and cholesterol esters. The major apolipoproteins are 
apoA-1 and apoA-11. The HDL also contains proteins of central importance in lipoprotein 
metabolism, namely, the enzyme LCAT and the plasma lipid transfer proteins, CETP and 
phospholipid transfer protein (PLTP) (Tall, 1996). ApoA-1 is synthesised in approximately equal 
proportions in the liver and small intestine, whereas apoA-11 is made exclusively in the liver 
(Eisenberg, 1984; Tall, 1996). ApoA-1 forms three types of stable structure with lipids: small 
lipid-poor complexes (prebeta-1 HDL); flattened discoidal particles (prebeta-2 HDL) containing 
only polar lipids (phospholipid and cholesterol); and spheroidal particles (HDL) containing both 
polar and nonpolar lipids which form the bulk of the HDL (Fielding and Fielding, 1995). ApoA-1 
is present in at least one copy (and usually two to four copies) in each HDL particle of normal 
plasma (Fielding and Fielding, 1995). HDL can be formed as a direct result of cellular secretion, 
or is derived from surface remnants shed during the catabolism ofTGRL. A major proportion 
of the apolipoprotein and phospholipid destined to become HDL is initially secreted on VLDL 
and chylomicrons. 
During lipolysis of chylomicrons and VLDL, surface lipids (phospholipid and cholesterol) 
and proteins (apoA-1, apoA-11, and apoC's) are transferred into the HDL fraction. These 
components may form nascent discoidal particles, which are rapidly acted on by LCAT to 
generate mature spherical HDL3, or they may be incorporated into preexisting HDL particles. 
LCAT modifies HDL particles by transforming the cholesterol into cholesterol ester. This neutral 
lipid accumulates in the HDL core, making the HDLparticle spherical. The depletion of surface 
cholesterol by LCA T causes the development of a chemical gradient which favours the continual 
transfer of excess cholesterol from cellular membranes to HDL. This constant flow of free 
cholesterol, succeeded by esterification and movement of the ester into the core, together with 
surface remnants from TGRL, expands the HDL3 particle and shifts the density range to the less 
dense HDL2 particle. As this HDLi particle increases in size, two other enzymatic reactions 
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occur. Firstly, CETP facilitates the transfer of the cholesterol ester to other lipoproteins 
(chylomicron and VLDL remnants) in exchange for triglyceride. This allows the movement of 
cholesterol ester originating from HDL to the liver by chylomicron and VLDL remnants, where 
they are catabolised and the cholesterol is excreted into the small intestine as bile. Secondly, the 
HDL2, now enriched in triglyceride, provides a good substrate for HTGL, which converts the 
particle back to the HDL3 size range. Thus the small dense HDL 3 can originate by LPL action; 
be modified by LCAT, resulting in HDL2 formation; undergo further processing mediated by 
CETP and HTGL; and be transformed into HDL3 in the liver and released back into the 
circulatory system to begin the process once again (Eisenberg, 1984; Tall, 1996). 
Recently it has been shown that HDL subclasses may be further subdivided according to a 
functional classification, into HDL containing apoA-I only (LpA-I) and HDL containing both 
apoA-I and apoA-II (LpA-I/LpA-II) (Leroy et al., 1993). A number of studies indicate that LpA-I 
and LpA-I/LpA-II are metabolically distinct and may perform different functions. ApoA-I 
injected as part of LpA-I particles is catabolised at a higher rate than apoA-I injected as part of 
LpA-I/LpA-II particles (Mowri et al., 1994). Particles containing only apoA-I may be the 
physiologic acceptor of cellular cholesterol, and HDL2 containing both apoA-I and apoA-II 
constitute a better substrate for HTGL than HDL2 containing apoA-I only. 
HDLC concentration is known to be closely related to a number of lifestyle factors . 
(Heiss et al., 1980). Cigarette smoking is associated with substantially lower HDLC 
concentrations (Criqui et al., 1980). There is a strong positive gradient of HDLC concentration 
with reported alcohol intake in both men and women (Ernst et al., 1980). Body mass is 
significantly and inversely associated with plasma HDLC concentration and positively associated 
with plasma triglyceride concentration (Glueck et al., 1980). Correlation of HDLC concentration 
with obesity and physical activity appear to be affected primarily through their associations with 
triglycerides, and alcohol use and smoking through associations with apoA-I (Patsch et al., 1992). 
Many epidemiological studies have demonstrated that the risk for CHD is inversely correlated 
with plasma HDLC concentration (Gordon et al., 1989; Miller and Miller, 1975). This has 
created the widespread impression that the association between HDL and CHD is the opposite 
to that existing between LDL and CHD, in which a high concentration ofLDL directly promotes 
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CHD, and therapeutic lowering reduces the risk for CHD. The mechanisms underlying the 
relationship between HDL and CHD do however, appear to be far more complex, and is still 
unclear whether therapeutic intervention to raise HDLC concentration will decrease CHD risk 
(Vega and Grundy, 1996). There are several different theories that have attempted to explain the 
relationship between HDL and atherogenesis. These may be divided into theories that postulate 
a direct antiatherogenic action of HDL versus those that say that HDL is merely a marker for · 
some other event, such as a defect in the metabolism of triglyceride rich lipoproteins (Tall, 1996). 
Low HDL as a direct cause of atherosclerosis 
There is strong in vitro evidence that HDL provides direct protection against the development 
of atherosclerosis, through a process termed 'reverse cholesterol transport' (Fielding and 
Fielding, 1995). In brief, HDL removes excess cholesterol from peripheral cells by esterification, 
and either transfers the esterified cholesterol to TGRL triglyceride-rich lipoproteins, which are 
subsequently removed for catabolism in the liver by hepatic receptors, or itself delivers 
cholesterol directly to the liver. Accordingly, a low HDL concentration would be directly 
atherogenic by not counteracting the deposition of cholesterol at sites where an excessive 
cholesterol load could produce atherosclerosis. Despite the appeal of this theory, it has been 
difficult to gain supporting evidence in vivo (Tall, 1996). A direct link between HDL and CHD 
has been sought in genetic disorders of humans and animals which cause either very high or very 
low HDL concentrations. Three main genetic disorders have been investigated, those associated 
with abnormal apoA-I and apoA-II concentrations, abnormal CETP concentration, and abnormal 
HTGLa and LPLa. 
Humans having genetic mutations resulting in complete deficiency of apoA-1 have been 
described (Lackner et al., 1993; Matsunaga et al., 1991; Ng et al., 1994). While some individuals 
suffer from premature atherosclerosis, other family members with the same genotype appear to 
be healthy, suggesting that the rate of disease development may be modified by other factors such 
as elevated LDLC concentrations (Tall, 1996). There are other gene mutations which result in 
partial deficiency of apoA-1. Carriers of the apoA-IMitano mutation, are characterised by an average 
40% decrease in apoA-I and apoA-II concentrations, and a 67% decrease in HDLC concentration 
(Franceschini et al., 1980). Despite the low HDLC concentrations, subjects with the apoA-IMitano 
mutation do not have increased coronary artery disease; in fact, the opposite is suspected, with 
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longevity noted in some family members. Complete or partial LCA T deficiency is another 
genetic mutation showing no apparent increased risk of premature atherosclerotic disease, despite 
conferring markedly low HDLC concentrations, and a partial deficiency of apoA-I, and apoA-II 
(Norum et al.). An overexpression of the human apoA-I gene in transgenic mice does appear to 
reduce the progression of atherosclerosis when these animals are challenged with a 
hypercholesterolaemic diet (Rubin et al., 1993), whereas induction of high concentrations of 
apoA-II appears to mitigate or reverse the apparent protective effect of apoA-1 
(Warden et al., 1993). Surprisingly, mice which lack the apoA-1 gene fail to show increased 
aortic lesions even when fed an atherogenic diet (Li et al., 1993). 
A genetic deficiency of CETP results in a marked increase in ·HDLC concentration, resulting 
from defective transfer of cholesterol ester from HDL to TGRL. It might be anticipated that, if 
high HDLC concentration directly protect against CHD, CETP-deficient patients would not 
manifest CHD. To date, however no consistent evidence from human and animal studies has 
been produced to support this hypothesis. Rather, limited data in humans suggest that changes 
in HDLC concentrations based on differences in plasma CETP may not be closely linked to 
atherosclerosis (Vega and Grundy, 1996). Interestingly, individuals with abnormally elevated 
HDL concentration due to a combined reduction of CETP and HTGL may be susceptible to CHD 
(Hirano et al., 1995). 
The association between abnormal HTGLa and LPLa and reduced HDLC and HDL2C 
concentration are well known. High LPLa apparently raises HDLC concentration by lowering 
triglyceride concentration and by promoting transfer of cholesterol from TGRL to HDL. HTGL 
has the opposite effect on HDL; a high activity lowers HDLC concentration by hydrolysing 
triglycerides and phospholipid in HDL particles. Of the two lipases, HTGL appears to be more 
tightly linked to HDLC concentration than LPL, and higher HTGL activities in men appear to be 
largely responsible for the sex related differences in HDLC concentration (Blades et al., 1993). 
There is some evidence that elevated HTGL might give rise to an atherogenic form oflow HDLC 
concentration, as increases in HTGL activities frequently occur in patients having both low 
HDLC concentrations and premature CHD (Vega and Grundy, 1996). Two possibilities may 
explain the apparent association between high HTGLa, low HDLC concentration and premature 
atherosclerosis: (i) the high HTGL may be part of a more generalised metabolic disorder which 
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promotes atherosclerosis in other ways, and (ii) a change in the HTGL gene may cause a high 
HTGLa, indeed it has been shown that genetic factors may account for as much as 50% of the 
variation of HDLC concentration in the general population, and allelic variation in the HTGL 
gene alone could explain at least half of the genetic contribution (Cohen et al., 1994). In contrast, 
the absence of HTGL confers a phenotype, with high IDL and high and abnormal HDL 
concentrations, which may be aiherogenic (Connelly et al., 1990). 
Other genetic abnormalities provide some additional insight. A marked reduction ofHDLC 
concentration occurs in individuals having apoA-I gene cluster mutations, which results in a 
complete deficiency of apoA-I and apoC-III; this rare disorder is accompanied by premature 
atherosclerosis (Norum et al., 1982). Although the near absence ofHDL in this condition might 
directly promote development of atherosclerosis, the concurrent deficiency of apoC-ill could also 
induce an atherogenic change in VLDL metabolism, which makes it difficult to conclude that a 
low HDLC concentration per se is the cause of· enhanced atherogenesis (Vega and · 
Grundy, 1996). Tangier disease is an anomaly characterised by extremely low plasma HDLC 
· concentrations, caused by an excessive catabolism of apoA-I (Schmitz et al., 1985). Despite a 
high cholesterol/HDLC ratio, these patients do not have a high incidence of atherosclerosis. The 
· hepatic secretion of nascent HDL may be normal in these patients, which could explain why the 
majority of Tangier patients do not appear to accumulate cholesterol esters in their vessels (Vega 
and Grundy, 1996). 
Although evidence from studies on humans and animals with abnormal HDLC concentrations 
due to genetic mutations is confusing, studies in animal models and in humans, show that 
regression of atherosclerosis occurs in settings where LDLC concentration is lowered and HDLC 
concentration is raised, which suggests that it is likely that regression involves removal of 
cholesterol from lesions by HDL (Tall, 1996). Together with in vitro evidence, it can be 
concluded that the balance of evidence indicates that it is likely that HDL is directly involved in 
a process of reverse cholesterol transport from atheromata into plasma and back into the liver 
(Tall, 1996). What is less clear is the extent to which the 'protective' effect of HDL noted_}_n 
human epidemiological studies is mediated by changes in the efficiency of the reverse cholesterol 
transport system. For example, it has never been shown that variations in HDLC concentration 
similar to those in plasma, modulate cholesterol removal in the arterial wall (Tall, 1996). While 
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there may be a correlation between HDLC concentration and the rate of reverse cholesterol 
transport, it is not possible to derive a flux from a concentration without knowing the rate of 
entry of cholesterol from atheromata into the plasma cholesterol. ester pool, and the rate of 
clearance via the liver. 
Low HDL as a marker of other atherogenic lipoproteins 
Zilversmit (1979) originally proposed that some chylomicrons bearing dietary cholesterol 
would be hydrolysed on large blood vessels and subsequently enter the arterial wall and promote 
atheroma formation. The atherogenic remnant hypothesis was subsequently modified to say that 
low HDLC concentrations might be a marker for the accumulation of chylomicron or VLDL 
remnants in plasma (Patsch et al., 1983). TGRL may affect HDL2 concentration in two ways: 
(i) Rapid lipolysis of TGRL by the enzyme LPL generates excess surface material, predominantly 
phospholipid, which is assimilated by HDL. This uptake of lipid promotes the formation of the 
large HDL2 and thereby raises the cholesterol carrying capacity of HDL. The assimilation of 
lipolytic surface remnants by HDL not only effects the formation of HDL2, but may also protect 
arterial wall cells, as surface remnants, when not incorporated into HDL, are cytotoxic to 
macrophages in culture (Chung et al., 1989). (ii) Delayed lipolysis of TGRL increases the 
opportunity for the reciprocal transfer of triglycerides from TGRL into HDL and of cholesterol 
esters from HDL into TGRL. This neutral lipid exchange reaction is catalysed by CETP. 
Triglycerides transferred to HDL are hydrolysed by HTGL. In this way, HDL cholesterol is lost 
to TGRL, large HDL are converted into small dense HDL, and the cholesterol-carrying capacity 
ofHDL decreases (Patsch, 1994). Hence, rapid lipolysis ofTGRL keeps HDL2C concentration 
(and thus HDLC concentration) high by promoting the formation of the larger HDL2 as well as 
by preventing their catabolism. 
The response ofHDLC concentration to the rapid fluctuations of the concentrations ofTGRL 
is relatively slow and constitutes the biochemical basis for the 'memory function' ofHDL with 
respect to triglyceride transport. Therefore, HDLC concentration can be viewed as an integrative 
marker of triglyceride transport in all states of absorption, which explains why HDLC 
concentration tends to eliminate the rapidly fluctuating triglycerides as risk factor in multivariate 
analyses (Miesenbock and Patsch, 1992). 
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While little doubt exists that hypertriglyceridaemia and exaggerated postprandial 
triglyceridaemia usually result in low HDLC concentrations, there is some uncertainty about the 
prevalence of impaired triglyceride metabolism as a cause of low HDLC concentrations in the 
general population (Vega and Grundy, 1996). Indeed, recent reports from Cohen et al. 
( 1991, 1992) failed to identify exaggerated postprandial lipaemic responses in either long 
distance runners with relatively low HDLC concentrations, or in patients with categorically low 
HDLC concentrations. It is thus likely that many individuals with low HDLC concentrations can 
have a normal postprandial triglyceridaemia. More extensive epidemiological studies will be 
required to resolve the true prevalence of impaired triglyceride metabolism as a cause of low 
HDLC concentrations in the general population. 
Additional protective effects of HDL 
A large body of evidence suggests that oxidation of LDL is involved in atherogenesis 
(Chisolm et al., 1991; Hessler et al., 1979; Witzum an~ Steinberg, 1991; Witzum, 1994). Both 
extensively oxidised and minimally oxidised LDL may play roles in stimulating atherogenesis. 
In vitro experiments indicate that HDL can inhibit many of the effects of LDL oxidation. 
Parthasarathy et al. (1990) have showed that HDL may play a protective role in atherogenesis by 
preventing the generation of oxidatively modified LDL. Navab et al. (1991) have shown that 
HDL inhibits the stimulation of macrophage chemotaxis induced by minimally modified LDL, 
and Hessler et al. (1979) have shown that HDL inhibits the LDL-mediated cytotoxicity of 
vascular smooth muscle and endothelial cells. There are several potential mechanisms by which 
HDL may modify the formation or properties of oxidised LDL. These include (i) an exchange 
of lipid peroxidation products between HDL and LDL, sequestering oxidised lipids away from 
apoB and limiting apoB modification (Parthasarathy et al., 1990), (ii) binding of oxidation-
promoting transition metals by apoA-I (Kunitake et al., 1992), and (iii) two enzyme systems, 
platelet-activating factor acetylhydrolase and paraoxonase, associated with HDL may be able to 
inhibit the generation of oxidised lipids (Mackness et al., 1993; Mackness and Durrington, 1995; 
Watson et al., 1995; Watson et al., 1995a). 
ApoJ, also known as clusterin, is a glycoprotein that is present in a subpopulation of HDL 
together with paraoxonase and apoA-I, and has been reported to have diverse functions, including 
roles in complement regulation and prevention of cytolysis, lipid transport, apoptosis, membrane 
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protection at fluid-tissue interfaces where it is expressed, and may also reduce the oxidative 
potential ofLDL and of the arterial wall cells (Navab et al., 1997). Plasma apoJ concentrations 
increase significantly during inflammatory conditions, including in atherogenesis, which may 
allow it to serve a protective effect through its diverse biological interactions. Since antioxidant 
enzymes and apoJ are associated with only a small fraction of HDL particles, this may explain 
in part why some patients with low HDLC concentrations may not have clinically significant 
atherosclerosis, and others with relatively normal HDLC concentrations may have premature 
atherosclerosis (Navab et al., 1997). 
Summary 
'Atherogenic dyslipidaemia' is a lipoprotein phenotype which has more recently been 
identified as one of the two major patterns of atherogenic lipoprotein disorders along with 
hypercholesterolaemia. The underlying cause of this phenotype is usually an excessive dietary 
intake (of fat in particular), excessive VLDL production, and/or an impaired triglyceride 
clearance. This results in a prolonged plasma residence of high concentrations of chylomicron 
and VLDL, which manifests as a mild fasting hypertriglyceridaemia or an exaggerated 
postprandial triglyceridaemia. These TGRL can play a central role in atherosclerosis, both 
directly, and by modifying other lipoprotein classes, particularly LDL and HDL, in an atherogenic 
fashion. Delayed lipolysis of TGRL increases the opportunity for a neutral lipid exchange 
reaction catalysed by CETP, which allows the reciprocal transfer of triglyceride from TGRL into 
LDL and HDL, and of cholesterol esters from LDL and HDL into TGRL. Triglycerides 
transferred to LDL and HDL are hydrolysed by HTGL, and these lipoproteins become smaller 
and denser. In this way, the HDLC concentration decreases, and the predominance of small dense 
(atherogenic) LDL increases. Small dense LDL are susceptible to oxidation, which further 
increases their atherogenicity. A reduced HDL concentration may limit the inhibition of LDL 
oxidation by HDL associated antioxidant enzymes. An elevated TGRL concentration is also 
characterised by an increased concentration of atherogenic chylornicron and VLDL remnants. A 
reduced HDL concentration may exacerbate this increase, as many of these remnants are 
normally incorporated into HDL. 
A low HDLC concentration may not necessarily be caused by an exaggerated postprandial 
triglyceridaemia, but may also be caused by other factors such as an elevated HTGLa. The 
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suppressive effect of testosterone and AAS on HDLC concentration appears to be due primarily 
to an elevated HTGLa. Although a low HDLC concentration may be closely related to a 
reduction in reverse cholesterol transport, it is unclear whether changes in HDLC concentration 
reflect the efficiency of reverse cholesterol transport in all cases. At present, the possibility 
cannot be excluded that a low HDLC concentration may reflect an increased flux of cholesterol 
through the HDL cholesterol pool. Indeed, individuals having gene mutations which confer a 
partial suppression of HDLC concentration, are not necessarily predisposed to premature 
atherosclerotic disease. Until it is possible ·to show that therapeutic lowering of HDLC 
concentration in otherwise healthy individuals causes premature atherosclerosis, a measure of 
caution should be brought into the interpretation of the·atherogenicityof testosterone and AAS 
induced HDLC concentration reduction. · 
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Chapter 3: The general methodology for the experimental chapters 
. Similar clinical and laboratory methods were used in both experimental chapters. Therefore, 
the general methodological chapter provides detailed descriptions of these methods to avoid 
repetition. The methods described here are for triglyceride analysis, cholesterol analysis, Lp(a) 
analysis, the oral fat tolerance test (used to assess postprandial· triglyceridaemia), and non-
denaturing gradient gel electrophoresis (GGE) for assessment ofLDL and HDL particle size. 
Sample Collection and Processing 
Blood samples for analysis of total cholesterol, Lp(a) concentration and for GGE were taken from 
the fasted subjects between 06h45 and. 07h00, together with the first blood sample for the oral 
fat tolerance test. Subjects were seated, and fasted blood samples were drawn from an arm vein 
into Vacutainers containing EDT A ( ethylenediaminetetraacetic acid), by a trained phlebotomist. 
Samples were immediately placed upright in crushed ice. On completion of the oral fat tolerance 
test at ·I 7h00, all samples were centrifuged at 3000 rpm in a Beckman GS-6R for 15 minutes. 
Plasma was aspirated and divided between four cryovials. Samples were stored at -20°C until 
it was possible to perform a batch analysis. Analysis took place within three weeks after the 
second test day. Analysis of duplicate samples for test days 1 and 2 of the same individual were 
performed within the same assay. 
Triglyceride analysis 
General 
Triglyceride concentration was assessed using a commercially available GPO-PAP kit 
(Human, Germany, Kit no:10164). Lipases hydrolyse triglyceride to yield glycerol and free fatty 
acids. Glycerol is converted to glycerol-3-phosphate by glycerokinase and adenosine triphospate. 
The glycerol-3-phosphate is reacted with oxygen by glycerophosphate oxidase yielding 
dihydroxyacetone-phosphate and H20 2• Two molecules of the latter is used by peroxidase as well 
as 4-aminoantipyrine and 4-chlorophenol to generate quinoneimine, HCl and H20, yielding a 
pink-red colour, read spectrophotometrically at 500 nm in a 1 cm path (reference, package insert). 
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Materials 
Buffer solution contains: PIPES buffer (piperazine-N,N' -bis[2-ethanesulfonic acid]; 
1,4-piperazinediethanesulfonic acid) (pH=7.5) 40 mmol/L; magnesium ions 5 mmol/L; 
4-chlorophenol 5 mmol/L and sodium azide 0.095 g%. Enzyme reagent contains 
4-aminoantipyrine 0.4 mmol/L; adenosine triphospate 1 mmol/L; lipases ~ 150 U/ml; glycerol 
kinase ~ 0.4 U/ml; glycerol-3-phosphate oxidase ~ 1.5 U/ml; peroxidase ~ 0.5 U/ml. 
Method 
The enzyme lyophilisate is reconstituted with 15 ml buffer. This is stable at 4 cc for 21 days 
or 20 cc for 3 days. The design is for a final volume of about 750 µl, which allows for reading 
in a microcuvette in a spectrophotometer. Blank has no plasma while 10 µl of plasma sample is 
reacted. In turbid plasma it may be necessary to dilute the sample by a known amount. Add 
250 µl of saline, vortex. Add 500 µl of reagent, vortex. Incubate at room temperature for 
15 minutes and read absorbance within an hour. Duplicate test samples are read 
spectrophotometrically (500 nm) against the standards provided with the kit. Analysis is by linear 
regression. 
Intra-assay coefficient of variation was 3.8%. 
Cholesterol analysis 
General 
Cholesterol and cholesterol ester are released from lipoproteins by detergents. Cholesterol 
ester is hydrolysed by cholesterol esterase to yield cholesterol. Cholesterol oxidase is used to 
oxidise cholesterol, yielding delta-4 cholestenone, and releasing hydrogen peroxide in the 
process. The Boehringer Mannheim kit (290319) uses 2 molecules of hydrogen peroxide to react 
4-arriinophenazone and phenol to yield 4-(p-benzoquinone-monoimino )-phenazone and 4 H20 
by the enzyme peroxidase (reference, package insert). Note that bilirubin above 70 µmol/L and 
haemoglobin above 200 mg/dl may interfere with the test. 
Materials 
The concentrations of the reagent solution are: Tris buffer 100 mmol/L (pH=7. 7); magnesium 
ions 50 mmol/L; 4-aminophenazone 1 mmol/L; sodium cholate 10 mmol/L; phenol 6 mmol/L; 
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3,4-dichlorophenol 4 mmol/L; hydroxypolyethoxy-alkanes 0.3%; cholesterol esterase z0.4 Ulm.I, 
cholesterol oxidase z0.25 U/ml and peroxidase z0.2 U/ml. The reagent powder is dissolved in 
32 ml redistilled water, and is ready to use after 10 minutes. The reagent solution is stable at 4 cc 
for 4 weeks, and for 7 days at 15-20 cc. 
Calibration and standards 
Calibration is done by usmg a commercial plasma preparation (Precinorm) and/or 
gravimetrically prepared standards which have to be dissolved into the solution by means of 
ethanol and Triton X-100 (1 % in distilled water). Standards are prepared by dissolving 10.0 mg 
cholesterol (BDH Chemicals Ltd. Poole England) in 10.0 ml of benzene (analytical grade, 
SAARCHEM, Krugersdorp, South Africa); mix thoroughly for 1 µg/ µ1 (solution A). Exactly 1.0 
ml of this solution is brought to 10 ml in benzene for 0.1 µg/µ1 (solution B). Appropriate 
volumes of solution A and Bare transferred to eppendorftubes. For 1, 2, 5 and 10 µg standards 
use solution B and for 20, 30, 45, -60, 75, 90 and 105 µg standards use solution A. Benzene is 
then allowed to evaporate in the fume cupboard, with the dried standards remaining. Standards 
are stored at -2occ. 
Method 
This method has been standardised to use 20 µ1 of plasma. The procedure is done with the 
solvents in all tubes (essential for dissolving dried standards), although in the plasma samples 
it is best to add the solvents after bringing to volume (500 µI) to avoid turbidity. To the standards 
add 50 µI ethanol and vortex. Now add 15 µI of 1 % triton and vortex. Add 500 µl saline. Plasma 
samples are made up to 500 µl with saline. Add 50 µl ethanol to all plasma samples and vortex. 
Add 15 µl of 1 % triton to all plasma samples and vortex. Add 500 µl of reagent to all reaction 
vials, vortex and react at room temperature for 30 minutes. Measure the absorption at 500 nm 
(470-560 nm) within 2 hours. The cholesterol content is calculated from the calibration curve, 
usually linear regression is adequate (r = 0.99) for 2 to 90 µg. If the sample exceeds the range, 
dilute and repeat. 
Intra-assay coefficient of variation was 4.2%. 
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Lipoprotein(a) analysis 
General 
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Apolipoprotein(a) was measured in the plasma using the Mercodia Apo(a) ELISA, enzyme 
immunoassay (Mercodia AB, Seminariegatan 29, S-752 28 Uppsala, Sweden). Mercodia Apo(a) 
ELISA is a solid two phase two-site enzyme immunoassay. It is based on the direct sandwich 
technique in which two monoclonal antibodies are directed against separate antigenic 
determinants on the apolipoprotein molecule. During incubation, apo(a) in the sample reacts with 
peroxidase-conjugated anti-apcilipoprotein(a) antibodies and anti-apolipoprotein(a) antibodies 
bound to the microtitration well. A simple washing step removes unbound enzyme labelled 
antibody. The bound conjugate is detected by reaction with 3,3',5,5'-tetramethylbenzidine. The 
reaction is stopped by adding dilute acid to give a colorimetric endpoint (reference, package 
insert). The absorbance is read spectrophotometrically ( 450 run) in an ELISA plate reader. The 
. results are calculated from a standard curve. 
Calibration 
The kit is calibrated against a highly purified, fully validated, commercial Lp(a) preparation. 
The concentration of Apolipoprotein(a) is expressed in Units/L. It is not possible to express the 
concentration of Apo(a) in mass units as there are at least six different isoforms have been 
described, with molecular weights varying from approximately 300 kD to 900 kD 
(Uterman, 1989; MBewu and Durrington, 1990). Thus each patient sample will contain different 
proportions of the different isoforms. Therefore, no exact conversion factor can be given between 
Units of Apo(a) and milligrams of Apo(a), although 1 unit of Apo(a) is approximately equal to 
0.7 mg Lp(a). 
Intra-assay coefficient of variation was 3.5%. 
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The Oral Fat Tolerance Test 
General 
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Lipid and lipoprotein analysis has traditionally been confined to the post-absorptive 
( overnight fasting) state, when triglyceride metabolism, and lipid transport in plasma has reached 
a state of equilibrium (Foger and Patsch, 1993). In the past decade, however, interest has been 
growing in analysing lipoproteins in the postprandial state, since it has been demonstrated that; 
(i) triglycerides measured in the postprandial state can serve as an independent predictor for CHO 
in multivariate analyses (Patsch et al., 1992a), and · (ii) an exaggerated postprandial 
triglyceridaemia can modify the other major lipoprotein classes in an atherogenic fashion 
(Austin et al., 1988; Karpe et al., 1993; Patsch et al., 1983). The oral fat tolerance test describes 
the absorption and digestion in the gut as well as circulatory entrance and clearance of 
triglycerides. A standardised amount of fat is given by mouth and venous blood is sampled and 
measured for plasma triglyceride concentration. The oral fat tolerance test is contra-indicated in 
subjects with severe fat malabsorption and is also contra-indicated in subjects with severe 
hypertriglyceridaemia (> 10 mmol/L) because it may precipitate pancreatitis. 
Procedure for oral fat tolerance test 
The oral fat tolerance test was performed as described by Foger and Patsch (1993). Subjects 
were asked to abstain from exercise and alcohol the day before the test, and from food and 
beverages (excluding water) 12 hours before the test. Subjects typically arrived in the laboratory 
at 06h45, at which time their mass and height were measured. Surface area was predicted from 
a nomogram using mass and height (Geigy Scientific Tables, 1984). Subjects were seated and 
fasted blood samples were drawn from an arm vein into plain Vacutainers and Vacutainers 
containing EDT A ( ethylenediaminetetraacetic acid). The test meal was given to the subjects at 
07h00 and was consumed within 3 minutes. 
The content of the test meal was calculated per ni2 of body surface area, and prepared and 
mixed immediately before use; cream 175 ml (39.5% fat), powdered chocolate flavouring 15 ml, 
granulated sugar 2.5 ml, fat free milk powder 7.5 ml. This concoction delivers about 3050 J, of 
which 3% of energy content is derived from protein, 14% from carbohydrate and 83% (65 g) 
( 
from fat. The PUF A/SF A ratio is 0.06 and the cholesterol content is 240 mg. No other food was 
permitted during the day, although subjects are allowed to consume water or energy free drinks. 
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The test meal was well tolerated, although some subjects complained of nausea during the first 
three to four hours, and all of hunger during the last three to four hours. Subjects were then 
allowed to leave the lab and continue with their normal daily activities ( excluding exercise), and 
were asked to return to the lab at two hourly intervals for the next ten hours (up to 17h00), so that 
additional blood samples (5 ml) could be taken for assessment of triglyceride concentration. The 
total blood volume collected during the day is approximately 35 ml. 
Interpretation of oral fat tolerance test 
Triglyceride concentration was plotted against time. Postprandial . triglyceridaemia 
(mmol/L.hr) was calculated by integration of the area under the curve of triglyceride 
concentration versus time. Postprandial triglyceride excursion was calculated by subtracting the 
minimal triglyceride concentration, multiplied by 10 hours, from the total area under the curve. 
Three essential patterns can emerge from the oral fat tolerance test. The "flat pattern" reveals no 
increase of triglyceride with time and is indicative of malabsorption, homozygous 
hypobetalipoproteinaemia, intestinal lymphagiectasia, or obstruction or leak from the cysterna 
chyli or thoracic duct. The "desirable pattern A" is for a rise from an ideal (normal) baseline 
triglyceride of about 0.5 to 1.5 mmol/L to a peak of about 3 mmol/L at which stage the plasma 
is faintly turbid. The 6 hour triglyceride concentration is already close to baseline and the 8 and 
10 hour values have reached baseline. The "undesirable pattern B" may commence at a normal 
triglyceride concentration or slightly higher, has the same delay before rising to a peak at the 
same time as the desirable pattern, but there is a persistent hypertriglyceridaemia until 6 and even 
8 to ten hours after the test. The area under the curve is much greater and can be used to 
discriminate changes due to an intervention. The LDL particle sizes are generally smaller in 
subjects with the undesirable (B) pattern, with lower HDLC concentrations. These subjects also 
have higher risk of coronary artery disease (about 3 to 5 fold) and the undesirable pattern is 
prominent in myocardial infarction survivors with apparently normal range cholesterol 
concentrations (Austin et a(, 1992; Campos et al., 1992). 
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Non-Denaturing Gradient Gel Electrophoresis (GGE) for lipoproteins 
General 
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This technique allows separation of lipoproteins by size. The lipoproteins are demonstrated 
by staining lipid with Sudan Black before the procedure. Separation of chylomicron and VLDL 
is difficult because of the size of these lipoproteins. The IDL range is also not so distinctly 
separated. Gels may be selected to demonstrate LpB series (LDL) and LpA series (HDL). A 
2-16% gradient is usually recommended for LDL (Gambert et al., 1990) and a 4-30% is usually 
recommended for HDL (Meyer et al., 1989). The University of Cape Town Lipid lab uses a 
mini-gel of 2-8% acrylamide gradient for LpB, and a 4-18% for LpA. Fasted plasma samples 
should immediately be placed on ice and processed as soon as possible, although samples have 
been satisfactory for LDL characterisation for up to 1 week when stored at 4 °C. The samples 
can also be stored at -20 °C for a few weeks, and for several(> 12) weeks at -50 °C. 
Qualitative differences in LDL may be important. The first relation between smaller denser 
LDL and heart disease was shown by Austin et al. (1988), who recognised two types of LDL. 
Dormans et al. (1991) suggested that 3 LDL subtypes could be identified by either 
ultracentrifugation or GGE, although the latter method could on occasion identify 5 bands. 
Tashiro et al. (1993) found a "midband", which is probably Lp(a), that predicts heart disease in 
FH subjects: Similarly, HDL3 and HDL2 subtypes may influence atherosclerosis. 
Materials 
The lipid stain is Sudan Black, prepared by adding 1 % sudan black to ethylene glycol. This 
solution is passed through filter paper to remove undissolved fragments. An additional stain 
solution containing bromophenol blue 0.2% and sucrose 60% is also prepared. The acrylamide 
monomer solution contains 30% acrylamide of which 2.7% is bis-acrylamide. A fresh acrylamide 
solution provides better clarity of separation. Gel buffer A is prepared by adding 250ml water to 
68.1 g Tris base. Once the Tris base has dissolved, 150ml (187 .5g) glycerol is mixed into the 
solution. The pH is adjusted to 8.8 and the volume is brought up to 500ml. Gel buffer B is 
prepared in a similar manner to gel buffer A, except that glycerol is omitted from the solution. 
The stacking gel buffer is prepared by dissolving 8.4g Tris base, before adjusting the pH to 6.8 
and bringing the solution to 500ml. The electrode buffer stock is prepared by dissolving Tris base 
37.9g and glycine 180. lg, before making the solution up to 2.5L. This solution is five times (x5) 
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concentrated, and pH is adjusted to 8.3 after dilution. The required equipment is a minigel 
apparatus (Biorad) with 8 x IO.cm plates and a powerpack. 
Procedure LDL Gel 
Cast a 2-8% polyacrylamide gradient (running) gel. The 2% gel solution is prepared by 
mixing buffer B, and the 8% gel solution is prepared by mixing buffer A, with the appropriate 
volume of 30% acrylamide solution. Polymerisation of the gel solutions is initiated using 
ammonium persulfate (APS) 0.74% and TEMED 0.37%. The gradient is prepared using a Hoefer 
SG 15 gradient maker. A 4% stacking gel is cast on top of the running gel. The stacking gel is 
prepared using the stacking gel buffer mixed with the appropriate volume of 30% acrylamide 
solution. Polymerisation of the stacking gel solution is initiated using APS 1.95% and TEMED 
0.78%. Two gels are run in the system, with 15 lanes per gel. The gels are run in a cold room or 
in a refrigerator. 
Plasma samples (100µ1) are thawed at 4 cc, mixed with 50µ1 of lipid stain (Sudan Black), 
incubated for a minimum of 1 hour at 4 cc and spun for 20 minutes at 10 OOOG. An equal volume 
of supernatant (50µ1) is mixed with a saturated sucrose/Bromophenol Blue solution and 12µ1 is 
loaded per well. The addition of Bromophenol Blue to the sample helps to improve the resolution 
of the leading edge of the LDL bands, and the saturated sucrose increases the density of the . 
sample solution, facilitating sample loading into the wells. 
Prefocus the gel at 20V for 30 minutes. The gel is then run at a voltage which keeps current 
flow below 60mA. As the gel resistance decreases, voltage can be increased up to a maximum 
of 130V. The gel is placed in a refrigerator (4 cc) to minimise heating and is run for 16-17 hours 
(over night). 
Interpretation of LpB (LDL) GGE 
The gel is inspected without knowledge of clinical or biochemical detail. Some subject 
samples are rerun on subsequent gels to check the consistency of the resolution and evaluatiQil 
of lipoprotein subspecies. Comment should be made about material in the stacking gel. The 
origin (top or least dense part) of the separation gel reflects the largest particles. The minigel is 
about 60mm long. In our system the stain reflecting lipoproteins in the LDL density range, is 
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from approximately the junction of the top 2/3 with the bottom 1/3. The chief LDL-related bands 
are in the bottom 1/6 of the stained area. 
The gel is described by simple terminology avoiding terms inferring separation by density. 
Since the gel was developed to investigate LDL size, the zone between the origin and the LDL 
is referred to as "mid" and staining in this region is referred to as M, which was later modified 
to M-early, or M-late depending on whether the particles were larger or smaller. Subsequently 
it became clear that chylomicron-like particles tended to remain at the origin of the separation 
gel, and hence were termed 0. At the "LDL" range, the largest particle is designated "A" while 
some intermediate "I" bands may be discerned or the "B" band as the smallest (densest) LDL 
which has been associated with a higher risk of CHD in familial combined hyperlipidaemia and 
with hypertriglyceridaemia. Subsequently it became clear that even further size distinctions can 
be made, now abbreviated to A-early, A/I, I/Band B-post. Sometimes a band between A and M-
late can be made out and was then referred to as pre-A. This band was later identified to be due 
to Lp(a). A small letter is used to designate that the band stains faintly, and a capital letter is used 
to demonstrate dominant bands. 
Describing particles from large to small on this gel would thus be: 0, M-early, M-focus 
(in Me range usually), M-late, pre-A, A-early, A, A/I, I, I/B, B, B-post. Chylomicrons correspond 
to 0, VLDL1 (Sr 60-400) to Me, LpX to Mf, VLDL 2 (S1 20-60) to M-late, pre-A is likely to be 
Lp(a), A to B-post are all species of LDL. 
Calibration of LpB (LDL) GGE. 
It has not been possible to calibrate the system accurately so that the diameter of the particles 
can be properly calculated. Currently we readily identify A and B patterns amongst the 15 lanes 
and use one of each LDL type to carry across from gel to gel to bring some standardisation about. 
Although gels that are prepared from day-to-day are not identical, it has been found that the 
classification of repeat samples in different gels is extremely reproducible. 
Attempts to calibrate the system using commercially available latex beads with known 
diameters was unsuccessful, since these beads tended to clump and cause "ladders". We have 
generally accepted that LDL particles will have the typically published diameters and that there 
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is a broad size range for all other particles. This makes accurate diameter determinations less 
useful. The system has been standardised against ultracentrifugally prepared VLDL, (Sf 60-400), 
VLDL2 (Sf 20-60), IDL (Sf 12-20) and LDL (Sf 0-12). Taking the B particle as Rs= 1.0, the 
following Rs values are typically found : Vl = 0.2-0.45 ; V2 = 0.45-0.7; IDL = 0.7-0.85 ; 
LDL A-B = 0.85-1.0, and B-post about 1.05 . 
1 2 3 4 5 6 7 8 9 10 11 12 13 
Figure I. A 2-8% non-denaturing polyacrylamide gradient gel, showing how LDL particle size and the 
presence of VLDL can differ between individuals. Lane: (1) preA, All ; (2) M early; (3) M early, B post; 
(4) All; (5) M, PreA, B; (6) I; (7) A; (8) i\1, B; (9) M, JIB; (10) PreA, I; (11) I; (12) M late, B post; 
(13) M early, B. 
Procedure HDL Gel 
Cast a 4-18% polyacrylamide (running) gradient gel. The 4% gel solution is prepared by 
mixing buffer B, and the 18% gel solution is prepared by mixing buffer A, with the appropriate 
volume of 30% acrylamide solution. Polymerisation of the gel solutions is initiated using 
ammonium persulfate (APS) 0.74% and TEMED 0.37%. The gradient is prepared using a Hoefer 
SG 15 gradient maker. A 4% stacking gel is cast on top of the running gel. The stacking gel is 
prepared using the stacking gel buffer mixed with the appropriate volume of 30% acrylamide 
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solution. Polymerisation of the stacking gel solution is initiated using APS 1.95% and TEMED 
0. 78%. Two gels are run in the system, with 15 lanes per gel. 
Plasma samples are thawed at 4 cc, mixed with 50µ1 of lipid stain (Sudan Black) only, 
incubated for a minimum of 1 hour at 4 cc and spun for 20 minutes at 10 OOOG; 16µ1 is loaded 
per well. Prefocus the gel at 20V for 30 minutes, run at 130V for 4 hours. 
Interpretation of the LpA (HDL) GGE 
The gel is inspected without knowledge of clinical or biochemical detail. Some subject 
samples are rerun on subsequent gels to check the consistency of the resolution and evaluation 
of lipoprotein subspecies. After selecting from the many lanes, likely equivalents of HDL2 and 
HDL3 species are identified. The bands tend to be poorly staining and broad, and only 
occasionally can speciation be distinguished in the two regions. The LDL bands at the top may 
be classifiable as A or B but are often inadequately separated for comment. Gels can also be 
scanned on a densitometric scanner (Hoefer Scientific Instruments GS300) . The densitometric 
scan is used to confirm the visual analysis, and area under the curve can be calculated to assess 
the ratio of HDL2 to HDL3 subspecies. 
Terminology of "HDL GEL". 
Particles relating to HDL2b and HDLp as well as HDL-ji, HDLJJ, HDL Fare described in the 
review by Silverman and Pasternak (1993). In our system we find mostly 2 peaks, one with Mr 
of 135kD and another at about 165kD. The former appears to be HDL3 and the latter HDL2• In 
some patients there is a smaller size lipid-staining peak, at about 115kD. In some instances larger 
particles are seen in hyperalphalipoproteinaemia. 
Current practice is to assume that the common species of smaller size is HDL3, the larger is 
assumed to be HDL2. The description is thus of the intensities being dominant in either one of 
the two bands or equivalent. This agrees remarkably well with the area under the curve and the 
peak intensities on our gel scanner. Occasionally there may be small species of lipoproteins, to 
which the label HDL4 has been given, or larger species to which the label HDL1 has been given. 
These can range to a size close to the LDL band. The HDL gels are usually described as follows : 
2 > 3 indicates a more prominent HDL2 than HDL3 band; 2 = 3 indicates equivalent HDL2 and 
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HDL3 bands; 2 < 3 indicates less prominent HDL2 than HDL 3 bands; 3 indicates that only 
particles in the HDL3 size range are present (2 << 3 is intermediate between the latter two 
categories); flat indicates that HDL was not evident on the gel. 
Standardisation of particle size. 
This has not been satisfactorily performed yet. Usually the pattern can be described by 
comparison with the other 14 lanes on the same run. A subject, showing prominent HDL2 and 
HDL3 bands on a previous gel, is often run in parallel. Latex beads of defined diameter do not 
provide a single neat band on the LDL or HDL system, while on the HDL system the rainbow 
markers do not give neat bands when undenatured. Protein staining by Coomassie Blue on our 
system would be confusing especially in the HDL range as there are many proteins at these sizes. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Figure 2. A 4-18% non-denaturing polyacrylamide gradient gel, showing how the distribution of particles 
in the HDL size range differs between individuals. Lane: (]) 2 < 3; (2) 2 < 3; (3) 2 > 3 (? HDL 1), rare; 
(4) 2 < 3; (5) 2 < 3; (6) 2 < 3; (7) 2 < 3; (8) 2 < 3 (HDL 4), rare; (9) 2 > 3; (1 OJ 2 < 3; (11) 2 < 3; 
(12) 2 > 3; (13) 2 < 3; (14) 2 = 3; (15) 2 < 3. 
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Chapter 4: The effect of triptorelin, a testosterone lowering agent, on 
postprandial triglyceridaemia and lipoprotein profiles in normal men 
Abstract 
The aim of this study was to determine whether a reduction of endogenous testosterone 
concentration in healthy men and the consequent elevation ofHDLC concentration is associated 
with changes in the magnitude of postprandial triglyceridaemia, LDL particle size and Lp(a) 
concentration. A reversible reduction of testosterone was induced using triptorelin (D-Trp-6-
LHRH; Decapeptyl®), a powerful GnRH agonist. Lipoprotein profiles and postprandial 
triglyceridaemia were compared in normal men (T) (n=l 0) before triptorelin administration and 
five weeks later, when testosterone concentrations were minimal (23.9±4.9 vs 3.9±1.6 nmol/1, 
p=0.004): A control group (C) (n=8), which did not receive triptorelin, was assessed in parallel. 
Lipoproteins were assessed by non-denaturing gradient gel electrophoresis (GGE), lipoprotein 
concentrations by immuno and enzymatic assay, and postprandial triglyceridaemia by a 
standardised oral fat tolerance test (65g/m2). HDLC concentration increased significantly 
(1.07±0.18 vs 1.41±0.28 mmol/L, p=0.002) in T and did not change in C. HDL profiles assessed 
by GGE showed a relative increase of larger HDL species in five T subjects and showed no 
change in C. Total cholesterol concentration increased significantly ( 4. 77±0.80 vs 
5.24±1.04 mmol/L, p=0.039) in T with a slight, but non significant increase in LDLC 
concentration. Neither total cholesterol nor LDLC concentration changed in the controls. LDL 
size assessed by GGE increased in four T subjects, whereas no increases occurred in C. Lp(a) 
concentration increased significantly (277.9±149.1 vs 376.5±222.2 U/L, p=0.004) in T, and was· 
unchanged in the C group. Postprandial triglyceridaemia was similar for both T and C subjects. 
These results show that an acute reduction in endogenous testosterone concentration has no effect 
on the magnitude of postprandial triglyceridaemia. Thus, the elevated HDLC concentration is not 
likely to be due in part to a reduced postprandial triglyceridaemia. The results of this study 
suggest that endogenous testosterone has a suppressive effect on Lp(a) and HDLC concentration 
in normal men, without affecting LDLC and fasting triglyceride concentration or the magnitude 
of postprandial triglyceridaemia. 
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Introduction 
Men are more likely to suffer from premature atherosclerosis than women 
(Godsland et al., 1987). The onset of atherosclerotic disease usually begins 10-15 years later in 
women compared to men (Castelli, 1988). This difference could exist because males possess 
some factor which predisposes them to premature atherosclerosis, or because they lack some 
factor, inherent to females, which serves to protecl from atherosclerosis. It has been hypothesised 
that the sex difference in the endogenous sex hormone concentrations may make a significant 
contribution to the sex difference in the onset of atherosclerosis (Kalin and Zumoff, 1990). 
Accordingly, the high testosterone concentration in men may aggravate atherosclerosis, whereas 
their low oestrogen concentration may render them less resistant to the atherosclerotic process 
than women. While good evidence exists to support a protective function for oestrogen against 
atherosclerosis in women (Knopp et al., 1994), evidence that endogenous testosterone aggravates 
atherosclerosis is based largely on inferential evidence. 
Endogenous testosterone is the major determinant of the lower HDLC concentration in men 
compared to women (Aascheman et al., 1994; Bagatell et al., 1992). In population studies, the 
risk for an atherosclerotic event is strongly and inversely related to HDLC concentration 
(Gordon et al., 1989). Accordingly, it has been concluded that endogenous testosterone may 
contribute to the increased risk of cardiovascular disease in men (Bagatell and Bremner, 1995). 
However, it is difficult to determine if the suppressed HDLC concentration accounts for a 
significant portion of the sex difference in risk for premature atherosclerosis. Moreover, no direct 
evidence exists to indicate that an elevated HDLC concentration, induced by a suppression of 
testosterone, will reduce the risk of premature atherosclerosis in men. The possibility also exists 
that an equivalent HDLC concentration may not confer equivalent risk in men and women. 
Indeed it has been noted that an equivalent reduction of HDLC concentration is associated with 
a greater increase in risk for CHD in woman than in men (Gordon et al., 1989), which suggests 
that HDLC concentration is a stronger predictor of atherosclerotic disease in women than in men 
(Knopp et al., 1994). A recent review by Alexandersen et al. (1996) casts further uncertainty ~I! 
the role of endogenous testosterone as a significant risk factor for premature atherosclerosis in 
men. These authors concluded that prospective and cross sectional studies which have examined 
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the relationship between endogenous testosterone and CHD, suggest either a neutral or a 
beneficial effect of testosterone on CHD in men. 
A clinical trial for a GnRH agonist (triptorelin), which induces a reversible suppression of 
testosterone, provided the opportunity to investigate the effects of an acute reduction of 
endogenous testosterone in normal men on a phenotype termed 'atherogenic dyslipidaemia'. The 
phenotype is characterised by a low HDLC concentration, increased small dense LDL particles 
and an abnormal triglyceride metabolism which can manifest as an exaggerated postprandial 
triglyceridaemia or a mild fasting hypertriglyceridaemia. This phenotype has more recently been 
identified as a lipoprotein profile which frequently rivals hypercholesterolaemia as a risk factor 
for premature atherosclerosis (Grundy, 1996). Although it is known that men tend to have a 
greater prevalence of the small dense LDL particles than women (McNamara et al., 1987), it is 
unclear how endogenous testosterone may influence LDL size. Moreover, there is a paucity of 
information about the effect of endogenous testosterone on the magnitude of postprandial 
triglyceridaemia and Lp(a) concentration in healthy men. It is also unclear whether an elevated 
HDLC concentration following testosterone suppression (Bagatell et al., 1992; 
Goldberg et al., 1985) may be caused, at least in part, by a reduced postprandial triglyceridaemia 
as proposed by Patsch et al. ( 1983 ). By doing this study it was hoped to gain new insight into the 
influence of endogenous testosterone on 'atherogenic dyslipidaemia', in so doing providing new 
insight into the role of testosterone as a risk factor for premature atherosclerosis in males. 
Methods 
Clinical trial 
A clinical trial for a GnRH agonist, triptorelin (D-Trp-6-LHRH; Decapeptyl®) was conducted 
by Debiopharm, Lausanne Switzerland, at the Department of Physiology, University of Cape 
Town. The trial was approved by the Ethics and Research Committee of the University of Cape 
Town. The aim of the trial was to compare the efficacy and tolerance of two triptorelin sustained 
release formulations. Although the physiological role of GnRH is to stimulate the release of 
gonadotropins from the anterior pituitary gland, the chronic administration of GnRH results in 
a decrease of gonadotropin secretion, and an associated reduction in plasma testosterone 
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concentration. It provides a means of reversibly suppressing testosterone production, indicated 
in males for the treatment of prostate cancer. The study was an open, randomised, balanced, 
crossover design. The second leg of the study followed three months after the commencement . 
of the first leg, once testosterone concentrations had returned to normal for several weeks. 
Substudy protocol 
A substudy was approved by the Ethics and Research Committee of the University of Cape 
Town, to allow investigation of some additional aspects of lipoprotein metabolism, and was 
conducted during the second leg of the crossover. Subjects were assessed both before triptorelin 
administration and five weeks later. Testosteror:ie concentrations were known to have been 
minimal for the longest possible period at five weeks, from experience gained in the first leg of 
the study. Lipoprotein profiles, particle size and postprandial triglyceridaemia were therefore 
compared in the subjects before the administration of triptorelin and five weeks later. 
Subjects 
The substudy group consisted often healthy men who volunteered from the original clinical 
trial study group of twelve subjects. The ages of the subjects ranged from 23 to 55 years, and all 
had normal testosterone concentrations (inclusion criteria for clinical trial). A control group of 
eight men, which did not receive triptorelin, was matched with the trial group on the basis of age, 
socioeconomic status and relative physical activity. The control group was assessed in parallel 
with the trial group. All the subjects were fully informed about the protocol prior to the study and 
provided written informed consent prior to commencement. Medical histories were collected, and 
each subject underwent a physical examination, and liver function tests (assessed by pathologists 
Penman and partners, Loop St. Cape Town) on each test day. All the subjects were asked not to 
modify any of their lifestyle habits, exercise regimen and diet, throughout the duration of the 
study. 
Anthropometry 
Anthropometric measurement was performed by the same experienced individual, using 
standardised anthropometric landmarks to locate the measuring sites (Ross and 
Marfell-Jones, 1991 ). Calculation of body fat percentage requires the measurement of four 
skinfold sites: triceps, biceps, subscapular, and suprailiac. The log of the sum of these 
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measurements is substituted into the appropriate age and sex specific equation as described by 
(Durnin and Womersley, 1974). The calculation of muscle mass requires the measurement of 
stature, mid-thigh girth, mid-thigh skinfold, calf girth, calf skinfold, and forearm girth. The 
muscle mass is calculated by substitution into the appropriate equation as described by 
Martin et al (1990). 
Dietary history 
Subjects receiving triptorelin were asked to complete three day dietary records ( covering one 
weekend day and the two preceding or following weekdays) as close to the test days as possible. 
Dietary analysis was performed using the Foodfundi® nutritional advice software (South African 
Medical Research Council) to determine mean daily energy, protein, carbohydrate, fat, 
cholesterol, saturated, monounsaturated and polyunsaturated fat intake. 
Plasma lipids and lipoproteins 
The concentration of total, LDL and HDL cholesterol was evaluated by pathologists Penman 
and partners (Loop St. Cape Town). These assays were done with commercially available enzyme 
kits on automated machines using conventional laboratory quality control techniques. Total 
cholesterol was confirmed in our laboratory using an enzymatic assay (Boehringer Mannheim 
kit no. 1442341). Apolipoprotein(a) was measured in the plasma using the Mercodia Apo(a) 
ELISA, enzyme immunoassay (Mercodia AB, Seminariegatan 29, S-752 28 Uppsala, Sweden). 
A detailed description of these methods can be found in the General Methodology chapter. 
Oral fat tolerance test 
The oral fat tolerance test was performed as described by Foger and Patsch (1993). Plasma 
triglyceride concentration was measured using a commercially available GPO PAP kit (Human, 
Germany, Kit no:10164.), and plotted against time. Postprandial triglyceridaemia (mmol/L.hr) 
was calculated by integration of the area under the curve. Postprandial triglyceride excursion was 
calculated by subtracting the fasting triglyceride concentration from the total area under the 
curve. A detailed description of this method can be found in the General Methodology chapter. 
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Non-Denaturing Gradient Gel Electrophoresis (GGE) for lipoproteins 
The size of LDL and HDL particles were determined by polyacrylamide GGE using the 
Biorad minigel apparatus; 2-8% for LDL, and 4-18% for HDL. Samples from both the test days 
were run on the same gel. Visual interpretation of the gels was confirmed by densitometric scan 
(Hoeffer Scientific Instruments GS300). A detailed description of these methods can be found 
in the General Methodology chapter. 
Statistical analysis 
A statistical software package (Graphpad Instat) was used for data analysis. Data are 
expressed as a mean (x) ± standard deviation (sd). Data were analysed using non-parametric 
methods, using the Wilcoxon matched pairs test. A value of p < 0.05 was accepted to define -
statistical significance. 
Results 
Subject characteristics and anthropometry 
The mean age was 31±10 years, and 28±11 years for the T and C subjects respectively 
(Table 1 ). Anthropometric data are available for nine T subjects and seven C subjects. The other 
two subjects were not measured in error. Neither body mass, muscle mass, nor fat percentage 
changed between tests 1 and 2 in either the T or the C subjects. However, body mass in T 
subjects tended to be slightly greater than in C subjects; with the difference consisting mostly of 
fat mass. 
Medical assessment 
The subjects were all judged to be in good health following an examination by a medical 
practitioner. Although no significant side effects were reported, loss of libido, mild impotence 
and hot flushes were reported by some subjects. Liver function tests revealed no extreme 
derangements, i.e. no deviations three times greater than the reference range upper limit, for the 
test laboratory. The T group had a mean LDH concentration (351±99 U/L) which was elevated 
compared to the C group (257±54) and the upper reference range limit (290 U/L). 
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Table I. Age and anthropometric values oftriptorelin trial and control subjects 
Subject age height body mass muscle mass fat percentage 
(yr) (cm) (kg) (kg) (%) 
Triptoreli Test I · Test 2 Test I Test 2 Test I Test 2 
n 
' 
I 23 175.1 77.2 77.3 42.4 40.2 15.9 15.5 
2 55 186.2 95.5 95.3 45.3 42.9 27.8 27.8 
3 26 166.0 70.5 70.5 35.9 38.3 20.1 19.4 
4 39 179.6 95.6 96.0 52.1 52.7 23.2 . 23.0 
5 27 181.0 76.0 81.5 
- - - -
6 30 180.4 72.2 71.1 37.4 37.9 18.6 17.7 
7 37 173.5 94.5 96.8 45.2 49.4 28.8 29.7 
8 29 187.0 86.5 87.0 52.5 50.7 11.3 10.4 
9 20 166.0 59.4 58.3 36.5 35.5 10.2 10.0 
10 25 164.6 80.7 80.4 42.2 43.7 25.3 25.2 
mean 31 175.9 80.8 81.4 43.3 43.5 20.1 19.9 
±sd ±10 ±8.3 ±12.2 ±li.7 ±6.1 ±6.2 ±6.8 ±7.1 
Control NS NS NS 
II 25 185.7 85.7 84.5 49.4 49.6 8.5 8.1 
12 20 182.3 59.7 58.5 33.1 32.9 9.1 7.8 
13 21 189.1 74.0 73.5 - - - -
14 29 180.5 63.3 63.5 38.5 38.3 10.5 8.1 
15 33 173.5 88.1 92.5 47.9 46.0 26.4 27.0 
16 24 177.5 86.0 86.0 46.2 46.1 18.9 19.4 
17 21 180.5 79.6 79.5 40.9 40.0 17.1 18.5 
18 52 168.5 72.6 72.6 38.0 39.9 26.2 25.4 
mean 28 179.7 76.1 76.3 42.0 41.8 16.7 16.3 
±sd ±II ±6.6 ±10.7 ±11.6 ±6.0 ±5.7 ±7.7 ±8.4 
NS NS NS 
Dietary analysis 
Seven of the T group completed both dietary records (Table 2). There was no difference in 
diet between test days 1 and 2 in this group. Mean daily dietary consumption for the T group was; 
energy 25640±9320 kJ, protein 16±4%, carbohydrate 55±10%, fat 30±7% (saturated 23±10 g, 
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monounsaturated 23± 10 g, polyunsaturated 13±6 g), cholesterol 810±340 mg. The C group were 
not asked to complete dietary records. A verbal interview indicated that these subjects made no 
changes to their dietary habits between the test days. 
Table 2. Analysis of dietary recall in triptorelin subjects 
Subject energy protein CHO fat SF MUF PUF chol. 
(Kj) (%) (%) (%; (g) . (g) (g) (mg) 
Pre triptorelin 
1 36178 17.4 35.6 49.4 38.8 39.9 22.7 1162 
2 31857 14.2 27.4 54.3 24.3 28.4 18.8 860 
4 14255 15.2 27.7 58.7 11.4 13.6 7.8 428 
6 17208 11.5 26.1 65.7 11.3 7.8 4.1 370 
7 25321 18.4 45.4 37.1 30.7 41.5 15.1 779 
8 35290 15.2 19.2 71.8 25.4 14.9 10.7 743 
10 12466 22.3 40.2 42.6 12.4 16.9 8.2 406 
mean 24654 16.3 31.7 54.2 22.0 23.3 12.5 678 
±sd ±10086 ±3.5 ±9.1 ±12.3 ±10.8 ±13.4 ±6.6 ±292 
Five weeks post triptorelin 
1 30449 12.3 30.0 59 31.1 28.8 15.4 723 
2 38529 13.3 28.6 55.9 37.9 31.7 20.5 1160 
4 19259 22.1 27.4 52.3 14.8 16.2 9.6 1374 
6 21528 13.1 30.4 56.5 26.8 21.8 6.1 654 
7 23717 16.1 34.6 51.1 20.2 25.3 19.9 1411 
8 37859 14.3 20.8 70.0 26.6 19.5 9.4 555 
10 15017 25.6 32.6 44.2 14.4 17.7 7.7 725 
mean 26623 16.7 29.2 55.6 24.5 23.0 12.7 943 
±sd ±9183 ±5.1 ±4.4 ±8.0 ±8.6 ±5.8 ±5.9 ±361 
Total 
mean 25638 16.5 30.4 54.9 23.3 23.1 12.6 810.0 
±sd ±9323 ±4.2 ±7.0 ±10.0 ±9.5 ±9.9 ±6.0 ±344.2 
CHO - carbohydrate; SF - saturated fat; MUF - monounsaturated fat; PUF • polyunsaturated fat; chol. • cholesterol 
-
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Testosterone 
Testosterone concentration was similar in the T group (7.32±1.92 ng/ml) compared to the C 
group (7.30±2.08 ng/ml), at test 1, prior to triptorelin administration (Table 3). Testosterone 
concentration was significantly reduced by triptorelin administration in the: T group, from 
7.32±1.92 ng/ml at testl to 1.15±0.57 ng/ml at test 2 after five wee~s (p=0.002).· Testosterone 
did not change in the C group at testl ( 7.30±2.08 ng/ml) compared to test2 (6.50±2.18 ng/ml). 
A plot of testosterone concentration versus time in the T group (Figure 1), confirms that test 2, 
performed 37 to 41 days (5.3 - 5.8 weeks) after triptorelin administration, occurred when mean 
testosterone concentration had reached baseline and been suppressed for the maximum time 
period. 
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Figure 3. Effect oftriptorelin on testosterone concentration in normal men (n=JO, x± sd). 
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Lipoprotein values 
In the T group, mean total cholesterol was increased after five weeks ( 4.8±0.8 vs 
5.2±1.0 mmol/L, p=0.04) (Table 3). Mean total cholesterol did not change in the C group 
(4.9±1.1 vs 4.9±0.9 mmol/L). Mean LDLC concentration was unchanged at test 1 compared to 
test 2 in both groups. In the T group, mean HDLC concentration increased significantly at test 2 
from 1.1±0.2 to 1.4±0.3 mmol/L, p=0.002. HDLC concentration showed no change in the C 
group (l.2±0.2 vs 1.2±0.1 mmol/L). Lp(a) concentration increased after five weeks in the T 
group (277.9±149.1 vs 376.5±222.2 U/L, p=0.004) (median; 322.7 U/L test 1 and 397.6 U/L 
test 2). Lp(a) concentration did not increase in one individual. Lp(a) concentration showed no 
change in the C group (239.0±223.2 vs 235.9±298.9 U/L). 
LDL gradient gel electrophoresis 
LDL particle size increased in four triptorelin subjects, decreased in two subjects, and showed 
no change in four subjects (Table 4). LDL particle siz.: decreased in three C subjects and showed 
no change in the other five C subjects. 
HDL gradient gel electrophoresis 
HDL profiles showed a relative increase of high density lipoprotein in the HDL2 size range 
in five triptorelin subjects and showed no change in the other five T subjects (Table 4). HDL 
profile did not change in seven of the control subjects. One control subject showed a decrease 
of high density lipoprotein in the HDL2 size range. 
Triglycerides and postprandial triglyceridaemia 
Fasting triglyceride concentrations were unchanged between test 1 and test 2 in both T and 
C subjects (Table 4). Postprandial triglyceridaemia, expressed as the total area under the curve, 
and as a triglyceride excursion were unchanged between test 1 and 2~ in both T and C. Control 
subject 15 had an exaggerated postprandial triglyceridaemia at test 2. Subsequent inquiry 
revealed that his level of physical activity decreased following the first test. Data for control 
subject 15 were nevertheless included in the statistical analysis of the data for the control subjects 
and did not affect the statistical outcome. 
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Table 3. Lipoprotein and testosterone values oftriptorelin trial and control subjects 
Subject Total Chol. LDLC HDLC Lp(a) Testosterone 
(mmol/L) (mmol/L) (mmol/L) (Units/L) (ng/ml) 
Triptorelin Test I Test 2 Test I Test 2 Test I Test 2 Test I Test 2 Test 1 Test 2 
I 3.9 3.9 2.2 2.1 1.2 1.5 94.1 107.4 8.31 2.32 
2 6.2 7.3 4.4 5.2 1.3 1.6 387.5 654.5 7.32 0.62 
3 5.7 6.0 3.8 4.0 1.3 1.7 272.1 347.1 6.58 2.04 
4 4.9 6.1 3.2 3.5 1.2 1.5 373.2 507.1 9.88 0.70 
5 3.7 5.2 2.3 3.1 I. I 1.8 382.4 478.5 5.98 1.07 
6 4.3 4.7 3.2 3.0 0.8 I.I 373.2 448.1 7.84 I.IO 
7 4.5 4.4 2.9 2.7 1.0 1.3 498.9 695.2 4.21 0.86 
8 5.1 5.7 2.9 3.5 . 1.0 1.5 62.1 86.7 8.59 0.96 
9 4.2 4.2 2.8 2.8 1.0 1.2 220.7 333.6 9.66 1.00 
IO 5.2 4.9 3.3 3.2 0.8 0.9 115.2 106.4 4.80 0.81 
mean 4.8 5.2 3.1 3.3 I.I 1.4 277.9 376.5 7.32 1.15 
±sd ±0.8 ±1.0 ±0.7 ±0.8 ±0.2 ±0.3 ±149.1 ±222.0 ±1.92 ±0.57 
Control p=0.04 NS p=0.002 p=0.004 p=0.002 
II 4.9 5.1 3.0 3.0 1.4 1.4 759.8 962.0 7.92 6.77 
12 4.2 4.3 2.8 3.1 1.0 1.0 240.5 249.6 7.34 7.95 
13 4.4 4.2 2.7 2.7 1.4 I. I 109.5 111.8 7.60 8.76 
14 5.3 4.2 3.7 2.6 1.4 1.2 119.6 93.5 9.07 9.36 
15 7.2 6.9 5.3 4.0 1.2 I.I 251.8 156.2 4.87 2.97 
16 4.0 4.4 2.5 2.8 I.I 1.2 253.9 171.7 9.33 5.59 
17 4.2 5.1 2.6 3.1 1.0 1.2 68.5 72.7 3.51 4.38 
18 5.3 5.2 3.7 3.5 1.2 1.2 108.7 77.5 8.78 6.22 
mean 4.9 4.9 3.3 3.1 1.2 1.2 239.0 236.9 7.30 6.50 
±sd ±1. I ±0.9 ±0.9 ±0.5 ±0.2 . ±0.1 ±223.2 ±298.9 ±2.08 ±2.18 
NS NS NS NS NS 
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Table 4. Lipoprotein size by GGE and postprandial triglyceridaemia in triptorelin trial and control subjects 
Subject LDLGGE HDLGGE Fasting TG Area Under Curve TG Excursion 
(mmol/L) (mmol/L.hr) (mmol/L.hr) 
Triptorelin Test I Test 2 Test I Test 2 Test I Test 2 Test I Test 2 Test I Test 2 
I I All 2<3 2=3 I. I 0.6 13.6 9.5 6.5 4.3 
2 All All 2<3 2<3 0.9 1.3 13.4 17.1 5.6 8.9 
3 1/B I 2<3 2=3 1.2 0.7 21.2 15.0 13.7 8.4 
4 I 1/B 2<3 2<3 1.5 2.6 13.4 25.2 4.3 11.8 
5 I I 2<3 2=3 1.2 0.7 16.7 16.1 6.6 9.3 
6 I I 2<3 2<3 1.3 1.7 14.6 16.0 9.1 7.9 
7 1/B I 2<3 2<3 1.2 0.8 19.5 18.8 . 8.1 12.1 
8 I 1/B 2<3 2=3 0.8 1.5 12.9 18.0 5.8 10.8 
9 1/B 1/B 2<3 2=3 1.0 0.6 17.1 10.5 10.0 4.9 
10 1/B I 2<3 2<3 1.3 2.0 23.8 20.7 15.1 9.1 
mean I.I 1.2 16.6 16.7 8.5 8.7 
±sd ±0.2 ±0.7 ±3.8 ±4.6 ±3.5 ±2.6 
Control NS NS NS 
11 I I 2=3 2=3 1.9 1.5 21.6 18.1 10.7 9.0 
12 1/B 1/B 2<3 2<3 0.8 0.6 11.8 11.2 6.6 5.1 
13 I 1/B 2=3 2<3 0.6 0.8 7.6 13.9 3.1 8.6 
14 All All 2=3 2=3 0.6 0.7 9.3 13.9 5.9 8.1 
15 1/B B 2<3 2<3 1.4 3.9 17.3 53.5 6.7 24.5 
16 I I 2<3 2<3 0.9 1.0 13.2 18.7 7.0 9.5 
17 I 1/B 2<3 2<3 I. I 1.6 12.1 23.2 5.3 9.0 
18 I I 2=3 2=3 0.9 I.I 11.4 18.9 5.4 11.9 
mean 1.0 I.I 12.4 16.8 6.3 10.7 
±sd ±0.5 ±0.4 ±4.5 ±4.1 ±2.2 ±5.9 
NS NS NS 
Chapter 4. Effect of triptorelin on. lipids and lipoproteins in normal men 64 
Discussion 
Plasma testosterone concentration was significantly reduced in a small group of normal men 
following the administration of triptorelin, a powerful GnRH agonist. It was found that after five 
weeks Lp(a) and HDLC concentration were significantly increased, whereas the concentrations 
of LDLC, triglyceride and the magnitude of postprandial triglyceridaemia were unchanged. The 
increased HDLC concentration was associated with a greater distribution of HDL particles in the 
HDL2 size range in five of the triptorelin subjects. Four of the triptorelin subjects also showed 
an increase in LDL particle size. The results of this study suggest that endogenous testosterone 
has a suppressive effect on Lp(a) and HDLC concentration in normal men, without affecting 
LDLC and fasting triglyceride concentration or the magnitude of postprandial triglyceridaemia. 
The significant increase in HDLC concentration associated with triptorelin induced 
hypoandrogenism, is consistent with other studies which have used. either GnRH agonists or 
antagonists to induce hypoandrogenism (Bagatell et al., 1992; Goldberg et al., 1985). Although 
it is possible that triptorelin may have had a direct effect on HDL metabolism, Bagatell et al. 
(1992) and Goldberg et al. ( 1985) showed that HDLC concentration was restored following 
synthetic testosterone replacement, which led them to conclude that their respective GnRH 
agonist/antagonist had no intrinsic effect on plasma lipids. While this finding does not exclude 
an intrinsic effect unique to triptorelin, it is nevertheless unlikely. The significant reduction in 
HDLC concentration is also in keeping with the hypothesis that endogenous testosterone is the 
major determinant of sex differences in plasma HDLC concentration (Asscheman et al., 1994; 
Goldberg et al., 1985). 
It should be noted that a suppression of testosterone in men also causes a significant 
secondary reduction in oestrogen, as much of the endogenous male oestrogen is derived from the 
aromatisation of testosterone (Bagatell et al., 1992). Endogenous male oestrogen inhibits the 
suppressive effect of testosterone on HDLC and particularly HDL2C concentration 
(Bagatell et al., 1994a), apparently by counteracting the stimulatory effect of testosterone on 
HTGLa (Friedl et al., 1990; Zmuda et al., 1993). This in turn reduces the catabolic rate of HDL, 
and particularly HDL2 (Tikkanen and Nikkila, 1987). However, the stimulatory effect of 
oestrogen on HDLC and HDL2C concentration does appear to be relatively minor compared to 
the powerful suppressive effect of testosterone. The reduced testosterone concentration induced 
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by triptorelin may cause a re.duction in HTGLa, and increase HDLC concentration by reducing 
the catabolism ofHDL. The increased HDLC concentration may also be caused by an increased 
synthesis ofHDL. GGE studies indicate that a marked increase occurred in the HDL2 size range 
in half of the T subjects. There are no previous studies which have described changes in the HDL 
profile in terms of particle size. This finding is, however, consistent with other studies which 
report a predominant increase in the cholesterol concentration in the HDL2 rather than HDL 3 
subfraction following changes in endogenous testosterone concentration (Asscheman et al., 1994; 
Bagatell et al., 1992). 
An acute reversible suppression of testosterone was associated with a 26% increase in the 
mean Lp(a) concentration. This finding is consistent with a study by von Eckardstein et al. (1997) 
who reported a significant increase in Lp(a) concentration using the GnRH agonist cetrorelix. 
. This finding is also consistent with a study by Berglund et al. ( 1996) who reported that 
orchidectomy in elderly men with prostatic carcinoma, resulted in a 20% increase in Lp(a) 
concentration, a change which was reversed following the replacement of testosterone. Moreover, 
synthetic testosterone supplementation significantly reduces Lp(a) concentration in both 
hypogonadal (Ozata et al., 1996) and normal males (Marcovina et al., 1996; Zmuda ei al., 1996). -
The reduction of testosterone concentration may influence Lp(a) concentration by permitting 
increased apo(a) synthesis or secretion, increased Lp(a) assembly, or reduced Lp(a) catabolism 
(Crook et al., 1992). An elevated Lp(a) concentration is a risk factor for premature 
atherosclerosis, although the pathogenicity of Lp(a) does appear to be modulated by the 
concentration ofLDLC (Armstrong et al., 1986). The suppressive effect of testosterone on Lp(a) 
concentration in males may indicate an antiatherogenic effect of endogenous testosterone in 
males. It is, however, intriguing that there appears to be no sex difference in Lp(a) concentration 
(Jenner et al., 1993). 
The significant elevation in total cholesterol with triptorelin is accounted for mostly by the 
elevated HDLC concentration, and to a lesser extent by an elevated LDLC concentration in some 
individuals. The cause of the increased LDLC concentration in these subjects is unclear. 
Bagatell et al. (1992, 1994a) reported that suppression of both endogenous testosterone and 
oestrogen had no effect on LDLC concentration, whereas Goldberg et al. (1985) found that apoB 
was increased. GGE studies on LDL subfractions indicated a modest increase in the LDL particle 
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size in fourtriptorelin subjects, none of whom showed any remarkable changes in LDLC, HDLC 
or fasting triglyceride concentration compared to the other triptorelin subjects. The cause of the 
increased LDL particle size in these subjects is unclear, but may reflect a reduction in HTGLa, 
as HTGLa may be inversely associated with a preponderance of small, dense LDL 
(Watson et al., 1994; Zambon et al., 1993), and a lack of HTGL is accompanied by a massive 
triglyceride enrichment of LDL (Auwerx et al., 1989; Breckenridge et al., 1982). Endogenous 
testosterone may account in part for the tendency towards smaller, denser LDL in men compared 
to women (McNamara et al., 1987), possibly through a stimulatory effect on HTGLa. The 
absence of a common pattern within the triptorelin group indicates that testosterone is probably 
not a major determinant ofLDL size in men. This hypothesis is, however, not consistent with the 
finding that low concentrations of sex hormone-binding globulin and testosterone are associated 
with smaller, denser low density lipoprotein in normoglycemic men (Haffner et al., 1996). The 
latter finding reflects the paradoxical observation that synthetic testosterone suppresses HDLC 
concentration, whereas endogenous testosterone is positively correlated with HDLC 
concentration (Bagatell and Bremner, 1995). It is thus possible that some factor which 
predisposes to small dense LDL also predisposes to a reduced testosterone concentration. 
The fasting triglyceride concentration and the magnitude of postprandial triglyceridaemia 
were unaffected by an acute reduction in endogenous testosterone concentration. No previous 
study has assessed the effect of hypoandrogenism on postprandial triglyceridaemia. The results 
of the fat tolerance test conducted in the present study indicate that a possible decrease in 
HTGLa, caused by a reduction of testosterone, would be insufficient to significantly influence 
the clearance of triglyceride. The triptorelin induced hypoandrogenism does not appear to 
influence the other major lipolytic enzyme, LPL. Other studies which have assessed the effect 
of acute reversible hypoandrogenism on fasting triglyceride concentration in normal men have 
found no change (Bagatell et al., 1992; Goldberg et al., 1985). It is therefore unlikely that the 
elevated HDLC concentration, associated with a suppression of testosterone, is related to changes 
in postprandial triglyceridaemia as proposed by Patsch et al. (1983) 
In summary, plasma testosterone concentration was significantly reduced after five weeks in 
normal men following the administration of triptorelin, a powerful GnRH agonist. The 
concentration of Lp(a) and HDLC were significantly increased, whereas the concentrations of 
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LDLC, fasting triglyceride and the magnitude of postprandial triglyceridaemia were unchanged, 
during the triptorelin induced hypogonadal state. The increased HDLC concentration was 
associated with a greater distribution of HDL particles in the HDL2 size range in five triptorelin 
subjects. These results support the hypothesis that endogenous testosterone is. the major 
determinant of the lower HDLC and particularly the lower HDL2C concentration in men 
compared to women (Asscheman et al., 1994 ). An increased LDL particle size in four triptorelin 
subjects indicates that endogenous testosterone may play a limited role in determining LDL size 
in men. Circulating testosterone does not appear to influence postprandial triglyceridaemia, 
indicating that the metabolic changes which permitted an increase in HDLC concentration are 
insufficient to influence the magnitude of postprandial triglyceridaemia, at least for the duration 
of the testosterone reduction obtained in this study. The suppressive effect of testosterone on 
Lp(a) concentration suggests an antiatherogenic effect of endogenous testosterone in men, . 
although it is uncertain whether this effect will counteract the atherogenic effect of a reduced 
HDLC concentration. 
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Chapter 5: The effect of anabolic-androgenic steroids on postprandial 
triglyceridaemia and lipoprotein profiles in bodybuilders 
Abstract 
Although users of anabolic-androgenic steroid (AAS) are often regarded as having an 
increased risk of developing premature atherosclerosis, due to unfavourable plasma lipid 
changes, particularly in HDLC concentration, no direct link between AAS use and atherosclerosis 
has yet been made in humans. 'Atherogenic dyslipidaemia' is a phenotype characterised by 
increased postprandial triglyceridaemia, smaller, denser LDL particles and a low HDLC 
concentration, which is frequently associated with premature CHD. This study investigated how 
self administered AAS use in bodybuilders influences 'atherogenic dyslipidaemia', in an attempt 
to better describe their risk for premature atherosclerosis. The magnitude of postprandial 
triglyceridaemia, LDL and HDL particle size, and LDLC, HDLC and Lp(a) concentration were 
compared in male (n=9) and female (n=3) subjects after self administration of AAS for 5-6 weeks 
(on-cycle) and again after a 4-6 week (x = 5.5 weeks) 'washout' period. AAS use was confirmed 
by urinalysis. Lipoproteins were assessed by non-denaturing gradient gel electrophoresis (GGE), 
lipoprotein concentrations by immuno and enzymatic assay, and postprandial triglyceridaemia 
by a standardised oral fat tolerance test (65g/m2). HDLC concentration decreased in male subjects 
(0.94±0.30 vs 0. 70±0.27 mmol/L, p=0.004; x ± SD) and female subjects (l.3±0.5 vs 
0.8±0.2 mmol/L) after using AAS. GGE studies suggested that mostly HDL2 was reduced. No 
significant reduction in LDL particle size was found in subjects using AAS, and two subjects had 
slightly larger species when using AAS. Total cholesterol, triglyceride and LDLC concentration 
were unchanged when the subjects were using AAS. Lp(a) concentration decreased significantly 
in male subjects (124.7±128.0 to 69.3±73.3 U/L, p=0.008), decreased in two female subjects, and 
increased in the third subject while they were using AAS. The magnitude of postprandial 
triglyceridaemia was unchanged in females; when corrected for fasting triglyceride concentration, 
the reduction of postprandial triglyceridaemia was significant in males (p=0.027). These results 
suggest that postprandial triglyceridaemia and smaller, denser LDL are not increased in AAS 
users. Thus, a low HDLC concentration associated with AAS use is not likely to be due, in part, 
to an increased postprandial triglyceridaemia. Decreased Lp(a) concentration and decreased 
small, dense LDL particles and postprandial triglyceridaemia, in individuals who are predisposed 
to 'atherogenic dyslipidaemia', may be antiatherogenic effects of AAS. 
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Introduction 
The use of anabolic-androgenic steroids (AAS) is usually associated with a marked reduction 
in HDLC concentration and frequently with an increase in LDLC concentration (Glazer, 1991). 
In population studies, the risk for an atherosclerotic event is strongly and inversely related to 
HDLC concentration (Gordon et al., 1989). Moreover, among the risk factors for premature 
atherosclerosis, the LDLC/HDLC ratio is considered to be the most predictive (McGill, 1996). 
Accordingly, it has been concluded that AAS users have a significantly increased risk for 
premature atherosclerosis (Glazer 1991 ). However, no prospective or retrospective studies in 
humans are available to show that AAS users have an increased risk of premature atherosclerosis 
compared to matched controls. Studies in female animals indicate that AAS may induce 
premature atherosclerosis (Adams et al., 1995; Obasanjo et al., 1996), whereas studies on male 
animals are equivocal (Fogelberg et al., 1990; Larsen et al., 1993; Toda et al., 1984). 
Unfortunately, none of these studies attempted to simulate the cyclical pattern of AAS use 
typically used by athletes and bodybuilders. Furthermore, it remains uncertain whether data from 
animal atherosclerosis models can be extrapolated to humans. 
To date, there have been nineteen case reports documenting adverse cardiovascular events 
associated with the use of AAS in twenty-one men, most of whom were bodybuilders 
(Akter et al., 1994; Appleby et al., 1994; Bowman et al., 1989; Bowman, 1990; 
Dickerman et al., 1995; Ferenchick et al., 1991; Ferenchick et al., 1992; Fisher et al., 1996; 
Frankie et al., 1988; Huie, 1994; Jaillard et al., 1994; Kennedy, 1993; Kennedy et al., 1993a; 
Laroche, 1990; Luke et al., 1990; Lyngberg, 1991; McNutt et al., 1988; Mewis et al., 1996; 
Mochizuki and Richter 1988; Siekierzynska-Czamecka et al., 1990). However, it is difficult to 
determine from these reports if AAS were responsible for the inferred atherosclerosis. Given that 
it is estimated that there are more than one million current or former AAS users in the United 
States (Yesalis et al., 1993), and that AAS were first used by athletes as early as the 1950's 
(Strauss and Y esalis, 1991 ), it is perhaps surprising that the prevalence of complications due to 
premature atherosclerosis are not more common. Although it has been argued that individuals 
may be reluctant to admit AAS use, and the identification of AAS as a causative factor in 
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cardiovascular events is difficult, it is likely that the intensity of medical interest in reporting 
assumed cases may compensate for under reporting (Rockhold, 1993). 
It has more recently become evident that a phenotype termed 'atherogenic dyslipidaemia' 
frequently rivals hypercholesterolaemia as a risk factor for premature atherosclerosis 
(Grundy, 1996). This phenotype is characterised by a low HDLC concentration, a predominance 
of small dense LDL particles and an abnormal triglyceride metabolism which can manifest as an 
exaggerated postprandial triglyceridaemia or a mild fasting hypertriglyceridaemia. Very little 
information exists about the possible effect of AAS on 'atherogenic dyslipidaemia'. Accordingly, 
the present study was undertaken to investigate the effect of AAS on the magnitude of 
postprandial triglyceridaemia and LDL particle size, so as to provide new insight into the effect 
of AAS on this phenotype. By combining this information with the effect of AAS on LDLC, 
HDLC and Lp(a) concentration it is hoped that the present study will better describe risk for 
premature atherosclerosis in AAS users. 
Methods 
Subjects 
This study was approved by the Ethics and Research Committee of the Universicy of Cape 
Town, Medical School. Since (i) AAS are widely believed to have potentially serious side effects, 
(ii) the use of AAS without prescription is unlawful in South Africa, and (iii) the recruitment of 
subjects for the study might be viewed as encouragement of the use of AAS, the Ethics 
Committee stipulated that all subjects be informed of the potential side effects of AAS, and be 
discouraged from using AAS by an impartial person,·not directly associated with the study. The 
study was publicised at regional bodybuilding competitions and at local gymnasiums. Twelve 
subjects, nine men, and three women, volunteered to participate in the study, providing written 
informed consent prior to commencement. They had been practising body building for 
approximately five years (range 2 - 8 years) and trained between four and six times a week. 
Training sessions typically comprised 1-1 Y2 hours of heavy resistance training and Y2 hour of 
'aerobic' training. All the subjects were in the 'bulking' phase of their training, apart from two 
female subjects (IO and 12) who were 'cutting' (dieting to reduce fat mass so as to improve 
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muscle definition for competition). Medical histories were collected, and each subject underwent 
a physical examination by a physician, electrocardiogram, and liver function tests (assessed by 
pathologists Penman and partners, Loop St. Cape Town) which included assessment oflactate 
dehydrogenase (LDH), bilirubin (total and conjugate), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), gamma glutamic transaminase (GGT), alkaline phosphatase (AP) total 
protein, total globulin and albumin concentration on each test day. 
Anabolic-androgenic steroids 
AAS used by participants were self-obtained and self-administered (Table 5). Subjects used 
a combination of both oral and parenteral AAS. All subjects, apart from one, (subject 6), had 
used AAS previously. Subjects 1,2,9 had used AAS for 5 years, subjects 4,7 for 4 years, subjects 
11,12 for 3 years, and subjects 3, 5, 8, 10 for 5: 1 year. The AAS users cycled on (ON) and off 
(OFF) use, with the OFF cycle, being regarded as a 'washout period', necessary to allow 
recuperation from any adverse effect of the ON cycle period. At the time of testing, most of the 
subjects had been OFF cycle for ~6 weeks. Subjects 2 and 5 had chosen a 5 week OFF cycle, and 
subjects 7 and 9 had elected to spend only 4 weeks OFF cycle. The mean ON cycle period was 
6.9 ± 1.8 weeks. The investigators were prohibited from giving subjects any advice regarding 
cycle lengths and AAS dosage. The two test days therefore occurred when subjects chose to 
finish each cycle. Seven of the subjects had their first test day at the end of their OFF cycle and 
five at the end of their ON cycle so as to prevent analytical bias due to test order. Subjects acted 
as their own controls. 
Subjects agreed to use no AAS during their OFF cycle period. Urine samples were collected 
for urinalysis at the University of the Orange Free State doping control laboratory, an IOC 
accredited laboratory, to confirm the use and type of AAS both ON and OFF cycle (Table 8). The 
procedure for detection of AAS involved gas chromatography with a mass selective detector after 
deconjugation and derivitisation of the urine extracts (Van der Merwe and Kruger, 1992). 
Although the assay can only identify AAS type, in some cases a relative estimate of concentration 
could also be made. 
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Table 5. Bodybuilding and AAS use history, length of OFF and ON cycle, and cycle at first test 
Subject Bodybuilding AAS use OFF cycle length ON cycle length Cycle at first test 
history (years) (weeks) (weeks) 
(years) -
I 6 5 6 6 ON 
2 8 5 5 10 ON 
3 2 0.5 8 7 ON 
4 5 4 ;?6 8 OFF 
5 3 0.5 5 6 ON 
6 3 - - 7 OFF 
7 5 4 4 5 OFF 
8 6 I 6 6 ON 
9 5 5 4 JO OFF 
JO 4 I ;?6 8 OFF 
II 4 3 ;?6 6 OFF 
12 5 2 ;?6 4 OFF 
Subjects I 0. 11 and 12 are female 
Anthropometry 
Anthropometric measurement was performed by the same experienced individual, using 
standardised anthropometric landmarks to locate the measuring sites (Ross and 
Marfell-Jones, 1991 ). Calculation of body fat percentage requires the measurement of four 
skinfold sites: triceps, biceps, subscapular, and suprailiac. The log of the sum of these 
measurements is substituted into the appropriate age and sex specific equation as described by 
Durnin and Womersley (1974). The calculation of muscle mass requires the measurement of 
stature, mid-thigh girth, mid-thigh skinfold, calf girth, calf skinfold, and forearm girth. The 
muscle mass is calculated by substitution into the appropriate equation as described by 
Martin et al. (1990). 
Dietary and exercise record 
Subjects were asked to complete three day dietary records (covering one weekend day and the 
two preceding or following weekdays) as close to the ON and OFF cycle test days as possible. 
Dietary analysis was performed using the Foodfundi® nutritional advice software (South African 
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Medical Research Council) to determine mean daily energy, protein, carbohydrate, fat, 
cholesterol, saturated, monounsaturated and polyunsaturated fat intake. Subjects were also asked 
to complete seven day physical activity diaries. 
Plasma lipids and lipoproteins 
The concentration of total, LDL and HDL cholesterol was evaluated by pathologists Penman 
and partners (Loop Street, Cape Town). These assays were done with commercially available 
enzyme kits on automated machines using conventional ·laboratory quality control techniques. 
Total cholesterol was confirmed in our laboratory using an enzymatic assay (Boehringer 
Mannheim kit no. 1442341). Apolipoprotein(a) was measured in the plasma using the Mercodia 
Apo(a) ELISA, enzyme immunoassay (Mercodia AB, Seminariegatan 29, S-752 28 Uppsala, 
Sweden). A detailed description of these methods can be found in the General Methodology 
chapter. 
Oral fat tolerance test 
The oral fat tolerance test was performed as described by Feger and Patsch (1993). Plasma 
triglyceride concentration was measured using a commercially available GPO PAP kit (Human, 
Germany, Kit no:10164.), and plotted against time. A detailed description of these methods can 
be found in the General Methodology chapter. Postprandial triglyceridaemia (mmol/L.hr) was 
calculated by integration of the area under the curve. Postprandial triglyceride. excursion was 
corrected by subtracting the area attributable to the fasting triglyceride concentration from the 
total area under the curve. Postprandial triglyceride excursion was also calculated by subtracting 
the mean fasting and ten hour triglyceride concentrations (in subjects who were deemed to have 
returned to fasting concentration) from the total area under the curve, and found to produce the 
same results. 
Non-Denaturing Gradient Gel Electrophoresis (GGE) for lipoproteins 
The size of LDL and HDL particles were determined by polyacrylamide GGE using the 
Biorad minigel apparatus; 2-8% for LDL, and 4-18% for HDL. Samples from both the ON and 
OFF cycle test days were run on the same gel. Visual interpretation of the gels was confirmed by 
densitometric scan (Hoeffer Scientific Instruments GS300). A relative comparison of the amount 
ofHDL at the OFF and ON cycle test could also be made by calculating the area under the curve 
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derived from the densitometric scan. A detailed description of these methods can be found in the 
General Methodology chapter. 
Statistical analysis 
A statistical software package (Graphpad Instat) was used for data analysis. Data are 
expressed as a mean (x) ± standard deviation (sd). Data were analysed using non-parametric 
methods, using the Wilcoxon matched pairs test. A value of p < 0.05 was accepted to define 
statistical significance. 
Results 
Subject characteristics and anthropometry 
The mean age was 25±2 years for the male, and 31 ± 7 years for the female subjects (Table 6). 
Body mass of the male subjects increased significantly ON cycle from 96.2± 11.1 to 99. 7± 11.1 kg 
(p=0.004). The range in the increase of body mass was from 1.2 to 93kg, or 1.2% to 9.8% of 
starting body mass. This could be partially attributed to a significant increase in muscle mass 
from 60.8±7.6 to 62.5±7.5 kg (p=0.03), since there was no increase in fat mass ON cycle. Female 
subjects 10 and 11 had increased muscle mass ON cycle, whereas the other female subject had 
a decreased muscle mass. Body and fat mass decreased in subjects 10 and 12 and increased in 
subject 11. 
Medical assessment 
The subjects were all judged to be in good health following an examination by a medical 
practitioner. No clinically significant adverse effects of AAS use were detected by general 
medical examination or by ECG. Resting blood pressure was within the normal range for all 
subjects, and did not change with one cycle of AAS use (Table 7). Abdominal examination 
revealed no hepatomegaly in subjects who had used AAS previously. 
Liver function tests revealed no extreme derangements, i.e. no deviations three times greater 
than the upper limit of the reference range (Table 7). In addition, there were no significant 
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differences between the mean OFF and ON cycle concentrations for any of the liver function 
tests. Subjects 2 and 8 had slight elevations (~2 µmol/L above reference range) in total bilirubin 
concentration. The mean lactate dehydrogenase (LDH) activity, both OFF (325±79 U/L) and ON 
cycle (311±80 U/L) were greater than the reference range upper limit of 290 U/L. The mean OFF 
cycle aspartate aminotransferase (AST) activity (32±9 U/L) was greater than the reference range 
upper limit of 25 U/L. The mean ON cycle AST activity (35±16 U/L) was greater than OFF 
cycle, although not significantly. The mean alanine aminotransferase (ALT) activity, both OFF 
(42±12 U/L) and ON cycle (40±15 U/L) were greater than the reference range upper limit of 
29 U/L. Alkaline phosphatase (AP) was elevated both OFF (227 U/L) and ON cycle (252 U/L) 
in subject 5, compared to the reference range upper limit of 207 U/L. 
Table 6. Age and anthropometric values of AAS using bodybuilder subjects 
Subject age height body mass muscle mass fat mass 
(yr) (cm) (kg) (kg) (kg) 
OFF cycle ON cycle OFF cycle ON cycle OFF cycle ON cycle 
I 27 183.0 109.0 110.6 71.1 74.4 11.5 11.9 
2 26 178.5 107.2 111.7 64.8 66.0 14.7 15.I 
3 22 170.3 77.3 81.8 48.4 53.6 9.7 9.8 
4 27 170.5 88.7 90.9 56.3 57.6 11.1 13.7 
5 21 182.9 93.2 97.3 56.2 55.9 20.0 17.1 
6 22 183.3 95.1 104.4 61.3 63.8 15.1 17.0 
7 27 183.0 104.0 105.2 67.7 66.5 10.6 IO.I 
8 26 178.0 85.0 86.4 53.8 54.3 9.5 9.6 
9 25 185.1 106.1 108.9 67.5 70.3 13.9 12.4 
mean 25 179.4 96.2 99.7 60.8 62.5 12.9 13.0 
±sd ±2 ±5.6 ±11.1 ±I I.I ±7.6 ±7.5 ±3.4 ±3.0 
p=0.004 p=0.03 NS 
JO 25 172.2 69.5 66.9 41.5 42.4 9.5 7.8 
11 30 172.2 75.5 77.7 41.2 43.7 14.4 16.0 
12 39 170.3 66.7 64.0 36.9 33.1 13.1 I I.I 
mean 31 171.6 70.6 69.5 39.9 39.7 12.3 11.6 
±sd ±7 ±I.I ±4.5 ±7.2 ±2.6 ±5.8 ±2.5 ±4.1 
Subjects I 0, 11 and 12 are female 
NS - not statistically significant 
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Table 7. Blood pressure and liver function test data of AAS using bodybuilder subjects 
Subjects I 2 3 4 5 6 7 8 9 IO 11 12 mean ±SD 
BP OFF - - 145/ 150/ 160/ 150/ 150/ 120/ 120/ 110/ - 120/ 
80 95 80 80 90 70 70 70 80 
mmHg ON - 140/ 135/ 145/ 130/ 140/ 140/ 140/ 130/ 130/ 100/ 130/ 
90 75 95 75 70 80 70 80 80 70 90 
Bilir. OFF 13 13 10 10 12 14 20 *22 13 12 17 13 14 ±4 
total ON 12 *23 II 17 16 10 18 12 II 20 14 8 14 ±4 
Bilir. OFF 2 0 I I 2 3 5 2 2 I 2 I 2 ±1 
conj. ON I 5 I 2 4 I 2 0 5 3 I 0 2 ±2 
LDH OFF 256 245 257 257 *311 *511 *415 *320 *357 *342 *355 268 325 ±79 
ON 247 *361 247 243 *474 *401 *297 273 261 *412 272 247 311 ±80 
AST OFF 22 *30 *31 *28 25 *35 *42 *28 *29 *34 *54 20 32 ±9 
ON *30 *59 *27 *28 *40 *74 *30 *27 *29 *40 24 16 35 ±16 
ALT OFF *30 *31 *53 *44 *40 28 *62 *49 *48 *35 *59 *30 42 ±12 
ON *33 *51 26 *33 *36 *62 *56 *41 *61 *44 22 18 40 ±15 
GGT OFF 8 12 12 33 37 12 17 19 26 14 23 14 19 ±9 
ON 8 13 13 21 35 12 II 12 16 15 19 13 16 ±7 
AP OFF 112 142 114 154 *227 147 141 141 152 91 123 96 137 ±36 
ON 109 127 178 129 *252 122 92 126 102 89 85 85 125 ±48 
Prot. OFF 70 74 66 77 74 75 78 68 72 76 73 63 72 ±5 
total ON 70 74 68 72 73 69 68 67 70 78 62 65 70 ±4 
Alb. OFF 43 45 43 47 45 45 43 45 47 49 44 40 45 ±2 
ON 44 48 44 44 43 42 42 43 41 50 40 43 44 ±3 
Glob. OFF 27 29 23 30 29 30 35 23 25 27 29 23 28 ±4 
total ON 26 26 24 28 30 27 26 24 29 28 22 22 26 ±3 
Reference r1IDges 
Bilirubin (total) 8 - 21 µmol/L Bilirubin (conjugate) 0, 8 µmol/L LDH 120 - 290 U/L 
AST 0- 25 U/L ALT 0 - 29 U/L GGT 8- 38 U/L 
AP 73 - 207 U/L Protein total 60 - 85 g/L Albumin 35 - 55 g/L 
Globulin total 20 - 35 g/L 
* indicates values which fall outside the reference range 
Subjects I 0, 11 and 12 are female 
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Anabolic-androgenic steroid use 
Some AAS reported by subjects were not detected by urinalysis (Table 8) including: 
Metonolone enanthate (subject 2), Oxymetholone (subjects 3,9), Methandrostenolone (subject 4), 
and Mesterolone (subjects 8,10). Mesterolone was detected in subject 12, although its use was 
not reported by the subject. Nandrolone was detected at the OFF cycle test in all subjects who 
had used AAS previously, excepting subjects 8, 11, 12 who had no detectable AAS. Nandrolone 
detected in subjects 4 and 9 OFF cycle could be attributed to use of this agent in a previous cycle. 
Testosterone and stanozolol were detected in subject 7 at the OFF cycle test, the first test day for 
this subject, and can be attributed to use of these agents in a previous cycle. Stanozolol was 
detected nine weeks later in the same subject, at the ON cycle test, although not reported by the 
subject for the ON cycle AAS regimen. Subjects 4 and 10 reported that their use 9f AAS was 
supplemented with growth hormone i.m. 25 iu's/wk for seven weeks. 
Dietary and physical activity record 
Seven male subjects each completed one dietary record, and only two subjects completed the 
second dietary record (Table 9). The other five subjects were not prepared to complete the second 
dietary record, claiming that their diets had not changed since the first test. Two male subjects 
failed to return their dietary records at any stage in the study. All three female subjects returned 
their first dietary record, two subjects returned the second dietary record, with the third subject 
claiming that her diet had not changed since the first dietary record. Three subjects completed 
activity records for both test days, and nine subjects completed either one only or neither. Some 
of the physical activity records were completed incorrectly, indicating that close supervision is 
required in order to obtain an accurate assessment of physical activity. Analysis of these data are 
thus not included. 
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Table 8. AAS use reported by bodybuilder subjects and as detected by urinalysis 
Subj. reported by subject mean dose /wk detected comments detected comments 
ON cycle x n weeks ON cycle OFF cycle 
I Nandrolone decanoate 200mg/wk.6 Nandrolone very high Nandrolone -5%! 
Testosterone cypionate 200mg/wk.6 Testosterone medium 
2 Metonolone enanthate 700mg/wk.8 Nandrolone medium Nandrolone -70% 
Testosterone propionate I OOOmg/wk. I 0 Testosterone high 
Testosterone cypionate 200mg/wk, I 0 
Testosterone undecanoate 200mg/wk.10 
3 Nandrolone decanoate 84mg/wk.7 Nandrolone high Nandrolone -20% 
Testosterone 315mg/wk.7 Testosterone high 
fenylpropionate 350mg/wk.7 
Oxymetholone 
4* Testosterone cypionate 550mg/wk.8 Nandrolone very low Nandrolone very low 
Testosterone proprionate I 200mg/wk.3 Testosterone medium 
Methandrostenolone 125mg/wk.l 
5 Nandrolone decanoate 50mg/wk.6 Nandrolone very high Nandrolone -20% 
Testosterone cypionate 200mg/wk.6 Testosterone high 
6t Nandrolone Jaurate 215mg/wk.7 Nandrolone - none -
Testosterone cypionate 285mg/wk.7 Testosterone 
7* Nandrolone 200mg/wk.6 Nandrolone very high Nandrolone -25% 
Testosterone cypionate 200mg/wk.6 Testosterone -60% Testosterone very high 
Stanozolol -60% Stanozolol very high 
8 Testosterone cypionate 300mg/wk.2 Testosterone medium none 
-
Testosterone proprionate I 400mg/wk.6 
Mesterolone 1400mg/wk.3 
9* Testosterone enanthate 800mg/wk.5 Nandrolone -10% Nandrolone medium 
Testosterone 50mg/wk.5 Testosterone very high 
fenylpropionate I 025mg/wk.8 Stanozolol high 
Testosterone proprionate 625mg/wk.8 
Oxymetholone 400mg/wk.10 
Stanozolol 
10• Nandrolone laurate 75mg/wk.8 Nandrolone medium Nandrolone -20% 
Mesterolone 350mg/wk.8 
11• Metenolone acetate 150mg/wk.6 Metenolone - none -
Methandrostenolone 15mg/wk.4 Methandro-
steno lone 
12• Metenolone acetate 210mg/wk.4 Metenolone 
-
none 
-
Boldenone 125mg/wk.4 Mesterolone 
Boldenone 
Subjects IO. 11 and 12 are female 
. - indicates that subject was OFF cycle prior to the first test 
t 
-
indicates subject with no prior AAS use 
+ indicates approximately x% of amount detected in the other sample of the same subject. + -
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Table 9. Analysis of dietary recall in AAS using bodybuilder subjects 
Subject energy protein CHO fat SF MUF PUF chol. 
(Kj) (%) (%) (%) (g) (g) (g) (mg) 
!OFF 13791 27.6 50.5 21.9 22.1 25.5 18.5 1083 
ION 15677 28.7 49.9 21.4 24.3 27.6 24.7 1009 
3 10756 28.8 47.9 23.3 18.5 15.0 27.5 272 
4 21840 27.5 59.6 12.9 11.2 29.4 16.7 428 
5 OFF 8396 21.3 63.0 18.4 13.6 15.4 7.9 181 
50N 16329 28.4 50.5 21.1 27.4 25.9 16.2 490 
6 17710 31.7 51.6 16.7 19.4 21.7 27.9 420 
8 10504 31.4 48.8 19.8 13.9 19.6 15.4 457 
9 21806 20.5 55.5 24.0 50.1 44.2 28.8 551 
mean 15201 27.3 53.0 19.9 22.3 24.9 20.4 543 
±sd ±4817 ±3.9 ±5.2 ±3.5 ±11.7 ±8.9 ±7.2 ±306 
10 5014 48.3 24.7 27.0 5.9 22.1 5.0 122 
11 OFF 7618 27.4 57.8 14.8 8.1 9.6 9.0 229 
11 ON 7984 28.9 58.3 12.8 6.9 8.9 7.9 247 
12 OFF 7909 34.7 54.4 10.9 5.5 7.2 6.6 325 
120N 6909 36.4 55.5 8.1 3.0 4.4 5.7 252 
Subjects I 0, 11 and 12 are female 
CHO - carbohydrate: SF - saturated fat; MUF - monounsaturated fat; PUF - polyunsaturated fat; chol. - cholesterol 
Lipoprotein values 
In the male subjects, mean total cholesterol and mean LDLC concentration tended to be lower 
ON cycle, although the trend was not statistically significant (Table 10). Total cholesterol 
decreased in two female subjects, and increased in the third female subject when ON cycle. 
LDLC concentration decreased in one female subject, showed no change in one and increased 
in the other. In the male subjects, mean HDLC concentration decreased consistently when 
subjects were ON cycle from 0.9±0.3 to 0.7±0.3 mmol/L (p=0.004). HDLC concentration 
decreased by 50% in two female subjects, and showed no change in the third. In the male 
subjects, Lp(a) concentration decreased significantly when subjects were ON cycle from 
124.7±128.0 to 69.3±73.3 U/L, p=0.008 (median; 80.0 U/L OFF and 45.5 U/L ON cycle). The 
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Lp(a) concentration does not appear to decrease as a fixed percentage of the initial concentration. 
Lp(a) concentration decreased ON cycle in two female subjects, and increased in the third. 
Female subject 11 was characterised by a particularly high Lp(a) concentration. 
Table IO. Lipid and lipoprotein values of fasted AAS using bodybuilder subjects 
Subject Total Chol. LDLC HDLC Lp(a) Triglyceride 
(mmol/L) (mmol/L) (mmol/L) (Units/L) (mmol/L) 
OFF ON OFF ON OFF ON OFF ON OFF ON 
cycle cycle cycle cycle cycle cycle cycle cycle cycle cycle 
I 4.3 4.7 2.5 3.3 1.4 I.I 95.2 71.6 I. I 0.7 
2 8.6 5.4 7.1 4.2 1.2 0.9 222.4 120.5 1.6 0.6 
3 4.4 4.6 3.2 3.6 1.0 0.6 80.0 22.7 0.6 0.8 
4 5.7 4.2 3.5 3.0 0.9 0.6 0.8 1.7 1.7 1.5 
5 6.2 5.3 4.5 3.8 0.9 0.8 53.9 43.8 1.6 1.4 
6 2.8 2.6 1.8 1.6 0.8 0.6 426.2 242.6 0.7 0.8 
7 8.3 6.1 7.3 5.4 0.4 0.3 60.7 49.7 I.I 1.0 
8 4.4 4.1 2.9 2.5 1.2 1.0 115.4 25.3 0.7 I.I 
9 3.9 6.5 2.9 5.5 0.7 0.4 68.2 45.5 0.7 1.3 
mean 5.4 4.8 4.0 3.7 0.9 0.7 124.7 69.3 I. I 1.0 
±sd ±2.0 ±1.2 ±2.0 ±1.3 ±0.3 ±0.3 ±128.0 ±73.3 ±0.5 ±0.3 
NS NS p=0.004 p=0.008 NS 
IO 3.6 4.6 2.3 3.4 0.9 0.9 53.0 77.6 0.9 0.7 
II 4.6 3.8 2.9 2.9 1.2 0.6 1556.5 1027.7 I.I 0.7 
12 5.5 3.4 3.2 2.2 1.8 0.9 72.3 45.3 I.I 0.9 
mean 4.6 3.9 2.8 2.8 1.3 0.8 1.0 0.8 
±sd ±0.9 ±0.6 ±0.5 ±0.6 ±0.5 ±0.2 ±0.1 ±0.1 
Subjects I 0, 11 and 12 are female 
LDL gradient gel electrophoresis 
Six of the male subjects showed no change in LDL size between OFF and ON cycle 
(Table 11 ); one subject had a decrease in LDL size from an All to an I pattern when ON cycle. 
The two male subjects showing the smaller Band 1/B LDL size when OFF cycle, showed an 
increase in LDL particle size into the 'intermediate' size range when they were ON cycle. 
Subjects 4,5,6, had mid bands. Female subjects 10 and 11 showed no change in LDL size ON 
cycle; LDL in subject 12 decreased in size ON cycle from A to All. 
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HDL gradient gel electrophoresis 
Five of the male subjects showed a reduction in HDL particles in the HDL2 size range 
(Table 11). The other four male subjects showed no change in HDL profile ON cycle. HDLwas 
not detectable by GGE in subject 9 when ON cycle and in subject 7 both OFF and ON cycle. Two 
of the female subjects showed a similar reduction in HDL size ON cycle; the third female subject 
showed no alteration in HDL profile ON cycle. The absence of a change in HDL GGE in female 
subject IO was consistent with the finding that he,· HDLC concentration did not change ON cycle. 
Densitometric scans of HDL GGE in subjects 3 and 8 .are provided in figures 1.1 - 1.4, to 
illustrate the reduction ofHDL in the HDL2 size range, OFF compared to ON cycle. 
HDL3 HDL3 I Q) u I C: ~ 
0 (I) 
~ 
(a) Distance migrated (b) Distance migrated 
HDL3 
HDL2 HDL3 I I Q) u C: ~ 
0 (I) 
~ 
(c) Distance migrated (d) Distance migrated 
Figure 4. Densitometric scans of HDL GGE for (a) subject 3 OFF cycle (2=3); (b) subject 3 ON cycle 
(2<3); (c) subject 8 OFF cycle (2> 3); (d) subject 8 ON cycle (2<3). The high absorbance at the beginning 
of the scan indicates the line drawn on the GGE plates to show the start of the separating gel, to allow 
exactly reproducible comparisons of migration distance. The first small peak near the origin indicates 
LDL. The high absorbance at the end of the scan indicates the edge of the gel (units are arbitrary). 
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Triglycerides and postprandial triglyceridaemia 
Fasting triglyceride concentrations were unchanged when subjects were ON cycle (Table 6). 
Postprandial triglyceridaemia, expressed as the total area under the curve, tended to be reduced 
ON cycle, although not significantly (p=0.055) (Table 11). However, when corrected for fasting 
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I-burs after oral fat challenge 
0 2 4 6 8 10 (b) 
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--oNcycle 
-o- OFF cycle 
-+-ON cycle 
Figure 5. Effect of a 65 glm2 oral fat challenge on plasma triglyceride concentration in (a) subject 4 OFF 
and ON AAS cycle; (b) subject 5 OFF and ON AAS cycle. 
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triglyceride concentration, and expressed as a triglyceride excursion above fasting concentration, 
postprandial triglyceridaemia was significantly decreased ON cycle (p=0.027). Moreover, peak 
postprandial triglyceride concentration was also significantly reduced ON cycle (p=0.027) .. The . 
two subjects who had type Band 1/B LDL profiles OFF cycle showed 42 and 58% reductions 
respectively in postprandial triglyceridaemia when ON cycle (Figure 2.1, 2.2). 
Table 11. Lipoprotein size by GGE and postprandial triglyceridaemia in AAS using bodybuilder subjects 
Subject LDLGGE HDLGGE Peak TG cone. Area Under Triglyceride 
(mmol/L) Curve excursion 
(mmol/L.hr) (mmol/L.hr) 
OFF ON OFF ON OFF ON OFF ON OFF ON 
cycle cycle cycle cycle cycle cycle cycle cycle cycle cycle 
l A/I All 2<3 2<3 2.0 1.7 12.3 12.1 4.5 6.3 
2 A/I I 2=3 2=3 2.1 1.0 15.4 9.4 8.1 3.2 
3 A A 2=3 2<3 1.9 1.6 12.5 12.4 6.4 5.0 
4 m,B m,I 2<3 3 7.8 5.3 52.8 33.9 36.3 21.2 
5 m,1/B m,I 3 3 4.5 2.2 27.9 15.3 17.9 7.6 
6 m,1 m,J 2<3 2<<3 1.6 1.5 10.8 10.8 5.9 5.2 
7 pA,A pA,A. flat flat 2.5 2.0 18.6 11.9 7.2 4.3 
8 A A 2>3 2<3 2.2 2.5 16.4 14.3 9.1 8.8 
9 I I 2<3 flat 2.5 2.6 16.3 19.0 9.0 6.2 
mean 3.0 2.3 20.l 15.7 11.6 7.5 
±sd ±2.0 ±1.2 ±13.3 ±7.5 ±10.0 ±5.4 
p=0.027 NS p=0.027 
IO A/I A/I 2<3 2<3 1.4 1.3 11.7 10.3 3.0 3.5 
JI pA,A pA,A 2=3 2<3 2.1 2.6 15.9 17.8 4.7 6.9 
12 A A/I 2=3 2<3 2.4 1.8 16.7 13.9 7.2 6.6 
mean 2.0 1.9 14.8 14.0 5.0 5.7 
±sd ±0.5 ±0.7 ±2.7 ±3.8 ±2.1 ±1.9 
Subjects 10, 11 and 12 are female 
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Discussion 
Postprandial triglyceridaemia and lipoprotein profiles were assessed in a small group of 
bodybuilders before and after one cycle of self-administered, high dose AAS. The results of this 
study suggest that postprandial triglyceridaemia and smaller, denser LDL are not increased in 
individuals who self-administer AAS in a cyclical pattern. Thus, a low HDLC concentration 
associated with AAS use is unlikely to be due in part to an increased postprandial 
triglyceridaemia. Decreased Lp(a) concentration may be an antiatherogenic effect of AAS use. 
An increase in LDL size and a reduced postprandial triglyceridaemia may be additional 
antiatherogenic effects of AAS use in individuals who are predisposed to 'atherogenic 
dyslipidaemia'. 
Urinalysis confirmed that all of the subjects were using AAS when ON cycle. Notably, AAS 
were still detectable after the OFF cycle period in the majority of the subjects. In most cases this 
was identified as nandrolone, a parenteral AAS. Nandrolone has a longer half life than the other 
AAS because the steroid nucleus is altered to slow the rate of inactivation (Wilson, 1988). One 
subject still had high concentrations of testosterone and stanozolol at the OFF cycle test, 
indicating that the short OFF cycle that he elected to take had not been sufficient to allow for 
significant AAS clearance from his previous heavy cycle. Although it is possible that this subject 
did not actually go OFF cycle, discussion with the subject indicated that this was not the case. 
The ON cycle urinalysis also revealed that some of the AAS used by the subjects were either 
counterfeit, or a different agent to that which they believed they were using, as was also found 
by Cohen et al. ( 1996). This did not influence the study adversely since the use of multiple AAS 
in these subjects provided alternatives. 
Subject compliance with dietary recall analysis was poor, and nutritional data is thus 
incomplete. Nevertheless, some useful information was obtained. Total energy and cholesterol 
intake in the bodybuilding subjects was not excessive by 'Western standards', but tended rather 
to be lower than that typically seen in their sedentary counterparts ( dietary analysis, Triptorelin 
study subjects, chapter 4), and lower than in another study on bodybuilders (Kleiner et al., 1989). 
Total energy and cholesterol intake certainly did not reflect the widely held opinion that all 
bodybuilders eat 'enormous', cholesterol rich diets. A cholesterol intake of greater than 500 mg 
per day is nevertheless excessive relative to recommendations for a prudent diet 
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(Chait et al., 1993). The percentage of total energy intake as fat was low, and the proportioning 
is roughly appropriate for prudent recommendations, but the absolute intake of saturated fat was 
a bit high. The fat intake. of the bodybuilding subjects in this study appear to be lower than 
reported previously for bodybuilders (Kleiner et al., 1989). Total dietary energy intake in 
subject 5 was double at the ON compared to the OFF cycle test five weeks later. An increase in 
energy intake for this duration is not expected to affect the magnitude of postprandial 
triglyceridaemia or other lipoprotein concentrations. However, the increase in dietary cholesterol 
intake in the range seen in this subject when ON cycle, would be expected to cause an increase 
in LDLC concentration. It is thus interesting that LDLC concentration decreased in this subject 
ON cycle despite an increased dietary cholesterol intake. While ids not possible to conclude that 
the other subjects in the present study did not alter their diet between the two test days, anecdotal 
accounts indicate that these subjects are acutely diet conscious, and tend to be regimental and 
habitual about their daily caloric intake, and were thus unlikely to have modified their dietary 
habits significantly. 
Anthropometric measurement indicates that muscle mass was increased ON cycle in most of 
· the subjects, a finding which is consistent with the view that AAS use with resistance training 
does increase muscle mass (Haupt and Rovere, 1984). The significant increase in mean body 
mass ON cycle can be attributed to a combination of increased muscle and fat mass in most 
subjects. The discrepancy evident in some subjects, and particularly subject 5, is frequently 
attributed to increased water retention with AAS use (Bagatell and Bremner, 1996). 
Medical examination did not reveal elevated blood pressure or irregularities in hepatic 
function, sometimes reported with AAS use (Lenders et al., 1988). Although AST, ALT and 
LDH activities were elevated, abnormalities in these liver function tests are also associated with 
weight training in the absence of AAS, and may not be good indicators of hepatic damage (Haupt 
and Rovere, 1984). Alkaline phosphatase activity was elevated in subject 5 only, although the 
magnitude of the elevation is not thought to be clinically significant. The slight elevations in 
bilirubin concentrations in subjects 2 and 12 are also not thought to be clinically significant. 
Mean total cholesterol and LDLC concentration were not elevated by one cycle of AAS use, 
as is typically reported for studies of this type (Baldo-Enzi et al., 1990;_ Faber et al., 1986; 
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Hurley et al., 1984; Kleiner et al., 1989; Lajarin et al., 1996; Lenders et al., 1988; 
Webb et al., 1984), but tended rather to be slightly reduced. The response of total cholesterol and 
LDLC concentration to one cycle of AAS use varied widely interindividually. The cause of the 
dramatic ON cycle reduction of total cholesterol and LDLC concentration in subjects 2 and 7, 
is unknown in subject 2, and was attributed to an acute phase reaction due to influenza at the 
beginning of the ON cycle of subject 7. Only one subject showed a marked increase in LDLC 
concentration ON cycle. The majority of subjects had LDLC concentrations less than 
4.9 mmol/L, which are not considered to be clinically significant, especially since hypertension, 
diabetes and smoking were absent. 
A significantly reduced HDLC concentration is consistently reported with AAS use (Alen and 
Rahkila, 1984; Alen et al., 1985; Baldo-Enzi et al., 1990; Faber et al., 1986; Hurley et al., 1984; 
Kleiner et al., 1989; Kuipers et al., 199 L; Lajarin et al., 1996; Lenders et al., 1988; Peterson and 
Fahey, 1984; Webb et al., 1984; Zuliani et al., 1988). The low OFF cycle HDLC concentration 
in subjects 7 and 9 is compatible with the urinalysis finding that these subjects still had high and 
medium concentrations of plasma AAS activity respectively, and illustrates the sensitivity of 
HDLC concentration to the presence.of AAS. The low HDLC concentration in female subject 
10 is also likely to be due to an effect of residual plasma AAS. Reductions in HDLC 
concentration associated with the use of AAS, occur predominantly in the HDL2 subfraction 
(Alen et al., 1985; Baldo-Enzi et al., 1990; Cohen et al., 1986; Kantor et al., 1985; 
Kleiner et al., 1989; Hurley et al., 1984; McKillop and Ballantyne, 1987). Changes in HDL 
subfractions have not previously been assessed by GGE studies of particle size. Results of these 
studies confirm that the reduction in HDL is in the HDL2 subfraction in most cases. Exceptions 
include two subjects who had no detectable HDL2 by GGE at the OFF cycle test, and two 
subjects in whom the reduction in HDL appeared to be equivalent in both subfractions. An 
increased lipolytic degradation due to an increased HTGLa is believed to be the principal cause 
of the reduced HDLC and .particularly HDL2C concentration in AAS users 
(Applebaum-Bowden, 1984; Baldo-Enzi et al., 1990; Crook et al., 1992; Haffner et al., 1983). 
The significant reduction in Lp(a) concentration with AAS use is consistent with findings in 
other studies (Albers et al., 1984; Cohen et al., 1996; Crook et al., 1992; Farish et al., 1995; 
Lajarin et al., 1996). The wide variability in Lp(a) concentration in the general population is 
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reflected in the results obtained for the subjects in this study (Lawn, 1992). It is unknown why 
there is such a wide variability in the percentage reduction ofLp(a) in different individuals. AAS 
may affect Lp(a) concentration by reducing apo(a) synthesis or secretion, by impairing Lp(a) 
assembly, or by affecting Lp(a) catabolism (Crook et al., 1992). Anabolic steroids modify the 
action of various enzyme systems, including hepatic hydrolytic enzymes, which could lead to an 
effect on synthesis or processing of Lp(a) (Crook et al., 1992). It remains unknown whether 
reduction of Lp( a) concentration will reduce the incidence of atherosclerosis and CHD, as no 
suitable Lp(a) lowering therapy is currently available (Lawn and Scanu, 1996). A reduction in 
Lp(a) concentration is expected to reduce the risk of premature atherosclerosis and CHD, since 
a high concentration is associated with an increased risk of myocardial infarction 
(Armstrong et al., 1986; Kostner et al., 1981; Schaefer et al., 1994), and Lp(a) shows 
proatherogenic and prothrombotic characteristics in vitro (Maher and Brown, 1995). 
The size of LDL particles has not been described previously in the context of AAS use. A 
predominance of small, dense LDL in plasma is thought to be particularly atherogenic, and has 
been associated with up to a three-fold increase in risk of acute myocardial infarction 
(Austin et al., 1988). Most of the subjects had average to good LDL profiles as judged by GGE, 
and showed no change in LDL size ON cycle. Interestingly, the two male subjects who displayed 
what is regarded as the more atherogenic B and 1/8 LDL size when OFF cycle, showed an 
increase in LDL particle size into the 'intermediate' size range when they were ON cycle. The 
use of AAS does not appear to be associated with any significant reduction in LDL particle size 
which might be viewed as atherogenic, but may be associated with an improvement in LDL size 
in individuals characterised by the smaller denser LDL. 
The postprandial triglyceride excursion, as well as peak postprandial triglyceride 
concentration, were significantly reduced ON cycle. Two subjects had an exaggerated 
postprandial triglyceridaemia in the absence of an elevated fasting triglyceride concentration 
confirming, that in some individuals, an impaired triglyceride clearance is only revealed 
following a fat challenge (Patsch et al., 1983). Both of these subjects showed marked reductions 
in postprandial triglyceridaemia ON cycle. Moreover, these subjects showed the small, dense 
LDL pattern OFF cycle, and the reduction in postprandial triglyceridaemia ON cycle was 
associated with an increase in the LDL particle size. This observation is consistent with the 
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hypothesis that an impaired triglyceride clearance, and consequent increased residence time of 
TGRL, is an important determinant of a reduced LDL particle size (Karpe et al., 1993). Two 
studies have investigated the relationship between AAS and intravenous fat tolerance. 
Thompson et al. ( 1989) reported a non-significant increase in the capacity to clear intravenous 
fat with AAS treatment. Their data indicate that stanozolol, a 17a-alkylated (oral) AAS may have 
induced a greater fat clearance rate than testosterone enanthate, a 17P-esterified (parenteral) 
AAS. Olsson et al. (1974) reported a decrease in fasting triglyceride concentration, and a 
significant increase in the rate of intravenous fat clearance with oxandrolone treatment (7.5 mg/d) 
in patients with 'hyperlipoproteinaemia'. 
It is unclear how AAS induce a reduction in triglyceridaemia following a fat challenge, 
although an increase in the activity of the lipase enzymes is the likely cause. While increases in 
LPLa associated with AAS are inconsistent, with some investigators reporting increases 
(Sorva et al., 1988 ; Thompson et al., 1989; Zmuda et al., 1993), and others finding no change 
(Hazzard et al., 1984; Haffner et al., 1983; Lenders et al., 1988; Taggart et al., 1982), HTGL 
activity is consistently and dramatically increased with the use of 17a-alkylated (oral) AAS but 
not With 17P-esterified (parenteral) AAS (Applebaum-Bowden et al., 1987; Friedl et al., 1990; 
Haffner et al., 1983; Taggart et al., 1982; Thompson et al., 1989). The latter finding may account 
for the difference in the rate of fat clearance between stanozolol and testosterone in the study by 
Thompson et al. (1989). The reduction in postprandial triglyceride excursion seen in this study 
may have been influenced by a reduced exercise intensity OFF compared ON to cycle, as an 
interruption of exercise training has been found to affect postprandial triglyceridaemia 
(Mankowitz et al., 1992). However, none of the subjects indicated that they had changed their 
training regimen in any way between the two test days. Moreover, anecdotal accounts indicate 
that the study subjects are regimental and habitual about their daily exercise regimen. The 
reduction in the postprandial triglyceride excursion ON cycle is thus unlikely to have been 
influenced by a change in exercise intensity between the two tests. 
In summary, postprandial triglyceridaemia and lipoprotein profiles were assessed in 
bodybuilders before and after one cycle of self-administered, high dose AAS. The results of this 
study suggest that postprandial triglyceridaemia and smaller, denser LDL are not increased in 
individuals who self-administer AAS in a cyclical pattern. Thus, a low HDLC concentration 
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associated with AAS use is unlikely to be due to an increased postprandial triglyceridaemia, as 
has previously been found in some other individuals with a low HDLC concentration 
(Patsch et al.; 1983). GGE studies indicate a predominant decrease ofHDL particles in the HDL2 
size range. Mean LDLC concentration was riot increased with AAS use. Decreased Lp(a) 
concentration may be an antiatherogenic effect of AAS use. An increase in LDL size and a 
reduced postprandial triglyceridaemia may be additional antiatherogenic effects of AAS use in 
individuals who are predisposed to 'atherogenic dyslipidaemia'. More studies, particularly on 
subjects who are predisposed to 'atherogenic dyslipidaemia', are required· to confirm these 
observations. 
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General Conclusions 
The aim of the experimental work described in this thesis was to better describe the effect of 
endogenous testosterone and AAS on lipid and lipoprotein risk factors for premature 
atherosclerosis in humans, but was not designed to unravel the underlying mechanisms for the 
observations. Although it is widely believed that endogenous testosterone and AAS may be 
atherogenic in humans, a literature review reveals that there are few studies which have sought 
a direct association between these hormones, and premature atherosclerosis. Moreover, data from 
the studies that have been done is limited, and difficult to interpret. The slow progression of 
research in this field may be because ethical and practical constraints have limited the feasibility 
of conducting studies of sufficient scope and duration to conclusively show a difference in the 
initiation or progression of atherosclerosis. As a consequence of this, current opinion is 
dependent largely on the interpretation of inferential evidence. 
Evidence to provide a direct link between endogenous and synthetic testosterone, and 
premature atherosclerosis, in otherwise normal men, is weak. The principal atherogenic effect 
of testosterone appears to be a suppression of HDLC concentration. While a lower HDLC 
concentration may be associated with a diminished reserve in reverse cholesterol transport and 
a reduction in the other protective effects ofHDL, it remains unknown whether this change will 
in fact manifest as premature atherosclerosis, or whether testosterone has other protective effects 
which may mitigate the impact of a reduced HDLC concentration. The present triptorelin study 
did not reveal any additional atherogenic effects of endogenous testosterone. While testosterone 
may tend to reduce the size of LDL in some individuals, testosterone does not appear to play a 
major role in the regulation of LDL particle size. Moreover, testosterone does not appear to 
influence LDLC concentration or postprandial triglyceridaemia in an atherogenic manner. A 
suppressive effect on Lp(a) concentration may, however, represent an antiatherogenic effect of 
endogenous testosterone in men. Although the duration of the testosterone reduction obtained 
in the present triptorelin study was short, the results of this study do not favour the hypothesis 
that endogenous testosterone is a significant risk factor in men. The metabolic mechanism for 
the differences between individuals in lipoprotein particle size changes and Lp(a) concentration 
changes with testosterone suppression require further study. 
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Resolution of the true atherogenic potential of endogenous testosterone in human males will 
require a long term follow up of atherosclerotic progression in hypogonadal compared to 
eugonadal males. Needless to say, ethical and practical constraints make such a study unlikely. 
This issue could, however, be resolved with a fair degree of certainty by conducting further 
equivalent male animal studies, although this data will have to be extrapolated to humans with 
caution. Renewed interest in the therapeutic use of synthetic testosterone as a male contraceptive, 
and for hormone replacement therapy in elderly men, has recently led to a dramatic increase in 
the number of clinical trials which have supplemented synthetic testosterone in normal men. Data 
from equivalent but more prolonged trials may provide new insight into the potential 
atherogenicity of endogenous testosterone. 
A lack of controlled trials into the effects of AAS in bodybuilders has hindered efforts to 
resolve whether these agents do in fact predispose users to premature atherosclerosis. Although 
the use of AAS causes a significant increase in the LDLC/HDLC ratio, no epidemiological data 
has been forthcoming to prove that AAS use is associated with premature atherosclerosis. Indeed, 
given the apparent atherogenicity of AAS, and the fact that AAS have been used since the 1950's, 
by more than one-million athletes and bodybuilders in the United States alone, it is surprising 
that there has not been an epidemic of AAS related atherosclerotic complications. It has been 
argued that the relative paucity of AAS related atherosclerotic complications may be because 
individuals are reluctant to admit AAS use, since non-therapeutic use of these agents is illegal 
in many countries (including South Africa), and because the identification of AAS as a causative 
factor in cardiovascular events is difficult. However, the intensity of medical interest in reporting 
assumed cases is likely to compensate for the afore mentioned problems (Rockhold, 1993). It is 
also possible that specific characteristics of athletes and bodybuilders, such as an increased 
consciousness about lean body mass, exercise and diet, may reduce atherosclerotic risk attributed 
to their AAS use. 
Results from the present study do not reveal any further adverse effects of AAS. Rather, these 
results indicate that AAS use may have two potentially antiatherogenic effects; (i) by reducing 
postprandial triglyceridaemia and increasing LDL particle size in individuals who are 
predisposed to 'atherogenic dyslipidaemia', and (ii) by causing a marked suppression ofLp(a) 
concentration. Anecdotal accounts indicate that AAS users are not convinced that premature 
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atherosclerosis will be a likely consequence of their drug use. Controlled clinical trials comparing 
atherosclerotic progression (possibly using non-invasive techniques) in AAS using versus 
matched volunteers are urgently required to conclusively prove whether AAS use is in fact 
associated with premature atherosclerosis. In such studies, close attention will have to be paid 
to the possible thrombogenic effects of AAS, and also to the possibility that adverse effects of 
AAS use may differ in males compared to females. 
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Appendix I 
Protein composition of lipoproteins in fasting plasma 
Chylomicrons .VLDL LDL HDL 
Total protein - 6 80 190 
. (mg/di plasma) 
-
Apoproteins 
(% of total protein) 
ApoA-1 Trace Trace Trace 66 
ApoA-II Trace Trace Trace 20 
ApoB 5-20 37 97 -
-
ApoC-1 15 3. Trace 3 
ApoC-Il 15 7 Trace Trace 
ApoC-III 40-50 40 2 .4 
ApoD - - - 5 
ApoE 4 13 1 I 
From: Thompson G.R. 1994 A Handbook ofHyperlipidaemia. Current Science Ltd., London, ISBN 1-
85922-140-8. 258pp. 
